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ABSTRACT

Trastuzumab targets the ErbB2 (HER2) receptor on breast cancer cells to
attenuate HER2 driven tumor formation. Trastuzumab reduces both downstream
PI3K/Akt and MAPK pathway signaling as well as the breast cancer stem cell
(BCSC) population. BCSCs are hypothesized to be responsible for tumor
recurrence, metastasis, as well as drug resistance. Today, resistance to
trastuzumab remains a major clinical problem for women diagnosed with HER2+
breast cancer. Attenuation of PI3K/Akt and MAPK pathways may occur through
the tumor suppressor, PTEN. Women with HER2+ breast tumors expressing less
PTEN and increased PI3K/Akt or MAPK activity have worse overall outcome.
Previously we have shown that trastuzumab resistant cells have increased
expression of Notch-1 which drives cell proliferation in vitro as well as tumor
recurrence in vivo. Here, we show, to our knowledge for the first time, that Notch1 directly represses PTEN transcript RNA expression to promote trastuzumab
resistant HER2+ breast cancer cell proliferation at least in part through activation
of ERK1/2. Furthermore, we demonstrate that Notch-1 mediated inhibition of PTEN
promotes BCSC survival and self-renewal both in vitro and in vivo.

xxvii

CHAPTER 1
INTRODUCTION

Breast Development and Anatomy.
At birth, the mammary gland is identical in both males and females as it is
comprised a series of ducts to form a tree-like structure (Moore and Persaud, 1998;
Pandya and Moore, 2011). In females, the mammary gland develops into an
exocrine gland that produces milk for the purpose of weening children. Thelarche
is the onset of breast development which occurs primarily during puberty. At this
time, an increase in ovarian estrogen and progesterone production in combination
with somatotropin (human growth hormone) secretion from the pituitary gland
promotes mammary gland formation inside the developing breast. Mammary gland
development is completed upon the onset of pregnancy. During pregnancy, the
breast enlarges due to estrogen, progesterone, prolactin, growth hormone, and
placental hormones. This burst of female hormones drives proliferation of the
glandular epithelium that replace breast tissue stromal elements. During the third
trimester of pregnancy, the epithelium differentiates into secretory cells for the
synthesis and secretion of milk. After birth, the release of oxytocin promotes
myoepithelial cell proliferation and differentiation in preparation for the nursing of
young (Beesley and Johnson, 2008). After delivery, estrogen and progesterone
levels fall while prolactin, insulin, and growth hormones rise for milk production.
1
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Milk secretion is induced reflexively by a suckling infant and regulated by oxytocin.
As nursing of the infant decreases, the glandular, stromal, and ductal elements of
the breast atrophy resulting in reduced breast size. Similarly, there is an overall
reduction in mammary gland ducts and lobules as well as fat and stromal elements
resulting in a reduction in breast size and volume during menopause (Macias and
Hinck, 2012).
During embryogenesis, mammary glands develop from the primary
epidermal ectoderm layer cells invading the underlying mesenchymal tissue (Drew
et al., 2007). As the mammary gland develops, the primary bud of the mammary
gland branches into 15 to 20 secondary buds that become lactiferous ducts. The
breast tissue is comprised of 15 to 20 lobes that are divided into 4 lobules and
each lobe is comprised of branched tubuloalveolar glands. The lobes drain into
major lactiferous ducts that then drain into a lactiferous sinus which can be
accessed through the nipple orifice. Similarly, the breast is divided into four
quadrants: upper inner, upper outer, lower inner, and lower outer. The most
common place for the development of breast tumors is in the upper outer quadrant
where a majority of the breast volume exists (Clough et al., 2010).
Breast Cancer.
Breast cancer remains the leading cause of cancer-related deaths among
women world-wide (ACS, 2015). In the United States, it is estimated that 246,660
women will be diagnosed with invasive breast cancer and 61,000 women will be
diagnosed with breast cancer in situ in 2016, according to the American Cancer
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Society. Additionally, it is estimated that 40,450 women in the U.S. will succumb
to breast cancer. For men, it is estimated that there will be 2,600 new cases of
invasive breast cancer as they tend to ignore breast cancer symptoms resulting in
breast cancer diagnosis at a later stage compared to women. Women have a 1 in
8 risk of developing invasive breast cancer within their lifetime. This statistic has
risen since 1975 (1 in 11 risk of breast cancer) mainly due to an increase in early
detection and breast cancer awareness (breastcancer.org).
Cancer is not a single disease but a group of diseases that causes cells in
the body to uncontrollably grow and proliferate compared to normal, healthy cells.
Unregulated proliferation of cancer cells can form a tumor which is named after the
tissue in which it originates; hence breast cancer is dubbed so due to the formation
of tumors in the breast tissue. Breast cancer can have several different forms
depending on the type of breast tissue that the tumor develops in as well as the
expression of various biomarkers by the breast cancer cell. Breast cancer typically
forms from cells of the lactiferous ducts (ductal carcinoma) or the lobules (lobular
carcinoma) that supply the milk. There are over 18 sub-types of breast cancer
which include tubular, medullary, mucinous, and papillary ductal carcinoma
depending on the tumor origin. Using histopathology techniques, breast cancer
grade as well as stage can help determine the progression of the disease. Cancer
grade indicates the amount of disorganization occurring in the cancer cell. Cancer
stage indicates the degree of invasiveness of the cancer. Both grade and stage of
the cancer assist in determining the prognosis of the cancer and the treatment
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course that will be taken. Several factors can affect breast cancer diagnosis
including differences in race, diet, alcohol consumption, smoking, physical activity,
hormone replacement therapy, and family history.
Breast Cancer Subtypes.
The intrinsic heterogeneity of breast cancer becomes apparent when
determining how to organize the various subtypes of breast cancer that can be
present in each woman. Beyond grading and staging of breast cancer,
determination of the biological features of the breast cancer provides a better
understanding of its cellular processes which in turn improves the treatment
strategy for the particular breast cancer subtype. Today, there are three major
classes of breast cancer: luminal, human epidermal receptor 2 (ErbB2, HER2),
and triple negative (TNBC) which lacks detectable overexpression of
pharmacologically targetable receptors. The first breast cancer “molecular
portraits” were pioneered by Perou et al. and Sorlie et al. (Perou et al., 2000; Sørlie
et al., 2001). These two research groups used microarray technology to establish
the five intrinsic subtypes of breast cancer that persist today. The five subtypes of
breast cancer are: Luminal A which overexpresses hormone receptors, estrogen
and / or progesterone (ER+/PR+); Luminal B, or triple positive, which
overexpresses

hormone

receptors

as

well

as

the

HER2

receptor

(ER+/PR+/HER2+); HER2 positive (HER2+) which overexpresses the HER2
receptor; triple negative breast cancer (TNBC), or basal breast cancer, which lack
overexpression of the hormone or HER2 receptors (ER-/PR-/HER2-); and normal-
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like breast cancer which has gene expression patterns much like those displayed
by cells in normal breast tissue. Many studies have been done to reinforce the
predominance of these molecular subtypes as well as continue to define subtypes
within these subtypes thereby further classifying breast cancer into specific
categories. Tissue Microarrays (TMAs) by Abd El-Rehim et al. validate the
categorization of breast cancer into five subtypes by further characterization of
protein expression pertinent to cell differentiation, epithelial cell lineage, hormone
and growth factor receptors, as well as proteins known to be altered in some breast
cancer subtypes (Abd El-Rehim et al., 2005). Breast cancer can be further
classified according to disease aggressiveness by comparing differences in: cell
proliferation markers Ki-67 (MKI67) (Cheang et al., 2009), Mitotic Index (MI),
Proliferating Cell Nuclear Antigen (PCNA) (Stuart-Harris et al., 2008); as well as
relapse-free and overall survival (Hu et al., 2006).
Formation of different biological characteristics for each breast cancer
subtype segregates these subtypes by distinct biological behaviors that lead to a
variety of treatment responses. Continued analysis of the different breast cancer
subtypes may complicate our understanding of the disease by diverging the
subtypes into more refined groups as well as converging the major subtypes.
Further assessment of breast cancer heterogeneity allows clinicians to gain insight
into tumor progression in order to more accurately diagnose and treat breast
cancer.
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Luminal A. Luminal A is the most common breast cancer subtype, affecting
nearly 70% of women (breastcancer.org). Luminal A breast cancer is categorized
by it is overexpression of ER and/or PR, low proliferation index (low Ki67), and
low tumor grade. Oncogenic mutations have been identified in the luminal A
subtype affecting multiple signaling pathways such as, PI3K (PIK3CA: 49%), p53
(TP53: 12%), MAPK (MAP3K1: 14%), as well as cell differentiation (GATA3: 14%)
which can be used as predictors for the luminal A subtype (TCGA, 2012). The
luminal A subtype has the best prognosis among the five breast cancer subtypes.
Luminal A breast cancer is commonly treated with endocrine disrupting therapies
such as aromatase inhibitors (AIs) or tamoxifen in conjunction with surgery such
as a lumpectomy, quandrantectomy, partial mastectomy, mastectomy, or double
mastectomy in an effort to reduce breast cancer recurrence.
The aromatase enzyme synthesizes forms of estrogen by converting
testosterone to 17-estradiol, or androstenedione to esterone (Santen and Harvey,
1999). There are two types of AIs, the irreversible (exemestane) and reversible
(anastrozole or letrozole) that act as competitive inhibitors by binding to the
aromatase enzyme. An AI is used to treat luminal A (ER+/PR+) breast cancer by
selectively targeting the enzymatic activity of the aromatase enzyme thereby
blocking estrogen synthesis. Tamoxifen is classified as a selective estrogenreceptor modulator (SERM) indicating that it acts directly on estrogen receptor 
(ER). Tamoxifen is a prodrug that is metabolized by the liver (Desta et al., 2004).
Once metabolized, tamoxifen is converted to many metabolites. The most
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abundant are 4-hydroxytamoxifen (4-OHT) and endoxifen which compete with
17-estradiol for ER resulting in reduced ER-mediated transcription in the
breast cancer cell. An aromatase inhibitor or tamoxifen is given as an adjuvant
therapy to prevent potential breast cancer relapse after surgery. Aromatase
inhibitors are primarily given to post-menopausal women who have hormone
sensitive tumors while tamoxifen is given to premenopausal women as AIs can
promote a compensational increase in estrogen production in younger women
(Mathew and Davidson, 2015). Anti-hormonal therapies have been proven
successful for the treatment of the luminal A subtype but current work shows that
approximately 50% of women may not benefit from adjuvant endocrine therapy
(Ejlertsen et al., 2010). Also, of the 50% of women that do show a response, about
40% will develop resistance to the AI or tamoxifen resulting in tumor recurrence or
metastatic spread.
Luminal B. The luminal B breast cancer subtype affects 10 to 20% of women
with breast cancer (ACS, 2015). Luminal A and B breast cancer cells are derived
from the luminal epithelium of ducts in the breast tissue. Luminal B breast cancer
is categorized by an increase in ER/PR expression as well as a high Ki67
positivity (Ades et al., 2014). Increased HER2 receptor expression occurs in
approximately 50% of women with the luminal B subtype causing this subtype to
also be referred to as the triple positive subtype. Luminal B breast cancer is a more
aggressive subtype compared to luminal A with similar DNA mutations except for
GATA3. Luminal B has a high incidence of p53 mutation (TP53: 32%) as well as
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chromatin hypermethylation compared to luminal A (TCGA, 2012). The luminal B
subtype has the second best prognosis and can be treated with targeted therapies
such as the anti-hormonal therapies used for luminal A as well as HER2 targeted
therapies. The targeted therapies are often combined with chemo- and/or radiation
therapy. Common chemotherapeutics used to treat breast cancer are tubulindestabilizing taxanes (docetaxel, paclitaxel), DNA stabilizers (doxorubicin,
camptothecin), DNA untangling (topoisomerase II), or DNA damaging alkylating /
methylating agents (cyclophosphamide, temozolomide).
Triple negative breast cancer. Triple Negative Breast Cancer (TNBC) affects
15 to 20% of women with breast cancer (ACS, 2015). TNBC is categorized by its
lack of ER, PR, and HER2 receptor overexpression and thus cannot be treated
with anti-hormonal or HER2-targeted agents. TNBCs have a high incidence of p53
mutations (TP53: 84%), loss of DNA repair protein expression (i.e. BRCA-1/2), as
well as chromatin hypomethylation to further distinguish TNBC from the other BC
subtypes (TCGA, 2012). TNBC includes basal-like and normal-like cancers which
also lack targetable receptor overexpression (Perou et al., 2000). Basal-like tumor
cells are similar to basal cells which surround the mammary duct and are also
known as myoepithelial cells. Basal-like tumor cells are so named because of their
expression of basal cell markers such as cytokeratin (CK) 5, 6, 14, and 17 (Perou
et al., 2000; Sotiriou et al., 2003). While most TNBCs are basal-like and most
basal-like are classified as TNBC, this is not true for all TNBC and basal-like BCs,
hence the distinction between the two subtypes. Due to the lack of targeted
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therapies for TNBC, it has the worst prognosis among the five BC subtypes. The
first line therapy for TNBC is surgery combined with chemo- and/or radiation
therapy.
Research continues to further classify TNBC in hopes of finding new
treatable targets for the disease. Thus far, six new subtypes of TNBC have been
established: Basal-like 1 and 2 (BL1, 2), immunomodulatory (IM), mesenchymal
(M), mesenchymal stem-like (MSL), and luminal androgen receptor (LAR)
(Lehmann et al., 2011). The basal-like 1 and 2 subtypes are classified by increased
cell cycle associated genes (CENPA, CCNA2) and DNA damage response
(BRCA/ATR) gene expression. BL1 and 2 show sensitivity to platinum-based
chemotherapeutics such as cisplatin as well as the single strand DNA repair
protein, poly-ADP ribose polymerase (PARP) inhibitor. The immunomodulatory
subtype displays increased signaling through the immune cell signaling pathways
(TH1, TH2, B cell, NK cell) and has a similar GEP to medullary BC, which is
associated with a favorable diagnosis. Mesenchymal and mesenchymal stem-like
subtypes have increased epithelial to mesenchymal transition (EMT) markers
(TWIST, SNAI2, ZEB1) and growth factor pathways (PDGF, EGFR, GPCR) as well
as a claudin-low (Claudin 3, 4, 7) gene signature. Claudin low is similar to the
M/MSL subtypes of TNBC as they both have high expression of EMT markers,
growth factor pathways (EGFR), and resemble basal breast cells (Prat et al.,
2010). Both mesenchymal and mesenchymal stem-like subtypes show increased
sensitivity to the PI3K/mTOR inhibitor NVP-BEZ235. The luminal androgen
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receptor (LAR) subtype is driven by increased androgen receptor signaling and is
sensitive to an androgen receptor antagonist such as bicalutamide.
Normal-like breast cancer. Some reports fold normal-like breast cancer under
the umbrella of TNBC as the normal-like breast cancer cells lack detectable
overexpression of pharmacologically targetable receptors. Like its name suggests,
normal-like breast cancer shares a GEP with normal cells in the breast tissue such
as adipose or myoepithelial (basal) cells and dissimilarity to luminal cells (Perou et
al., 2000). Normal-like breast cancer may be stratified by its overexpression of
Alcohol Dehydrogenase 1B (ALDH1B) (Perou et al., 2000) as well as increased
activation of the focal adhesion pathways (Smid et al., 2008). Normal-like breast
cancers have a tendency to have a better prognosis than basal-like cancers (Fan
et al., 2006), but typically do not respond to neoadjuvant chemotherapy (Rouzier
et al., 2005). This subtype is consistently the smallest subtype among the five as
it could be a luminal A subtype that is contaminated by normal breast cells during
GEP analysis.
HER2+ Breast Cancer.
HER2 activity has been shown to promote ductal elongation, ductal
branching, and modification of terminal end bud structures during pubertal
mammary gland development (Andrechek et al., 2004; Jackson-Fisher et al.,
2004). The role of HER2 during mammary gland development indicates that it is
also plays a role in breast cancer. Approximately 15 to 25% of breast cancers
overexpress the HER2 receptor. HER2 activity is a driving effector of signal
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transduction networks that become dysregulated in cancer cells (Slamon et al.,
1987). Increased HER2 expression in cancer cells is mostly due to amplification of
the ERBB2 gene located on chromosome 17. Overexpression of HER2 can drive
oncogenesis making HER2 a bonafide proto-oncogene. The oncogenic activity of
HER2 confers a strong proliferative advantage to tumor cells, which promotes an
increase in tumor size (van de Vivjer et al., 1988), lymph node invasion (Berger et
al., 1988), aneuploidy (Babiak et al., 1991) percentage of cells in S-phase (O’Reilly
et al., 1991), and tumor grade (Tsuda et al., 1990). HER2 overexpression has been
associated with aggressive disease and a worse, overall prognosis in women
(Adair et al., 2008). Several types of human solid tumors have displayed HER2
overexpression, including breast cancer, in which a majority of HER2 oncogenic
activity has been studied. Patient samples of the HER2+ subtype have undergone
further evaluation to begin separating the HER2+ subtype into HER2 low, medium,
and high expression profiles to better facilitate targeted treatment of HER2
expressing cancers (Wulfkuhle et al., 2012). ER status has been shown to induce
expression of different genes when coupled with HER2 overexpression creating
two distinct subgroups: HER2+/ER+ and HER2+/ER- within the HER2+ breast
cancer subtype (TCGA, 2012). Fortunately, HER2 overexpression primarily occurs
in tumor cells and not in normal tissue making it an ideal target for breast cancer
therapy.
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EGFR/HER pathway. HER2 is a type 1 transmembrane protein receptor
tyrosine kinase (RTK) and member of the Epidermal Growth Factor Receptor
(EGFR)/HER family of receptors (Reviewed in Yarden and Sliwkowski, 2001).
EGFR/HER receptors are expressed on the cell surface and activated by members
of the Epidermal Growth Factor (EGF) family of extracellular ligands. The
EGFR/HER family of receptors are comprised of four structurally related RTKs with
EGFR as the original member of the family. In humans, these include: EGFR
(EGFR, ErbB1), HER2 (Neu, ErbB2), HER3 (ErbB3), and HER4 (ErbB4). The gene
symbol for HER2, ERBB2, is derived from a homologous viral oncogene,
Erythroblastic Leukemia Viral Oncogene, and has the official name: V-Erb-B2
Avian Erythroblastic Leukemia Viral Oncogene Homolog or HER2 consequently
(USNLM, 2011). The HER2 gene has been mapped on chromosome 17q21 which
can be transcribed and translated into the 1225 amino acids to form the 185kD
(p185HER) transmembrane glycoprotein known as the HER2 receptor (Coussens
et al., 1985).
The EGFR/HER family of receptors are activated through receptor homoor hetero-dimerization induced by binding of a soluble, growth factor ligand.
EGFR/HER receptor ligands are produced by ectodomain shedding of the
membrane anchored ligand precursors from the surface of the cell by matrix
metalloproteinases such as MMP9 or ADAM12 (Reviewed in Higashiyama et al.,
2008). EGFR/HER receptor activation results in activation of downstream
pathways to elicit an appropriate intracellular response to extracellular stimuli.
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EGFR is activated by at least 11 different growth factor-ligands including EGF,
Heparin binding EGF (HB-EGF), amphiregulin (AREG), or Transforming Growth
Factor alpha (TGFα). In contrast, HER3 and HER4 are activated by the heregulin
(neuregulin) family of growth factors (Hrg/Nrg 1, 2, 3, 4) (Figure 1). The EGFR/HER
receptor ligands are classified by their epidermal growth factor-like domain which
is comprised of three intramolecular loops formed by disulfide bonds (Harris et al.,
2003). The EGFR/HER receptors contain an extracellular, transmembrane, and
intracellular domain. The extracellular domain is made up of four subdomains, IIV. The ligand binds to extracellular subdomains I-III which take on a “C” shape to
receive the ligand (Ogiso et al., 2002; Garrett et al., 2003) (Figure 2). The ligand
binds to subdomains I and III which result in the conformation of the receptor to
“open” in preparation for dimerization. Dimerization of ligand bound receptors is
facilitated by a β-hairpin structure from the cysteine rich subdomain II otherwise
known as the “dimerization loop”. The dimerization loop holds the neighboring
receptor by making specific contacts that stabilize dimerization of the two
receptors. Dimerization is also stabilized by interactions between subdomain IV,
the transmembrane domain, and the intracellular domain (Dawson et al., 2005).
EGFR/HER receptors unbound by a ligand are in a “closed” or “autoinhibited” state
in which subdomain II and IV interactions sequester the dimerization loop
(Ferguson et al., 2003).
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Figure 1: EGFR/HER Receptors
Members of the EGFR/HER family of receptors: EGFR/HER1, HER2, HER3, and
HER4. Each receptor is composed of 4 extracellular domains (I-VI) and a tyrosine
rich (Tyr) intracellular domain. Growth factor ligands such as amphiregulin
(AREG), Epidermal Growth Factor (EGF), heparin binding EGF (HB-EGF), and
heregulins 1-4 bind to and activate the EGFR/HER1 and HER3/4 receptors,
respectively. Ligand binding causes rearrangement of the receptor exposing the
dimerization domain (D.D.) to assume an open and active conformation. The
HER2 receptor takes on a fixed active conformation while HER3 has a truncated,
inactive intracellular domain. HER receptor activity can be blocked by small
tyrosine kinase inhibitors [(TKIs) Gefitinib or Lapatinib], antibodies (pertuzumab or
trastuzumab), or antibody-drug conjugates (T-DM1).
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Figure 2: EGFR/HER Receptor Dimerization
EGFR/HER binding of a ligand exposes the dimerization domain (D.D.) of the
receptor enabling the formation of homodimers (left: EGFR-EGFR) or
heterodimers (right: HER2-HER3).
EGFR/HER receptors have a highly conserved tyrosine kinase domain in
the intracellular domain of the receptor. After ligand-mediated dimerization of
EGFR/HER

receptors,

the

dimerized

receptors

autophosphorylate

then

transphosphorylate tyrosine residues in the tyrosine kinase domain (Figure 3).
Tyrosine phosphorylation enables the activation of downstream pathways through
the recruitment of adaptor proteins containing phosphotyrosine binding (PTB) or
Src homology 2 (SH2) domains. Adaptor protein docking to the EGFR/HER
receptors is able to elicit the activation of several downstream pathways including
the Protein Kinase B (PKB/Akt) and the Mitogen Activated Protein Kinase (MAPK)

16
pathway (Figure 4). Activation of downstream pathways is dictated by the tyrosine
phosphorylation pattern of the tyrosine kinase domain as 5 to 8 amino acids around
the phosphorylated tyrosine residues confer specificity of PTB or SH2 binding
(Songyang et al., 1995). Ligands can regulate RTK dimerization as well as the
strength and duration of downstream signaling by influencing the tyrosine
phosphorylation pattern (Olayioye et al., 1998; Sweeney et al., 2000). EGFR/HERmediated activation of downstream pathways enables a ligand to elicit proliferation,
survival, and/or migration signals to the cancer cell.

Figure 3: EGFR/HER Receptor Phosphorylation
EGFR/HER
dimerization
promotes
auto-phosphorylation
then
transphosphorylation of the tyrosine residues in the receptor intracellular domains.
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Figure 4: EGFR/HER Receptor Activation of Downstream PI3K/Akt and
MAPK Pathways.
Activated EGFR/HER receptors are able to activate downstream PI3K/Akt (left)
and/or MAPK (right) pathways.
All four members of the EGFR/HER family of RTKs share structural
similarities, but they each have specific features that confer unique regulatory
characteristics. Unlike EGFR, the extracellular region of HER2 resembles a ligand
activated or “open” state, making HER2 an orphan receptor as there is no known
ligand that binds to HER2 with high affinity. Thus the constitutively active state of
HER2 does not necessitate ligand binding for its activation and is primed for
dimerization with other RTKs (Cho et al., 2003; Garrett et al., 2003). HER3 is a
kinase dead RTK meaning that its intracellular domain does not possess kinase
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activity and can only potentiate downstream signaling when dimerized with another
HER receptor. The fixed state of HER2 makes it the preferred dimerization partner
of the HER receptors, particularly HER3. HER2-partnered heterodimers are more
stable and display increased ligand binding and kinase activity compared to other
heterodimers. In addition, HER2 has been shown to dimerize with other RTKs,
such as Insulin-like Growth Factor-1 Receptor (IGF-1R) (Nahta et al., 2005). HER2
dimerization requires one ligand whereas dimers without HER2 require two ligands
for downstream signaling. Therefore, dimerization with HER2 lowers the amount
of ligands necessary for activation of downstream pathways (Graus-Porta et al.,
1997). Together, EGFR/HER signaling is a complex mechanism capable of
activating a number of downstream pathways. HER2 can act as a lateral signal
transmission between other HER receptors (Graus-Porta, et al., 1997) as well as
amplifying activation and strength of other RTKs (Karunagaran et al., 1996).
HER2 activation of downstream PI3K/Akt and MAPK pathways. An
important trait of the HER family of receptors is their ability to activate protein
kinase B (PKB/Akt) and MAPK pathways. Activation of downstream pathways is
executed through a series phosphorylation events. HER2:HER3 dimerization
preferentially activates the PI3K/Akt pathway (Graus-Porta et al., 1997). PI3K is a
heterodimer comprised of the regulatory subunit, p85, bound to the catalytic
subunit, p110. The p85 subunit uses its SH2 domain to dock to specific
phosphotyrosine residues on the activated HER receptor [Figure 4 (on EGFR)].
Binding of p85 to EGFR recruits the p110 subunit through its Src homology domain
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3 (SH3).

PI3K is now fully activated and it phosphorylates the 3’OH of

phosphatidylinositol (4,5)-bisphosphate (PIP2) to phosphatidylinositol (3, 4, 5)trisphosphate (PIP3). PIP3 can be dephosphorylated by the Phosphate and Tensin
Homolog Deleted on chromosome TEN (PTEN) phosphatase back to PIP 2 thereby
attenuating PI3K signaling. PIP3 interacts with the Plekstrin homology domain
(PHD) within the catalytic domain of phosphoinositol dependent kinase-1 (PDK1)
thus activating the kinase. The lipid binding PHD recruits Akt to the intracellular
surface of the plasma membrane where it docks to PIP3. It is important to note that
the physical interactions and activations of PI3K, PTEN, PDK1, and Akt occur at
the outer surface of the plasma membrane inside the cell. PDK1 is able to
phosphorylate Akt at the threonine308 residue and mTORC2/PDKs is able to
phosphorylate Akt at serine473. Phosphorylation of Akt at both threonine308 and
serine473 is necessary for full activation of Akt. Activated Akt can activate the
mechanistic target of rapamycin (mTOR) which is made up of two protein
complexes: mammalian target of rapamycin complex 1 (mTORC1) and 2
(mTORC2). Activated Akt is able to disrupt the formation of the tuberous sclerosis
1/2 (TSC1/2) dimer. The TSC1/2 dimer inhibits hydrolyzation of the GTP binding
protein, Ras homolog enriched in brain (Rheb). Akt-mediated inhibition of the
TSC1/2 complex allows Rheb to activate mTORC1. The mTORC1 complex is able
to promote cell growth, proliferation, and autophagy by directing protein translation
through eukaryotic initiation factor 4F complex [eIF4F (eIF4E, G, B, etc.)] and
ribosomal protein S6 kinase beta-1 (S6K1 or p70S6K). Both eIF4F and S6K1
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initiate transcription and ribosomal protein synthesis, respectively. The mTORC2
complex is involved in cellular metabolism but largely facilitates fluctuations in
cytoskeletal formation and degradation throughout the cell via serum and
glucocorticoid-regulated kinase 1 (SGK1).
Activation status of PI3K has been implicated in promoting tumorigenesis
through the expression of PIK3CA (p110 gene) mutations. PIK3CA mutations
constitutively activate PI3K which in turn increase oncogenic signaling by Akt.
Additionally, increased PI3K activity can be promoted by loss of the PIP 3
phosphatase, PTEN. Due to the role of Akt in a variety of solid tumors and
hematological malignancies, several therapies have been developed to target
effectors of the Akt pathway in an attempt to diminish tumor survival. Akt pathway
targeted therapies include: Wortmannin and LY294002, which are reversible and
non-reversible inhibitors of PI3K, respectively; and Rapamycin which targets
mTOR signaling downstream of Akt.
HER2 overexpression can result in homodimerization of HER2 which
preferentially activates the MAPK pathway (Ghosh et al., 2011). Similar to p85, the
SH2 domain of Grb-2 is able to dock to phosphorylated tyrosine residues on the
intracellular domain of HER2 [Figure 4 (on HER2)]. Grb-2 is a scaffold protein that
contains both SH2 and SH3 domains. Once Grb-2 is bound to phosphotyrosine
residues on HER2, it can recruit the son of sevenless (SOS) protein. SOS contains
a proline rich regions that binds to the SH3 domains of Grb-2. SOS is a guaninenucleotide exchange factor (GEF) that acts on Ras-GDP. SOS facilitates the
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exchange of guanosine diphosphate (GDP) for guanosine triphosphate (GTP)
binding to form Ras-GTP, and initiating the MAPK phosphorylation cascade.
GTPase Activating Protein (GAP) reduces Ras GTPase activity by hydrolyzing
GTP bound to Ras thereby returning Ras to its inactive state (Ras-GDP), and thus
limiting downstream phosphorylation of the MAPK pathway. Ras activation initiates
the MAPK phosphorylation cascade, which is executed through a series of
serine/threonine specific kinases. The rapidly accelerating fibrosarcoma/mitogen
activated protein kinase kinase kinase (Raf/MAPKKK), mitogen activated protein
kinase kinase (MEK/MAPKK), and extracellular signal-related kinase 1/2 / mitogen
activated protein kinase (ERK/MAPK) are the main MAPK proteins. Ras-GTP
binds Raf and initiates activation of Raf. Subsequently, Raf phosphorylates MEK
and active MEK phosphorylates ERK. Activation of ERK1/2 facilitates
phosphorylation and activation of transcription factors such as c-Fos and c-Myc.
Activation of c-Myc and c-Fos initiate transcription of cyclin D1 and many other
genes critical for coordination of cell motility, invasiveness, and proliferation
(Reviewed in Hynes and Lane, 2005).
Both the MAPK and Akt pathways are known as central nodes in cancer
whose increased activity have been shown to trigger tumorigenesis and
metastasis. Several inhibitors have been designed to target the MAPK pathway
such as: vemurafenib which inhibits Raf or U0126 which inhibits MEK1/2. Inhibition
of Raf or MEK1/2 reduces downstream ERK1/2 phosphorylation and subsequent
MAPK activity. EGFR or HER2-meidated stimulation of cell proliferation and
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survival pathways can result in cancer cells to become addicted to these pathways
in order to maintain tumor growth and survival (Sharma et al., 2006).
HER2 crosstalk. It has come to light that cancer cells are able to become
resistant to targeted therapies by increasing compensatory pathways that continue
downstream activation of protein synthesis, i.e., the Akt pathway, and/or
transcriptional up-regulation of survival genes mediated by the MAPK pathway.
Crosstalk, or bidirectional communication, between pathways to sustain cancer
cell growth and survival is one mechanism by which cancer cells evade targeted
therapy. Extensive research has been done on G-Protein Coupled Receptor
(GPCR) crosstalk with EGFR/HER2 as some GPCR agonists such as
Lysophosphatidic acid, carbachol (muscarinic acetylcholine inhibitor), and
thrombin are known to increase HER activation by two independent mechanisms
(Reviewed in Carpenter, 1999). The first consists of a GPCR-dependent surge in
ectodomain shedding of HER ligands thus releasing them to bind and activate HER
signaling. The second includes GPCR activation of c-Src to facilitate
phosphorylation of tyrosine residues on HERs. HER activation via GPCR may be
necessary for GPCR-mediated mitogenic activity via the MAPK pathway. Both
HER-MAPK pathway initiation, as well as activation of a number of steroid
hormone receptors, can initiate the transcription of HER ligands and trigger a
positive feedback loop. HER2 has been shown to increase p53 expression through
an unknown mechanism in skin squamous-cell carcinoma (Casalini et al., 2001).
HER2 has been shown to induce p53 expression in HER2+ breast cancer cells
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which may attribute to changes in the Cyclin Dependent Kinase (CDK)/Cyclin
activity and regulation of cell division. Mechanisms of crosstalk between the HER
family of RTKs and several other pathways including the: Wnt/β-catenin (Ayyanan
et al., 2006), TNFa/IKK/NF-κB (Cao et al., 2007), and Notch pathways (Yamaguchi
et al., 2008) have been under investigation for nearly a decade. Current data
indicate that new mechanisms of crosstalk have been implicated in treatment
resistance, Epithelial to Mesenchymal Transition (EMT), as well as enrichment and
survival of the breast cancer stem cell (BCSC) population.
Anti-HER2 Therapies. Trastuzumab. HER2 is an ideal target for cancer cells
as targeting of HER2 was found to be highly specific and have little off-target
effects through the use of a murine anti-p185 antibody against HER2 which was
shown to selectively inhibit growth of murine-derived neu-transformed cells and
not Ras-transformed cells (Drebin et al., 1986). Consequently, a humanized,
monoclonal antibody against HER2 in humans was shown to be highly effective in
reducing proliferation of HER2-amplified cells in vitro, and promoted the antitumor
effect of doxorubicin and paclitaxel in HER2+ breast cancer tumor xenograft
models in vivo (Pegram et al., 1998). Anti-HER2 therapies have significantly
improved the outcome of women with HER2+ breast cancer (Hicks et al., 2015;
Michiels et al., 2016).
Trastuzumab is a first generation, FDA-approved, HER2 targeted therapy
for women with HER2+ breast cancer. Primary therapy for HER2+ breast cancer
includes the humanized, IgG1, monoclonal antibody, trastuzumab (Herceptin TM),
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which targets domain IV in the extracellular domain of the HER2 receptor.
Trastuzumab as a monotherapy has shown poor efficacy as the first randomized
trial was stopped early due to poor pathological complete response (pCR) in the
trastuzumab group compared to the control group (Buzdar et al., 2005). The term
pCR indicates an absence of residual invasive disease in the breast or lymph
nodes upon completion of neoadjuvant treatment prior to definitive surgery.
Trastuzumab gains significant efficacy when combined with a taxane-based
therapy and/or the second generation of HER2 targeting antibodies, pertuzumab
(Untch et al., 2011; Baselga et al., 2010). Trastuzumab is effective in early stage
breast cancer, but approximately 15% of women treated with trastuzumab go on
to develop metastatic disease within the first year of treatment (Piccart-Gebhart et
al., 2005) and 20 to 50% of women develop trastuzumab resistance (Cobleigh et
al., 1999; Slamon et al., 2001). So far, there are several potential mechanisms of
HER inhibition by trastuzumab. The benefits of trastuzumab treatment are limited
in some women due to intrinsic resistance to trastuzumab or the development of
acquired resistance to trastuzumab treatment.
Trastuzumab and the immune response. The immune system response has
proven to be important in the efficacy of antibody treatments such as trastuzumab.
In the clinic, there is consistently a positive correlation between immune cell
infiltration and positive patient prognosis in HER2+ breast cancer (Reviewed in
Bianchini and Gianni, 2014). One such method of immune cell infiltration is
mediated by ADCC. ADCC is activated by the Fc (Fragment crystallizable region)
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receptors (FcR) on the surface of immune cells recognizing the IgG1 Fc heavy
chain of a monoclonal antibody bound to the surface of the target cell. The BIG 0298 (Loi et al., 2013) and FinHER (Loi et al., 2012) clinical trials have shown that a
correlation exists between the benefits of trastuzumab-based therapy in early
stage breast cancer and tumor infiltrating lymphocytes. Building from this work
which demonstrates that both cytotoxic and targeted cancer therapies can improve
immune function, researchers have begun manipulating these therapies to
enhance immune function in tumors.
Researchers have been modifying trastuzumab to improve its ability to
direct the immune system against HER2 overexpressing tumor cells. Removal of
the fucose group from trastuzumab creates afucosylated trastuzumab which has
increased FcγIIIRa binding to enhance ADCC activity resulting in reduced tumor
growth in a HER2+ xenograft tumor (Junttila et al., 2010a). Trastuzumab-activated
ADCC can be reduced in tumors with high matrix metalloproteinase expression.
The
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metalloproteinases thereby inhibiting its ability to activate ADCC resulting in
reduced trastuzumab efficacy (Fan et al., 2012). An IgE homolog of trastuzumab
can initiate monocyte-mediated ADCC as well as induce mast cell degranulation
to promote an anti-tumor response in vivo (Karagiannis et al., 2008; Karagiannis
et al., 2011). Natural Killer (NK) cells can induce ADCC to improve trastuzumab
treatment through the upregulation of CD137, a member of the tumor necrosis
factor (TNF) family of receptors, when exposed to HER2+ cells coated with
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trastuzumab. To focus the lytic activity of NK cells on the trastuzumab coated
tumor cells, an anti-CD137 antibody was used to enhance the killing function of
the activated NK cells (Kohrt et al., 2012). The adaptive immune system plays a
role in murine anti-HER2 treatment as tumor regression is dependent on cyctotoxic
CD8+ T cell activation which is lowered when combined with chemotherapy. This
finding suggests that trastuzumab may be more beneficial if administered after
chemotherapy (Park et al., 2010a). Continued work is being done to develop
vaccines against HER2 such as the peptide-based vaccine E75 which was shown
to stimulate cytotoxic T lymphocytes against the HER2 peptide to improve disease
free survival (DFS) and reduce tumor recurrence (Mittendorf et al., 2012).
Lapatinib. Lapatinib is a first generation small molecule tyrosine kinase
inhibitor (TKI) that dually targets HER2 and EGFR. Lapatinib is administered to
women with HER2+ breast cancer as a second line therapy. This is due to clinical
evidence showing that lapatinib is effective against HER2+ breast cancer that has
become resistant to trastuzumab (Scaltriti et al., 2010). Mechanistically, lapatinib
is an ATP mimicking molecule that competitively blocks binding of ATP in the
kinase pocket of HER2 or EGFR. Lapatinib is more effective than trastuzumab at
attenuating both the PI3K/Akt and MAPK/ERK1/2 pathways in vivo (Xia et al.,
2002). One important advantage of lapatinib over trastuzumab is its ability to cross
the blood-brain barrier to inhibit or treat brain metastases in women with metastatic
HER2+ breast cancer (Gril et al., 2008). Combined trastuzumab and lapatinib
treatment improves overall survival of women with trastuzumab resistant,
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metastatic HER2+ breast cancer compared to lapatinib alone (Blackwell et al.,
2012)

suggesting

that

trastuzumab

and

lapatinib

have

complementary

mechanisms of action. Surprisingly, lapatinib alone (Piccart-Gebhart et al., 2014)
or combined lapatinib and trastuzumab (Gelmon et al., 2012) was unable to extend
DFS. One major problem with lapatinib is its poor bioavailability and thus lapatinib
requires high doses to achieve optimal kinase inhibition. These high doses have
been shown to increase skin rash, gastrointestinal toxicity, and other side effects
making it difficult to achieve anti-tumor efficacy.
Pertuzumab. A new anti-HER2 antibody has been developed that targets
extracellular domain II of HER2 to inhibit HER2 heterodimerization with EGFR or
HER3 and therefore activation (Cho, et al., 2003). Pertuzumab is able to block
HER2:HER3 dimerization thus attenuating HER2 activation and has proven to be
effective in HER2+ breast cancer cell lines as well as in both high and low HER2
overexpressing breast tumor xenografts (Lee-Hoeflich et al., 2008). Combined
trastuzumab and pertuzumab treatment resulted in significant regression of
HER2+ breast tumor growth in vivo through blockade of HER2 dimerization and
decreased formation of the truncated HER2 that evades trastuzumab treatment,
p95HER2 (Scheuer et al., 2009). Currently, the combined trastuzumab plus
pertuzumab therapy is standard of care for HER2+ breast cancer. Additionally,
trastuzumab and pertuzumab combined with docetaxel for the treatment of
metastatic HER2+ breast cancer significantly improved pCR and prolonged DFS
in clinical trials (Baselga et al., 2014).
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Trastuzumab-emtansine. Trastuzumab-emtansine (T-DM1) is an antibodydrug conjugate in which cytotoxic emtansine is covalently linked to the trastuzumab
antibody. Emtansine (Mertansine, DM1) is a maytansinoid that disrupts
microtubule function by binding to tubulin resulting in cell cycle arrest of dividing
cells. T-DM1 binds to the HER2 receptor on the surface of the cell. HER2 bound
TDM-1 is internalized into the cytoplasm where emtansine is released from
trastuzumab via lysosomal enzymes (Erickson et al., 2006). Besides the site
directed anti-mitotic action of emtansine, T-DM1 retains trastuzumab mechanisms
of action such as induction of ADCC, inhibition of PI3K activation, and prevention
of p95HER2 truncation along with inhibiting growth of lapatinib resistant HER2+
breast cancer cell lines and tumor xenografts (Junttila et al., 2010b). TDM-1 is now
used in the clinic as a second line therapy for metastatic, HER2+ breast cancer
due to extending overall and progression free survival with less adverse side
effects in clinical studies (Verma et al., 2012).
Trastuzumab Resistance.
Unfortunately, cancers have become resistant to many types of therapies
that specifically target HER2 or effectors of HER2-mediated downstream
pathways. Resistance to targeted treatments leads to tumor recurrence and in
some cases a more aggressive, metastatic cancer that invades vital organs and
ultimately ends in death. Cancer cells can adapt to treatments using a variety of
mutations that enable them to propagate under specific treatment conditions.
Approximately 50% of women respond to the first course of trastuzumab treatment
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suggesting that inherent resistance occurs in the other 50% that have no response
to trastuzumab treatment. Roughly 40% of women with HER2+, metastatic breast
cancer are inherently resistant to trastuzumab treatment and worst of all, most
women who initially respond to trastuzumab treatment will develop acquired
resistance to trastuzumab within a year (Marty et al., 2005; Slamon et al., 2001).
Acquired resistance to trastuzumab leads to a more aggressive, recurrent tumor
that is difficult to treat. The prevalence of resistance to trastuzumab underscores
the need for more predictive biomarkers in addition to HER2 to accurately predict
the course of resistance.
Mechanisms of trastuzumab resistance. Changes in HER2 status. Women
can become insensitive to trastuzumab treatment due to changes in HER2
expression in tumors. Primary and metastatic tumors can lose HER2+ expression
status which is associated with a decrease in recurrence-free survival (Mittendorf
et al., 2009; Niikura et al., 2012). Conversely, an increase in HER2 expression
suggests that the tumor may be becoming more dependent on HER2 activity.
However, this is not always the case as resistant cells in culture can display
elevated levels of HER2 receptor expression and activation as measured by
increased HER2 phosphorylation and sustained proliferation under trastuzumab
treatment conditions (Ginestier et al., 2007a). Trastuzumab may inhibit HER2
signaling through endocytosis or degradation of the receptor but some studies
report that trastuzumab has no effect on HER2 receptor expression (Gennari et
al., 2004). Fluctuations in tumor HER2 status may call for continued assessment
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of HER2 expression throughout treatment in order to adjust and potentially improve
therapeutic regimens.
Impaired HER2-Trastuzumab interaction. Resistance to trastuzumab can
occur by masking of the HER2 receptor or disrupting trastuzumab binding. One
such mechanism of HER2 alteration to evade trastuzumab occurs through
expression of a HER2 splice variant, Δ16HER2. The Δ16HER2 splice variant is
generated by exon 16 skipping of the HER2 gene resulting in a conformational
change of the HER2 receptor that promotes stable HER2 homodimerization.
Ectopic expression of the Δ16HER2 variant in vitro increased cell invasion,
receptor dimerization, and trastuzumab resistance-mediated through direct
interaction of Δ16HER2 to Src kinase (Mitra et al., 2009). Increased expression of
Δ16HER2 in an in vivo mouse model as well as in patient samples correlated with
increased tumorigenesis. Interestingly, the expression of the Δ16HER2 variant
increased sensitivity to trastuzumab treatment compared to wild type HER2
(Castagnoli et al., 2014). Given that expression of the Δ16HER2, as well as other
HER2 splice variants such as Herstatin and p100, correlate to increased
trastuzumab efficacy, detection of these variants could potentially change
treatment options for women with HER2+ breast cancer.
An NH2 terminally-truncated form of the HER2 receptor, p95HER2, lacks
extracellular subdomain IV resulting in resistance to trastuzumab treatment
(Molina et al., 2001). The p95HER2 protein can be generated two ways. One is by
proteolytic cleavage of the HER2 ectodomain (HER2 ECD) by a matrix
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metalloproteinase which is referred to as ectodomain shedding. HER2 shedding
releases a portion of the HER2 ECD into the blood. HER2 ECD can be measured
in patient serum and elevated HER2 ECD has been associated with poor
prognosis and reduced response to both endocrine and chemotherapy in
metastatic breast cancer (Colomer et al., 2000; Leitzel et al., 1995). Alternatively,
p95HER2 can be expressed endogenously by an alternative translation initiation
site on the HER2 mRNA which produces a 100-115 kDa size p95HER2 protein
that is smaller than the wild type HER2 protein of 185 kDa. This p95HER2 protein
is also referred to carboxyl terminal fragment (611CTF). The truncated form of the
HER2 receptor is able to constitutively homodimerize and is considered a potent
oncogene (Pedersen et al., 2009). Increased expression of p95HER2 is associated
with worse overall patient outcome and importantly, trastuzumab resistance
(Scaltriti et al., 2007). However, expression of p95HER2 in patient derived tumor
xenografts and cell lines showed an increased sensitivity to chemotherapies such
as doxorubicin. This increased sensitivity to chemotherapy also increased
sensitivity to trastuzumab treatment (Parra-Palau et al., 2014). It is hypothesized
that the doxorubicin treatment may have stabilized the HER2 protein in the cell
membrane thereby increasing its sensitivity to trastuzumab treatment.
The HER2 receptor can be shielded from trastuzumab binding by interacting
with other proteins to confer trastuzumab resistance. Mucin-4 (MUC4) is a high
molecular weight membrane associated glycoprotein that has been shown to
interact with and activate the HER2 receptor. MUC4 overexpression inhibits

32
trastuzumab binding to HER2 yet has no effect on the level of HER2 expression
(Price-Schiavi et al., 2002). MUC4 levels were shown to be elevated in a
trastuzumab resistant cell lines as well as reduce trastuzumab binding compared
to a trastuzumab sensitive cell line, JIMT-1. The resistance phenotype was shown
to be reversible by MUC4 inhibition (Nagy et al., 2005). MUC4 was also shown to
disrupt HER2 interaction with other HER receptors, HER3 and EGFR.
Upregulation of MUC4 in a ER+/HER2+ tumor xenograft model resulted in
resistance to anti-HER2 therapies, trastuzumab and lapatinib, as well as antiestrogen therapies, tamoxifen and estrogen deprivation (Chen et al., 2012).
Interestingly, these tumors shifted their dependence from ER/PR expression to
HER2 upon MUC4 upregulation. Trastuzumab resistance has also shown to be
induced by increased expression of the MUC1 cleavage product, MUC1*. Both
acquired and intrinsic trastuzumab resistance as well as chemotherapeutic
resistance were reversed by MUC1* inhibition using a MUC1* antagonist (Fessler
et al., 2009). These results suggest that the mucin family of glycoproteins may be
heavily involved in trastuzumab resistance and could serve as potential markers
of resistance.
Augmented signaling through the HER receptor family. HER2 can
escape the effects of targeted trastuzumab treatment through activation of other
members of the EGFR/HER family of receptors. Trastuzumab-mediated growth
inhibition in BT474 and SkBr3 cells can be modulated by expression of the EGFR
receptor as well as the heregulin or EGF ligand (Diermeier et al., 2005).
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Trastuzumab resistant BT474 cells were shown to have increased EGFR
expression as well as an elevated EGFR:HER2 heterodimerization suggesting that
targeting of EGFR in HER2+ breast cancers may be a viable therapeutic option for
some women (Ritter et al., 2007). Upregulation of EGFR expression was observed
in 15% of HER2+, metastatic breast cancers and associated with worse overall
survival in these women who received trastuzumab treatment (Gallardo et al.,
2012). Targeting EGFR with the TKI gefitinib reduced HER2 activation and HER2mediated cell proliferation in vitro (Moulder et al., 2001), yet trastuzumab combined
with gefitinib failed to provide any clinical benefit to women with HER2+, metastatic
breast cancer (Arteaga et al., 2008). Similar results were seen with the EGFR
selective TKI, erlotinib (Dickler et al., 2008), yet the combination of gefitinib,
trastuzumab, and docetaxel did improve progression free survival in some women
(Somlo et al., 2012).
Trastuzumab has demonstrated the ability to inhibit the formation of HER2
homodimers as well as the potent, oncogenic HER2:HER3 heterodimers (Ghosh
et al., 2011; Junttila et al., 2009). Yet, Akt signaling can be activated in a
compensatory manner by ligand stimulated HER2:HER3 heterodimers allowing
evasion of HER2 targeted trastuzumab treatment. Attenuation of Akt signaling
through inhibition of PI3K resulted in an increase in HER3 expression which
amplified ERK1/2 activation in a compensatory manner. These data suggest that
compensatory signaling in HER2+ cells may be overcome by dual targeting of
HER2 or MEK and PI3K/Akt (Serra et al., 2011). High HER3 expression in women
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with HER2+, metastatic breast cancer who received trastuzumab treatment was
associated with shorter overall survival (Lipton et al., 2013) as well as shorter
progression-free survival post trastuzumab and taxane treatment (Park et al.,
2014).
HER4 has been shown to play opposing roles in trastuzumab resistance.
The fact that HER4 has 4 different splice variants may be the reason why its role
in HER2+ breast cancer has been difficult to understand. Among the 4 variants,
the JM-a/CYT1 and JM-a/CYT2 were associated with better event free survival in
women with ER+ and HER2+ breast cancer (Machleidt et al., 2013). Localization
of HER4 appears pertinent to its activity as cytoplasmic HER4 has been associated
with increased survival while nuclear HER4 has been associated with trastuzumab
resistance and may be a poor prognostic indicator for women with HER2+ breast
cancer (Mohd Nafi et al., 2014). Interestingly, trastuzumab treatment was shown
to promote upregulation of HER4, its cleavage, and nuclear translocation,
suggesting that HER4 localization may be a potential therapeutic predictor of
trastuzumab resistance.
Trastuzumab sensitivity can be affected by endogenous inhibitors of HER2
such as mitogen-inducible gene 6 (MIG-6) [also known as ERBB receptor
feedback inhibitor 1 (ERRFI1) or receptor-associated late transducer (RALT)].
MIG-6 is a cytoplasmic protein that is upregulated during cell growth, specifically
during the G1 phase of the cell cycle. MIG-6 has been shown to interact with and
inhibit HER2 and EGFR activation enabling MIG-6 activity to counteract
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EGFR/HER ligand-mediated trastuzumab resistance (Anastasi et al., 2005;
Fiorentino et al., 2000).
Increased expression of EGFR/HER ligands such as heregulin-1 (Hrg-1)
have been shown to confer resistance to cancer therapies. A subset of women
with HER2low/HER2- breast cancer have displayed clinical benefit from
trastuzumab treatment (Paik et al., 2008). These clinical data spurred the work that
demonstrated that HER2:HER3 activation through Hrg-1 promotes BCSC survival
and self-renewal in HER2- low expressing cells in vitro and in vivo (Lee et al.,
2013). BCSC from low HER2 expressing cells secreted Hrg-1 to form a positive
feedback loop in which Hrg-1 activated HER3/HER4 dimers in BCSCs. Similar
results were seen in head and neck cancer (Wilson et al., 2011) and melanoma in
which Notch-1 was shown to directly activate transcription of Hrg-1 to perpetuate
the autocrine feedback loop and progress cancer cell growth (Zhang et al., 2012).
HER2 interaction with other receptors. Trastuzumab resistance has been
shown to be facilitated by the interaction of HER2 with other non-HER receptors.
Trastuzumab resistant cell lines have displayed overexpression of the RTK, Ephrin
type-A receptor 2 (EphA2). Inhibition of EphA2 in vivo increased sensitivity to
trastuzumab treatment as elevated EphA2 expression correlated with worse
overall survival in women with HER2+ breast cancer (Zhuang et al., 2010). Another
RTK commonly overexpressed in HER2+ breast cancer is the c-Met receptor.
Trastuzumab treatment in vitro resulted in a rapid upregulation of c-Met which
contributes to trastuzumab resistance as inhibition of c-Met sensitizes cells to
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trastuzumab treatment (Shattuck et al., 2008). Interestingly, the accelerated upregulation of c-Met by trastuzumab treatment results in resistance to trastuzumab.
Increased expression of c-Met and its ligand, HGF, in HER2+, metastatic breast
cancer correlates with failure of trastuzumab treatment as well as shorter time to
cancer progression (Minuti et al., 2012).
HER2 has been shown to interact with growth factor receptors such as the
insulin-like growth factor 1 receptor (IGF-1R) to promote trastuzumab resistance
(Nahta et al., 2005). IGF-1R activation by its ligand, IGF-1, results in increased
HER2 phosphorylation and activation of Akt and MAPK pathways in trastuzumab
resistant cells compared to sensitive. IGF-1-mediated stimulation of IGF-1R is
more prevalent in trastuzumab resistant cells and can promote downregulation of
p27Kip1. The p27Kip1 protein is a cyclin dependent kinase (CDK) inhibitor that binds
to CDKs to prevent CDK/Cyclin formation that is necessary for cell division. An
increase in p27Kip1 activity stops cell cycle progression and results in the cell
remaining in the G1 phase of the cell cycle. HER2 is able to heterodimerize with
IGF-1R. Overexpression of IGF-1R amplifies trastuzumab resistance and
correlates with shorter progression-free survival and increased probability of
residual disease in women who received adjuvant trastuzumab treatment.
Overexpression of IGF-1R was induced by epigenetic silencing of miR-375
expression, a known regulator of IGF-1R expression. The re-expression of miR375 could be a potential method to re-sensitize HER2+ breast cancers to
trastuzumab (Ye et al., 2014).
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Adipose tissue is a major component of the breast. In adipose tissue, it has
been shown that adipocytes can secrete macrophage inhibitory cytokine 1 (MIC1), also known as growth differentiation factor 15 (GDF15), to reduce trastuzumab
sensitivity (Ding et al., 2009). MIC-1 is related to TGF-β and can promote HER2
phosphorylation through Src as well as trastuzumab resistance. Inhibition of MIC1, TGF-β, or Src restores trastuzumab sensitivity in resistant cells indicating that
MIC-1 mediates TGF-β/Src crosstalk to evade trastuzumab treatment (Joshi et al.,
2011).
PIK3CA mutations in trastuzumab resistance. The most common
pathway attributed to promoting drug resistance is the PI3K/Akt pathway. Elevated
PI3K/Akt pathway activity has been identified as the source of resistance to
targeting the HER2 pathway (Berns et al., 2007). Akt activity can be increased by
expression of PIK3CA mutations, downregulation of PTEN, HER3 and HER2
overexpression, Akt-1 mutations, and loss of inositol polyphosphate-4phosphatase type 2 (INPPB) expression. Activation of the Akt pathway results in
resistance to apoptosis as well as increased cell migration, invasion, and survival.
In approximately 50% of HER2+ breast cancer cases, Akt signaling is
activated by expression of PIK3CA mutations or loss of PTEN expression (Jensen
et al., 2011). PIK3CA mutations confer trastuzumab resistance in vitro and in vivo
(Cizkova et al., 2012; Dave et al., 2010; Razis et al., 2011) and have proven to be
key biomarkers, and potential predictors, of trastuzumab resistance. PIK3CA
mutations were associated with lower rates of pCR in several clinical trials using
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lapatinib, trastuzumab, or combined neoadjuvant trastuzumab and lapatinib
treatment, yet no difference was observed in overall patient survival (Majewski et
al., 2015). Assessment of PIK3CA mutations in primary tumors predicted a worse
clinical outcome for women with the PIK3CA mutation in the CLEOPATRA study
which assessed pertuzumab, trastuzumab, and docetaxel treatment of HER2+,
metastatic breast cancer but failed to predict for resistance to trastuzumab
treatment (Baselga et al., 2014). As a potential biomarker, PIK3CA mutations were
found to be positively associated with survival but not with trastuzumab treatment
response (Loi et al., 2013; Pogue-Geile et al., 2015). These data indicate that the
role of the PIK3CA mutations in HER2+ breast cancer is not straightforward and
continued investigation is warranted.
Role of apoptotic and cell cycle regulators in trastuzumab resistance.
Cells can control their proliferation rate through cell cycle arrest leading to cell
quiescence and potentially programmed cell death or apoptosis. Cell cycle arrest
can be mediated by stabilization of CDK inhibitors such as p27Kip1. Trastuzumab
treatment of sensitive cells reduces Akt pathway activity and upregulates p27 Kip1
resulting in subsequent cell cycle arrest (Yakes et al., 2002). Conversely,
trastuzumab resistant cells express less p27Kip1 protein as well as CDK2 which
promotes an increased rate of cell cycle progression and proliferation (Nahta et
al., 2004). Similarly, trastuzumab resistant cells display higher expression of cyclin
E compared to trastuzumab sensitive cells (Scaltriti et al., 2011). Elevated cyclin
E expression is associated with shorter progression-free survival as well as

39
reduced clinical benefit from trastuzumab treatment compared to women whose
tumors express low levels of cyclin E. Interestingly, inhibition of CDK4/6 has no
effect on cyclin E overexpression, hence tumors with heightened cyclin E
expression may be resistant to CDK4/6 and HER2 targeted therapies. The p27Kip1
protein is positively regulated by phosphorylation. The protein phosphatase
PPM1H, encoded by the PPM1H gene, dephosphorylates serine/threonine
residues and is able to dephosphorylate p27Kip1 leading to protein degradation and
reversal of cell cycle inhibition. Inhibition of PPM1H resulted in increased
proliferation of HER2+ cells in response to trastuzumab treatment. Importantly, low
PPH1M expression correlates with worse patient outcome (Lee-Hoeflich et al.,
2011). These data suggest that p27Kip1 may be a marker of trastuzumab resistance
and its re-expression may re-sensitive resistant cells to trastuzumab treatment.
Acquired trastuzumab resistant BT474 (BT474TR) cells display an increase
in B-cell lymphoma 2 (Bcl-2), an anti-apoptotic protein. BT474TR cells have shown
sensitivity to the Bcl-2 inhibitor, ABT-737, compared to trastuzumab sensitive
(BT474TS) cells. Combined treatment of resistant cells with trastuzumab and ABT737 reduced cell proliferation. Bcl-2 activity was found to be mediated through
PI3K/Akt and IKK/NFκB activity (Crawford and Nahta, 2011). Inhibition of both
PI3K and IKK promoted downregulation of Bcl-2 thereby increasing sensitivity to
trastuzumab treatment in the BT474TR cell model.
In culture, trastuzumab resistant cells were found to overexpress cyclin D1
which activates cyclin dependent kinase 4 and 6 (CDK4/6) through MAPK and Akt
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pathway activity. Elevated cyclin D1 results in an increase in CDK-mediated
phosphorylation of cyclins to promote cell cycle progression and increase cell
proliferation. Inhibition of cyclin D1 reduced HER2-driven breast tumorigenesis in
vivo when MMTV-Neu (HER2) mice were crossed with cyclin D1-/- mice. (Choi et
al., 2012; Yu et al., 2001). CDK4/6 inhibition was shown to reduce resistant cell
proliferation in vitro (Roberts et al., 2012) and tumorigenesis in vivo (Witkiewicz et
al., 2014). Lapatinib has been shown to inhibit CDK4/6 and this may be one of the
reasons it has an additive effect on cell growth inhibition when combined with
trastuzumab treatment in HER2+ breast cancer.
Role of hormone receptors in trastuzumab resistance. Resistance to
trastuzumab treatment in ER+/HER2+ breast cancers may occur through an
escape route offered by ER activity (Giuliano et al., 2015). Conversely, HER2
activity can reduce sensitivity to anti-hormonal treatments as ER+/HER2+ tumors
have displayed resistance to endocrine therapy. The inverse relationship between
ER and HER2 is mediated through a number of different bi-directional crosstalk
mechanisms (Konecny et al., 2003). HER2 inhibition enables ER-mediated
upregulation of HER signaling through increased expression of IGF-1 and TNFα
ligands. ER can inhibit EGFR and HER2 as well as upregulate IGF-1R as a
compensatory mechanism to evade the HER2 blockade. The inverse relationship
between HER2 and ER suggests that targeting of both receptors may be
necessary to suppress ER+/HER2+ tumorigenesis. The combined use of
trastuzumab and anastrozole, an AI, with chemotherapy increased progression-
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free survival compared to anastrozole alone (Kaufman et al., 2009). Increased ER
activity has been associated with trastuzumab resistance in women with
ER+/HER2+, metastatic breast cancer that received trastuzumab combined with
chemotherapy. Interestingly, the addition of endocrine therapy post chemotherapy
was shown to increase progression-free survival indicating that tumors can retain
responsiveness to estrogen (Montemurro et al., 2012). These data suggest that
the role of ER is to promote trastuzumab resistance in women with ER+/HER2+
tumors and careful consideration of treatment options must be made to avoid
treatment resistance.
Role of microRNAs in trastuzumab resistance. MicroRNAs (miRNAs) are
small, non-coding RNAs that regulate protein translation. Similar to silencing RNAs
(siRNAs), microRNAs form base pairs with complementary mRNA to silence
mRNA translation into a protein. Post transcriptional regulation by miRNAs can
occur by: binding to the 3’ untranslated region (3’UTR) of mRNA causing truncation
of the poly(A) tail and destabilization of mRNA, cleavage of the mRNA, or blocking
ribosome binding to inhibit mRNA translation. Continued analysis of breast cancers
by microarray expression profiles attempts to better assess potential promoters of
breast cancer as well as future treatment options. Trastuzumab resistant, HER2+
cell lines have displayed upregulation of miR-21 which has been shown to reduce
PTEN protein expression in liver cancer as well as programmed cell death 4
(PDCD4) in colorectal and breast cancer cells (Talotta et al., 2008). Inhibition of
miR-21 increased PTEN expression both in vitro and in vivo resulting in reduce
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cell proliferation as well as increased sensitivity to trastuzumab treatment (Gong
et al., 2011). In BT474TR cells, miR-210 expression was higher compared to
BT474TS cells and increased circulating levels of miR-210 in women with HER2+
breast cancer were found to be associated with lower response to trastuzumab
treatment and increased lymph node metastases (Jung et al., 2012). Trastuzumab
treatment was found to induce miR-30b and miR-26a expression in HER2+ cell
lines, SkBr3 and BT474. miR-30b promotes G1 cell cycle arrest, apoptosis, as well
as reduce cyclin E2 protein expression (Ichikawa et al., 2012). These data suggest
that miRNA expression could provide important clues as to why some HER2+
breast cancers become resistant to trastuzumab.
Biomarkers of Trastuzumab Resistance.
A number of clinical trials have been done to identify potential markers of
anti-HER2 targeted resistance. Some of these trials include: NEO-ALTTO,
CLEOPATRA, TRYPHAENA, Neo-Sphere, and EMILIA to name a few. These
studies consistently show that HER2 expression is currently the only marker
appropriate for selecting patients for anti-HER2 therapy (Baselga et al., 2014;
Gianni et al., 2016; Schneeweiss et al., 2014). Nonetheless, previous markers
such as: HER2/IGF-1R heterodimerization, Src activation, low PTEN, and
increased p95HER2 expression were not consistently associated with overall or
disease-free patient survival. Poor patient prognosis, and not necessarily
trastuzumab resistance, was commonly associated with the presence of PIK3CA
mutations (Berns et al., 2007). These data indicate that today, the only biomarker
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suitable for determining anti-HER2 treatment is gene amplification and
overexpression of HER2 in breast cancer.
Stem Cells and the Cancer Stem Cell Hypothesis.
Stem cells (SCs) are characterized by their ability to self-renew into
undifferentiated stem cells and differentiate into specialized cells that can generate
or regenerate tissue. There are two general types of stem cells: embryonic and
adult stem cells. Embryonic SCs are retained in the inner mass of the blastocyst
where they are able to differentiate into the three primordial germ layers: the
ectoderm, endoderm, and mesoderm. Adult SCs are retained in various tissues
throughout the body where they act as a repair system to maintain the body. Adult
SCs are also critical for maintaining regenerative cells which can be found
throughout the adult body in locations such as the bone marrow (periosteum),
intestinal lining, or skin (epithelium) (Reviewed in Rumman et al., 2015). Adult SCs
can be used for stem cell therapies such as bone marrow therapy in which donor
adult SCs are extracted from the bone marrow or peripheral blood and used to
rebuild a cancer patient’s ablated immune system. SCs can be harvested from
previously collected umbilical cord blood for stem cell therapies. The continued
development of stem cell therapies has driven the creation of stem cells from
terminally differentiated somatic cells (dedifferentiation) or by nuclear transfer of
an oocyte nucleus into a terminally differentiated somatic cell. A majority of stem
cell work has been done in mice in which it has been shown that one multipotent
mammary stem cell is capable of regenerating the entire murine mammary gland
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in vivo (Shackleton et al., 2006). Cancer cells with stem like characteristics were
first discovered in human acute myeloid leukemia (Bonnet and Dick, 1997) then in
breast cancer (Al-Hajj et al., 2003) which laid the ground work to propose the
cancer stem cell hypothesis.
The cancer stem cell hypothesis challenges the traditional concept of
cancer development. Traditionally, the clonal evolution, or the stochastic model, of
cancer hypothesizes that cancer develops from normal, somatic cells through an
accumulation of mutations throughout the life time of the cell. These mutations give
the cell a selective growth advantage over healthy cells enabling them to grow
uncontrollably, invade neighboring tissues, become metastatic, resistant to
treatments, and contribute to cancer recurrence. The acquisition of mutations
creates a clonal subset of cancer cells in which any cancer cell can self-renew to
produce the number of different cells within a tumor. Support for the clonal
evolution model in breast cancer is exemplified by the most common mutation in
breast cancer, the PIK3CAH1047R mutation (Koren et al., 2015). The PIK3CAH1047R
mutation is able to induce cell dedifferentiation into a multipotent stem-like state
which may be involved in the formation of multi-lineage, heterogeneous breast
tumors.
The cancer stem cell hypothesis considers a small subset of stem cell-like
cancer cells [also referred to as tumor initiating cells (TICs)] that are at the top of
the cancer cell hierarchy. The CSCs are able to self-renew to create more
undifferentiated CSCs as well as differentiate into the various bulk cells that
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comprise a tumor. The ability of a stem cell, or cancer stem cell, to differentiate
into one or many different cell types is referred to as potency, such as pluripotent
or multipotent cells. Hypothetically, a single cancer stem cell can create all the
cells required for the construction of a complete, heterogeneous tumor, much like
a single totipotent stem cell can create an entire organ. Similarly, to stem cells,
CSCs have shown reliance on the microenvironment as interactions with stromal
or inflammatory cells can regulate their self-renewal or differentiation capabilities.
The origin of CSCs remains contested as it is hypothesized that CSCs arise from
transformed adult SCs or by lineage committed cells acquiring mutations resulting
in dedifferentiation into CSCs. Though the two cancer models are considered
mutually exclusive, as each fails to sufficiently address tumor heterogeneity, it is
possible that the genetic and cancer stem cell models coincide by CSCs acquiring
driver mutations during tumor progression (Reviewed in Kreso and Dick, 2014).
An increase in CSC mutational burden may enhance CSC properties and result in
enrichment of the CSC population residing within a tumor. In a heavily CSC
populated tumor, tumor functionality becomes homogenous as a majority of the
CSCs self-renew and few differentiate into progenitor cells.
CSC properties and BCSCs. Upon the discovery of cancer cells with stem cell
characteristics, a lot of work has gone into discerning the phenotype of these cells
and their role in tumor invasiveness, metastasis, therapeutic resistance, and
recurrence. There are two types of cancer stem cells, the epithelial-like and
mesenchymal-like CSCs (Liu et al., 2014). The mesenchymal-like CSCs are
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primarily quiescent and at the invasive tumor front. In the breast, these cells are
similar to basal stem cells found in the normal breast tissue that exist in the basal
layer (myoepithelial layer) of mammary ducts. The mesenchymal-like CSCs are
highly invasive yet largely non-proliferative. On the other hand, the proliferative
epithelial-like CSCs are primarily retained in the hypoxic zones at the center of a
solid tumor. This SC type has the multilineage capacity to differentiate into a wide
variety of cells to construct a heterogenic tumor. Epithelial-like BCSCs are similar
to luminal stem cells and can be found below luminal cells of mammary lobules. It
is important to note the plasticity of these two stem cell types as the mesenchymallike CSCs can transition to epithelial-like CSCs by undergoing mesenchymal to
epithelial transition (MET), Conversely epithelial-like CSCs can become
mesenchymal-like CSCs via epithelial to mesenchymal transition (EMT). The
ability of the CSCs to shift between epithelial and mesenchymal states perpetuates
their ability to promote an aggressive cancer phenotype. Remarkably, both
epithelial and mesenchymal-like BCSCs have similar GEPs across various breast
cancer subtypes. CSCs have been shown to transdifferentiate into endothelial and
vascular smooth muscle-like cells for improved tumor vascularization. Additionally,
women whose tumors have high levels of CSC markers have poorer overall
survival and these CSC markers may be used as prognostic factors for breast
cancer progression in the clinic (Zhou et al., 2010).
Transit amplifying cells (TACs) differentiate from stem cells that have not
completely transformed into specialized, terminally differentiated cells, hence the
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state of TACs is between that of undifferentiated stem cells and terminally
differentiated cells (Figure 5). TACs are highly proliferative yet short lived cells
whose progeny differentiate into the various lineages of mature cells necessary to
form a complete organ. Due to their high proliferation rate, TACs typically represent
a greater portion of the cell population compared to stem cells. The limited
proliferative nature of TACs can promote the accumulation of mutations, but these
are usually repaired within the cell offspring. It is possible that some mutations
remain in the TACs, resulting in dedifferentiation of this mutated TAC subset,
thereby allowing these mutations to enter the SC population. Similarly, mutations
retained by the TAC progeny may occur, in which they are more likely to transform
into cancerous cells. Therefore, targeting TACs may be a viable option to reduce
or prevent the initiation of tumorigenesis, in an effort to intercept the transition from
the mutated TAC to mutated SC and eventually into a CSC.
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Figure 5: Breast Cancer Stem Cell Self-Renewal and Differentiation
Pathways
The tightly regulated process of BCSC self-renewal and differentiation into transit
amplifying cells (TACs) then terminally differentiated cells can become
dysregulated in breast cancer. Loss of PTEN or upregulation of Notch or HER2
receptors can result in an increase in the BCSC population which is hypothesized
to promote drug resistance, metastasis, and the generation of new, heterogeneous
tumors.
Breast cancer cells with stem cell characteristics were first found in breast
cancer patient samples by Al-Hajj et al. (Al-Hajj et al., 2003). Breast cancer cells
with similar surface markers as multiprogenitor mammary stem cells [MaSCs
(CD44+/CD24-/Low/Lin-)] may originate from BCSCs. As few as 100 breast cancer
stem-like cells were able to form tumors in immune compromised mice while up to
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50,000 non cancer stem-like cells (CD44+/CD24+/Lin-) failed to form tumors. The
discovery of BCSCs opens the door to further investigate the role of BCSCs in
breast cancer.
BCSC markers. The first BCSCs were defined by their tumorigenicity in vivo
using models of mouse BCSC tumor xenografts and in vitro by colony formation,
sphere formation, migration, and invasion assays (Al-Hajj et al., 2003). These
assays allow serial dilution of BCSCs to determine the ability of a logarithmically
increasing amount of BCSCs, or non-BCSCs, to form tumors or display BCSC
properties. Initially, BCSCs were isolated from patient samples by flow cytometry.
Cell surface expression of CD44+/CD24-/low was the most common BCSC marker
within patient samples. This subset of cells was used in BCSC colony forming
assays and in an immunodeficient mouse model to determine tumorigenicity of
serial diluted (100 to 50,000) BCSC and non-BCSC populations. CD44 (Cluster of
differentiation 44) is a receptor for hyaluronic acid and is involved in cell to cell and
cell to extracellular Membrane (ECM) interactions. CD24 is a small glycoprotein
that negatively regulates the chemokine receptor CXCR4, which has been shown
to regulate metastasis of breast cancer cells (Schabath et al., 2006). To confirm
that tumor cells were being selected, Lineage- (Lin-) enabled selection of neoplastic
tumor cells from normal cell type lineage markers (CD2, 3, 10, 16, 18, 31, 64, and
104b). Cells were also selected by epithelial specific antigen (ESA +) expression,
or epithelial cell adhesion molecule (EpCAM), which is expressed on the surface
of most epithelial cells and is used to distinguish epithelial cancer cells from
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mesothelial cells (Al-Hajj et al., 2003). Establishment of the CD44+/CD24-/low
surface expression is now a common marker for epithelial BCSC as well as a poor
prognostic factor for women with early stage breast cancer (Buess et al., 2009).
Further research into the CD44+/CD24-/low BCSC marker found that its expression
does not always correlate with tumorigenicity (Fillmore and Kuperwasser, 2008)
and women with the opposite CD44-/CD24+ status had a worse breast cancer
prognosis (Ahmed et al., 2012).
Infrequencies with the use of CD44+/CD24-/low as a marker of BCSCs has
initiated the search for other BCSC markers. BCSCs have been shown to express
aldehyde dehydrogenase 1 (ALDH1), an enzyme that catalyzes the oxidation of
toxic aldehydes into inert carboxylic acids. ALDH1 can be fluorescently tagged and
used as a stem cell marker in breast cancer (Ginestier et al., 2007b). ALDH
expression is a good marker of epithelial BCSCs as they have been shown to
express ALDH (Liu et al., 2014). CD133 (Prominin 1) expression was found to be
similar to CD44+/CD24-/low expression in cells derived from BRCA-1 knockout mice
as a marker of BCSCs (Wright et al., 2008). CD44+/CD24-/low as well as increased
vimentin (Borgna et al., 2012), and IL-1/prostaglandin E2 (Li et al., 2012)
expression have been developed as markers of mesenchymal stem cells in breast
cancer. BCSC markers continue to be found which include integrin markers: CD29,
CD61 (Vaillant et al., 2008), CD49f (Cariati et al., 2008); a mucin family marker,
MUC1 (Engelmann et al., 2008); as well as the Delta ligand from the Notch family
of receptors, DLL1 (Pece et al., 2010). Other markers of BCSCs continue to be
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found and verified both in vitro and in vivo and can vary greatly between breast
cancer subtypes. The discovery of multiple markers of BCSCs strongly suggests
that BCSCs are heterogeneous and their diversity may be the main reason that
breast cancers are intrinsically heterogeneous. None the less, the most relevant
markers of BCSC still need to be identified for incorporation into the breast cancer
treatment strategy.
Role of BCSCs in metastasis. Metastasis of breast cancer to vital organs is
one of the major contributors to breast cancer-associated mortality. There remains
no targeted therapeutic approach for the treatment of metastatic breast cancer
outside of chemotherapy. Metastasis may be mediated by a small set of BCSCs
from the primary tumor that can invade and migrate to distal vital organs to form
secondary tumors. BCSC-mediated metastasis has been demonstrated in several
studies. Genetic expression profiling of CD44+/CD24-/Low isolated cells from
primary tumors was found to be similar to metastatic breast cancer cells isolated
from the distant organs and in tumors from women with worse overall outcome (Liu
et al., 2007). Early metastatic cancer cells found in the bone marrow of breast
cancer patients expressed a CD44+/CD24-/Low profile (Balic et al., 2006).
Additionally, ALDH positive cells displayed greater metastatic capacity compared
to ALDH negative cells in a xenograft mouse model (Charafe-Jauffret et al., 2009).
Combined, these studies underline the importance of BCSCs in promoting
metastasis in breast cancer.
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The role of BCSCs in EMT / MET. Epithelial to mesenchymal as well as
mesenchymal to epithelial transition are fundamental processes in early
embryogenic morphogenesis and are proposed to be critical regulators of tumor
metastasis. Epithelial cells convert to mesenchymal cells (EMT) and mesenchymal
cells re-convert to epithelial cells (MET) to promote secondary tumor growth at
distal sites away from the primary tumor. EMT occurs by epithelial cells losing their
epithelial characteristics: cell to cell adhesion and apical-basolateral polarity, to
take on mesenchymal cell characteristics: spindle shape and motility (Mani et al.,
2008; Morel et al., 2008). Cells undergoing EMT downregulate epithelial cell
markers such as E-cadherin and lose occludins, adherins, and/or tight junctions.
During EMT, the epithelial cell upregulates mesenchymal cell markers: NCadherin, vimentin, and fibronectin, as well as transcription factors: SNAIL, SLUG,
ZEB1, ZEB2, TWIST 1 and TWIST2 (Reviewed in Thiery et al., 2002). The
transcription factors inhibit E-Cadherin, specifically claudins, and Zonula
Occludens 1 [(ZO1) a tight junction protein], Platelet-Derived Growth Factor
(PDGF), Hepatocyte Growth Factor (HGF), Transforming Growth Factor β (TGFβ), or matrix metalloproteinase expression. EMT can be induced in vitro by over
expressing TWIST or SNAIL, or exposing the cells to growth factors such as EGF
or TGF-β (Morel et al., 2008).
Continued research on BCSCs makes it clear that this small subset of cells
can be generated through EMT to promote cancer progression. It is hypothesized
that BCSCs can become metastatic by undergoing EMT as it has been shown that
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CD44+/CD24- cells have an increase in EMT markers and the potential to invade
and migrate to distal organs. The constitutively active protein, AXL, in BCSCs
induces EMT by inhibiting E-Cadherin while upregulating N-Cadherin, Snail, Slug,
Zeb1, and fibronectin expression (Asiedu et al., 2013). AXL has also been shown
to regulate a number of pathways including STAT, Akt, NF-κB, and MAPK, which
may be pertinent to EMT. EMT can be induced in vitro by the increased activation
of the transcription factor, FOXC2, which has been shown to promote a more
aggressive cancer phenotype (Mani et al., 2007). EMT can be activated through
metadherin (MTDH)-mediated activation of Twist to induce the BCSC phenotype
(Liang et al., 2015). The more aggressive breast cancer subtypes (TNBC and
HER2+) have increased markers for BCSCs and EMT compared to less
aggressive subtypes (Luminal A) (Park et al., 2010b).
The two types of BCSCs, epithelial and mesenchymal, can be further
characterized by their expression of mesenchymal or epithelial cell markers (Liu et
al., 2014). Mesenchymal-like BCSCs are identified as having low E-cadherin and
high vimentin at the invasive edge of a tumor. The mesenchymal BCSCs are ready
to enter the blood or lymphatic circulation to form new, small tumors
(micrometastasis) at distant organ sites. The invasive mesenchymal BCSCs can
transition to more proliferative epithelial BCSCs (METs) to generate a secondary
tumor. The more proliferative epithelial BCSCs express high levels of E-cadherin
and low vimentin in the center of the tumor. The central epithelial BCSCs can
transition to the more invasive mesenchymal state on the outside of the tumor to
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promote metastatic formation of secondary tumors. The two BCSC states can
switch between invasive mesenchymal and proliferative epithelial to promote
tumor spread and growth, respectively. The transition between these two states
may be regulated by chemokine and cytokine signaling as the plasticity of the
BCSCs

enables

them

to

readily

metastasize

or

adapt

to

changing

microenvironment conditions.
BCSC maintenance and non-coding RNAs. BCSCs are able to transition
between stem-like and non-stem-like states. BCSC plasticity indicates that there
are regulatory mechanisms that are able to induce or maintain the stemness of
BCSCs. Stemness of BCSCs can be regulated through interactions with noncoding RNAs (ncRNAs), the tumor microenvironment, or fluctuations in cell
signaling pathways within the cell.
There are many types of ncRNAs including: long non-coding RNAs (lnc
RNAs), transfer RNAs (tRNAs), ribosomal RNAs (rRNAs), and miRNAs that are
not translated into a protein. ncRNAs have a wide variety of functions but here we
will focus on a set of ncRNAs associated with BCSC plasticity (Reviewed in Liu et
al., 2013). Expression of miRNAs are altered in BCSCs compared to bulk tumor
cells. Some miRNAs altered in BCSCs are the: miR-183 cluster, miR-200 cluster,
miR-221-222 cluster, miR-142, miR-214, and let-7. These miRNAs may target a
variety of pathways that are responsible for maintaining the stemness of BCSCs.
Assessment of the BCSC population can be tested in vitro by using mammosphere
forming assays in which BCSC survival and self-renewal are determined through
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primary and secondary mammosphere formation, respectively. It has been shown
that let-7a reduces both cell proliferation and mammosphere formation in a k-Rasdependent manner both in vitro and in vivo (Ma et al., 2015). The lncRNA,
Linc00617, induces stem cell properties in breast cancer cells by upregulating the
stem cell marker, Sox2 (Li et al., 2017). BCSC properties may be inhibited by
targeting ncRNAs as a possible therapeutic strategy.
Role

of

BCSCs

in

the

tumor

microenvironment.

The

tumor

microenvironment creates a “niche” that supports and maintains survival and selfrenewal capacity of CSCs. CSCs interact with a variety of cells in the tumor
microenvironment

such

as:

Tumor-associated

Macrophages

(TAMs),

Mesenchymal Stem Cells (MSCs), Cancer-Associated Fibroblasts (CAFs),
Extracellular Matrix (ECM), endothelial cells (ECs), and immune cells. CSC
interaction with other cells in the tumor microenvironment occurs through a
complex network of cytokine and growth factor expression. These ligands
stimulate CSC self-renewal, angiogenesis, as well as stromal and immune cell
recruitment into the CSC niche to perpetuate the production of additional factors
in order to promote tumor cell invasion and migration.
Hypoxic conditions can induce the CSC phenotype as well as enrich the
CSC population in various types of cancer. The BCSC population of TNBC cells,
MDA-MB-231, is enriched by hypoxia (Xie et al., 2016). Hypoxia has been shown
to enrich the BCSC population in primary epithelial and tumor cells (Iriondo et al.,
2015). ALDH+ BCSCs were shown to be dependent on Hypoxic-Inducible Factor
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1 alpha (HIF1α). Downregulation of prolyl hydroxylase 3 (PHD3) mimics hypoxic
conditions and was found to increase the CD44 +/CD24-/low population of BCSCs.
Hypoxic activation of HIF1α has been shown to upregulate embryonic stem cell
markers OCT4, SOX2, KLF4, NANOG, c-MYC, and microRNA-302 resulting in
expansion of the BCSC population (Mathieu et al., 2011). Hypoxia-mediated
enrichment of the BCSC population has been shown to be dependent on HIF1αmediated expression of AlkB Homolog 5 (ALKBH5) which stabilizes NANOG
mRNA thereby increasing NANOG protein expression (Zhang et al., 2016). The
hypoxic environment and hypoxia-induced pathways may be potential therapeutic
targets to prevent BCSC expansion.
Tumor cells can increase cytokine and growth factor production which has
been shown to stimulate CSC proliferation and survival as well as promote
recruitment of stromal and immune cells into the CSC niche. Enrichment of stromal
and immune cells into the CSC niche results in the secretion of additional growth
factors creating a positive feedback loop. This positive feedback loop between
CSCs and immune/stromal cells has been shown to increase tumor cell
metastasis. Autocrine or paracrine signals between BCSCs and stromal cells can
regulate BCSC phenotypes. In HER2-negative MCF-7 breast cancer cells, human
umbilical cord-derived MSCs stimulate Interleukin-6 (IL-6) and IL-8 autocrine
signaling which promotes the CD44+/CD24- BCSC population to migrate in vitro
and metastasize in vivo (Ma et al., 2015). TNBC cell lines, MDA-MB-231 and MDAMB-453, secrete IL-6 to activate OCT4 gene expression through an IL-6-JAK1-
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STAT3 signal transduction pathway in non-CSCs (Kim et al., 2013). The OCT4
transcription factor has been shown to promote dedifferentiation of non-CSCs into
CSCs. Primary breast CAFs and fibroblasts produce high levels of the chemokine
(C-C motif) ligand 2 (CCL2) to induce CSC self-renewal through upregulation of
Notch-1 (Tsuyada et al., 2012). BCSCs can be regulated though interactions
between endothelial cells and CD44+/CD24- cells. Tumor-endothelial cell
interactions can regulate BCSCs by establishing a feedback loop in which tumor
cells secrete endothelial stimulatory signals such as FGF12, VEGF, NF1, and PTN
causing endothelial cells to secrete PDGFB to promote cancer cell proliferation
(Buess et al., 2009). Cytokines and growth factors are critical to maintaining the
CSC population and require careful consideration when assessing the BCSC
environment.
A major cellular component of the breast tumor microenvironment is Tumor
Associated Macrophages (TAMs) which have been hypothesized to originate from
resident tissue macrophages or circulating monocytes to establish leukocyte
accumulation within the stroma of a tumor. The function of TAMs is debatable as
evidence has shown their involvement in tumor growth and metastasis by
stimulating angiogenesis as well as tumorostatic or tumoricidal processes (Bingle
et al., 2002). TAMs have been shown to promote a CSC-like phenotype through
paracrine EGFR/Stat3/Sox-2 signaling in murine breast cancer cells (Yang et al.,
2013). TAMs may play a critical role in BCSC maintenance as previous work has
demonstrated that an injection of TAMs with CSCs significantly amplifies tumor
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growth compared to the injection of CSCs cell alone. Increased TAM infiltration
around breast tumors correlates with increased tumor vascularization and a worse
overall prognosis for women with breast cancer (Leek et al., 1996). The
accumulation of CAFs, TAMs, stromal cells, and freshly produced blood vessels
at the tumor invasive front allow CAFs to secrete macrophage colony stimulating
factor (M-CSF) to activate TAM’s pro-angiogenic switch. The cellular milieu of the
CSC niche plays an important role in supporting the BCSC population.
T-cells can promote breast cancer when recruited into the tumor
microenvironment. TAMs and CD4+ T helper cells are able to secrete TNFα in
order to upregulate NF-κB signaling. This increase in NF-κB signaling stimulates
transcription of Snail, Slug, and Twist as well as increased crosstalk with the TGFβ pathway resulting in CSC maintenance and self-renewal (Reviewed in Smith et
al., 2012). Infiltration of FOXP3+ regulatory T cells and CD8+ cytotoxic T cells was
associated with high histological grade and steroid receptor negative status (Liu et
al., 2011). Elevated levels of CD4+ and CD8+ T cell infiltration are closely
correlated with EMT and the BCSC phenotype. Interestingly, infiltration of both T
cell types was also associated with the absence of residual invasive disease in the
breast or lymph nodes upon completion of neoadjuvant treatment (Seo et al.,
2013). Therefore, the presence of T cells in the tumor could be an early response
to therapy where the non-CSCs are targeted by the immune system but not
necessarily the CSCs.
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The ECM is critical in the niche of both normal and cancer stem cells as it
plays a multitude of roles in maintaining normal cell and stem cell properties. ECM
anchorage retains stem cells in the niche allowing them to be available to receive
critical paracrine signals necessary for maintaining stem cell properties. Cellular
differentiation processes can be obstructed by irregular changes in the ECM
resulting in enrichment of the stem cell population and a reduction in cell
differentiation (Reviewed in Lu et al., 2012). ECM stiffness in breast cancer can
promote transcriptional coactivator with PDZ-binding motif (TAZ) activity, resulting
in an increase in the BCSC population (Cordenonsi et al., 2011; Dupont et al.,
2011). These data suggest a possible role for the ECM in promoting BCSC selfrenewal resulting in breast cancer disease progression.
Role of BCSCs in HER2+ breast cancer. Treatment of HER2+ breast cancer
by biologics such as trastuzumab has greatly improved the clinical outcome of
women with tumors overexpressing the HER2 protein. Evidence has been
presented that shows a positive correlation between HER2 amplification and
BCSC frequency as assessed by ALDH1 expression (Korkaya et al., 2008) (Figure
5). Although the precise mechanism of trastuzumab’s actions remain unknown,
trastuzumab has been shown to reduce BCSC enrichment in trastuzumab
sensitive cells but not trastuzumab resistant cells in vitro (Magnifico et al., 2009).
Previous work has demonstrated that HER2 cooperates with c-Myc to promote a
stem-like phenotype and BCSC self-renewal (Nair et al., 2013a). The BCSC
population is enriched in cells that have developed acquired resistance to
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trastuzumab. The Akt pathway has been shown to be required for this enrichment
(Korkaya et al., 2008). Several markers for BCSCs have been found in HER2+
breast cancer cell lines and patient samples including: MUC1 + (Engelmann et al.,
2008), Vimentin+, CK18+, and GATA3+ (Park et al., 2010b) combined with CD24+
or CD44+ expression. It has been shown that inhibition of CXCR1 and 2
(CXCR1/2), which are regulated by IL-8, significantly reduces BCSC activity in
patient-derived HER2+ breast cancers (Singh et al., 2013). Trastuzumab may not
be inhibiting the BCSC population specifically but acting on the emerging TAC
population. Trastuzumab-mediated TAC inhibition may occur in resistant cells in
which trastuzumab inhibits CSC differentiation into TACs thereby increasing the
BCSC population. Another possibility is the occurrence of a mutation in the TAC
population promoted by prolonged trastuzumab treatment that results in TAC
dedifferentiation into BCSCs.
Role of BCSCs in treatment resistance. BCSCs have been shown to play a
role in drug resistance both in vitro and in vivo. TNBC BCSCs are enriched by
chemotherapy such as paclitaxel and thus are inherently resistant to this type of
therapy (Samanta et al., 2014). Therapy was shown to increase the BCSC
population in HER2+ breast cancer from patient biopsies post chemotherapy
and/or lapatinib treatment (Li et al., 2008). A number of BCSCs from different
breast cancer cell lines demonstrated resistance to radiotherapy (Phillips et al.,
2006). Additionally, the Wnt pathway has been shown to drive SOX2 gene
expression and increase the BCSC population to promote resistance to tamoxifen
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(Piva et al., 2013). Similarly, either letrozole or docetaxel treatment has been
shown to increase the BCSC population in patient tumor samples post therapy
(Creighton et al., 2009). Together, these data suggest that BCSCs have an intrinsic
resistance to some breast cancer treatments or their ability to be quiescence
enables the BCSC population to evade chemotherapy and/or radiotherapy.
Therefore, investigating novel therapies to target the BCSC population may prove
to be an effective strategy for the treatment of breast cancer.
The Notch Pathway.
The Notch receptor is a type 1, single pass, transmembrane protein (Kopan,
2009). The NOTCH1 gene is transcribed by the E26 transformation-specific (ETS)
family member, polymavirus enhancer activator 3 (PEA3) (Clementz et al., 2011)
in TNBC or by p53 in keratinocytes and epithelial cells (Lefort et al., 2007).
Furthermore, E2A (E-proteins E12 and E47) in conjunction with Notch-1 induce
NOTCH1 gene expression in the early stages of T cell development (YashiroOhtani et al., 2009), indicating that Notch-1 can regulate its own expression during
T cell maturation. Additionally, during T cell selection, the basic helix-loop-helix
(bHLH) transcription factor, Id3, is upregulated by the MAPK pathway to inhibit
Notch-1 transcription.
The mature Notch receptor (272,505 Da.) is constructed as a heterodimer
comprised of two domains bound by a non-covalent bond that is typically mediated
by a calcium (Ca2+) ion (Figure 6). During maturation, the nascent, full length Notch
polypeptide enters the Golgi apparatus where it is cleaved at the S1 (scissile bond
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1) site by a furin-like convertase, furin / proprotein convertase 5 / 6 (PC5/6), into
two domains: the Notch extracellular domain (NECD) and the Notch
transmembrane / intracellular domain (NTMICD). The extracellular domain of the
Notch receptor contains a series of EGF-like repeats that arbitrate ligand
interactions which are facilitated by Notch ligand expression on the surface of a
neighboring cell. The EGF repeats are preceded by the Negative Regulatory
Region (NRR) that inhibits Notch receptor activation in the absence of a Notch
ligand. In humans, there are five known Notch ligands: Jagged-1, -2 (Jag-1, -2),
Delta-Like-1, -3, and -4 (DLL-1, -3, -4) that are able to bind to and activate the
Notch receptor when expressed on the surface of a cell in close proximity to the
Notch receptor of a neighboring cell (Figure 7). The affinity of a Notch ligand to a
Notch receptor can be attenuated by the addition of sugar moieties to the Notch
receptor which is facilitated by Fringe glycosyltransferases (Lunatic, Manic, or
Radical). Fringe glycosyltransferases add N-acetylglucosamine moieties to the
NECD region.
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Figure 6: The Notch Receptor.
The Notch receptor is composed of several domains that can be divided by the
extracellular domain (NECD) and the transmembrane and intracellular domain
(NTMICD). The NECD starts at the N-terminal (NH3) end and contains ligand
binding epidermal growth factor-like (EGF) repeats as well as the negative
regulatory region (NRR). Fringe proteins are able to target the EGF repeats for
glycosylation, which can change their ligand binding ability to the Notch receptor.
The NRR is composed of Lin12-Notch repeats (L) and the heterodimerization
domain (HD). The NTMICD contains: the transmembrane domain (T, TMB), the
RBP-Jκ associating module (R) or RAM domain, one of two nuclear localization
signals (N), the ankyrin domain, a second nuclear localization signal, the cysteine
response region (NCR), the transactivating domain (TAD), and a proline/glutamic
acid/serine/threonine-rich motif (PEST) at the C-terminal (COOH) end of the Notch
receptor. Ligand bound Notch is cleaved at a series of scissile sites (S1, 2, 3, 4)
represented just outside of S1 and inside the transmembrane domain [S2, 3, 4
(TMB enlargement)]. Furin-like convertase cleaves immature Notch at S1 to create
the mature, heterodimeric Notch receptor, which is stabilized by a non-covalently
bound calcium ion (Ca+2). The RAM domain facilitates core binding factor-1 (CBF1) binding. NICD binding to CBF-1 allows binding of mammal-like mastermind-1
(MAML-1) to the Ankyrin domain to form a ternary complex. The histone
acetyltransferase, p300, is recruited to NICD bound CBF-1 to form the Notch
transcriptional complex. The PEST domain is responsible for protein stability of the
Notch intracellular domain (NICD).
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Figure 7: The Notch Pathway.
The Notch pathway is activated by a Notch ligand (Jagged-1, -2, DLL-1, -3, -4) on
the surface of a signal sending cell (top) binding to a Notch receptor (Notch-1, -2,
-3, -4) on the surface of a signal receiving cell (bottom). The ligand bound Notch
receptor undergoes a series of cleavages. ADAM/TACE-mediated cleavage at S2
generates the NEXT fragment then γ-secretase-mediated cleavage at S3/4
generates NICD. NICD is translocated to the nucleus to bind to CBF-1 allowing the
release of negative co-regulators (NCoR) and the recruitment of co-activators
(CoA) such as MAML-1 and p300 to form the Notch transcriptional complex (NTC).
Proper NTC formation allows NICD to act as a transcriptional activator of Notch
target genes (HEY-1, HES-1).
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The intracellular domain of the Notch receptor is comprised of the active
portion of the Notch receptor, the Notch Intracellular domain [NICD (110 kDa.)].
NICD is comprised of the: Recombining Binding Protein-Jκ (RBP-Jκ) associating
molecule (RAM) domain, Ankyrin domain, cysteine response region (NCR),
transactivation domain (TAD), proline/glutamic acid/serine/threonine-rich motifs
(PEST domain), and a pair of nuclear localization sequences (NLS) flanking the
Ankyrin domain. The NLSs direct the cleaved NICD to enter the nucleus where it
facilitates transcriptional activation of Notch target genes.
Activation of the Notch pathway requires a series of events beginning with
the expression of the Notch receptor on the surface of the signal receiving cell
binding to a Notch ligand on the neighboring signal sending cell. Subsequently,
ligation of the Notch ligand to the Notch receptor is necessary for removal of
inhibitory NECD from the NTMICD portion of the Notch receptor which results in
two subsequent cleavage events: S2 and S3 cleavage. S2 cleavage is mediated
by a disintigrin and matrix metalloproteinase 10 or 17 (ADAM10/17) which results
in the Notch Extracellular Truncated (NEXT) Fragment.

The S3 cleavage is

mediated by the γ-secretase complex. Cleavage by γ-secretase results in the
release of the NICD portion of the Notch receptor (Figure 7). NICD is translocated
to the nucleus where it binds the constitutive repressor, RBP-Jκ/Core Binding
Factor-1 (RBP-Jκ/CBF-1) poised on promoter regions of Notch target genes. In the
absence of NICD, CBF-1 is bound to co-repressor proteins such as SMRT/HDAC1 associated repressor protein (SHARP) and C-terminal-binding protein (CtBP)
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(Oswald et al., 2005). This CBF-1-co-repressor complex represses gene
transcription until NICD is available. Upon the binding of NICD to CBF-1, corepressors are replaced by co-activator proteins. NICD binding to CBF-1 results in
the recruitment of transcriptional co-activators beginning with Mammal
Mastermind-like-1 (MAML-1) followed by the Histone Acetyltransferase (HAT),
p300.

Recruitment of the transcriptional co-activators to NICD1 results in

unwinding of chromatin and exposing the promoter region of the target gene
thereby initiating transcription. The binding of NICD to CBF-1 and the recruitment
of transcriptional co-activators forms the Notch transcriptional complex. Canonical
Notch target genes are predominantly helix-loop-helix transcriptional repressors
including: Hairy/Enhancer of Split (HES-1-5) and Hairy/Enhancer of split with a
unique YRPW motif (HEY-1, HEY-L). In mammals, there are four Notch paralogs,
Notch-1, -2, -3, and -4. Each Notch paralog has unique structures that may
facilitate synergistic and/or counteracting functions depending on the context of
their expression (Figure 8).
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Figure 8: Notch Receptor Paralogs.
The Notch receptor paralogs (Notch-1-4) have a similar overall composition but
slight differences in their structure to facilitate diversification of their attributes.
Differences amongst the Notch paralogs include changes in the number of EGFlike repeats or the subtraction or addition of domains such as the PDZ domain or
cysteine response region.
The Notch pathway is most frequently associated with lateral inhibition in
which the Notch ligand, Delta, if expressed in one cell is capable of inhibiting Delta
expression on a neighboring cell. In a cluster of undifferentiated cells, when one
cell begins to differentiate into an epithelial cell, it signals the surrounding cells to
also differentiate into epithelial cells. Originally, an undifferentiated cell can
express both the Notch receptor and the Delta ligand. Stimulation of the Notch
receptor will inhibit Delta production in the same cell. Through juxtacrine signaling,
adjacent cells compete to produce Delta, causing a feedback loop that drives the
two neighboring cells to assume dissimilar cell fates established by the number of
Delta ligands or Notch receptors expressed by each cell. Notch signaling is used
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to institute a border between two different populations of cells such as progenitor
and stromal cells. Boundary development by oscillating Notch activity is most
prominent in somite formation in which the continuous inactivation and activation
of Notch-mediated transcriptional activity results in the segmented formation of
somites in vertebrates (Pasinia et al., 2001; Palmeirim et al., 1997). Notch is able
to direct cell lineage via asymmetrical inheritance of Notch regulators between two
dividing, daughter cells, and is most apparent during neurogenesis (Lowell et al.,
2006).
The Numb drosophila homolog (Numb) is encoded by the NUMB gene and
acts as an inhibitor/negative regulator of Notch activity. Asymmetric distribution of
Numb and Notch between two dividing cells determines if one daughter cell is a
signal receiving cell and if the other is a signal sending cell. This uneven
distribution of Notch and Numb is inherited through multiple cell divisions to sustain
stem cell populations as well as influence cell lineage decisions (Reviewed in
Chiba, 2006). The culmination of the Notch pathway outlines its capacity to act as
a method of short range communication between cells. Notch juxtacrine signaling
has been found to be involved in a variety of processes, most notably in stem cell
differentiation, self-renewal, and cell fate determination as well as cell growth,
proliferation, and survival (Reviewed in Artavanis-Tsakonas, 1999).
Notch targeted treatments include the use of γ-secretase inhibitors (GSIs).
GSIs inhibit the critical S3 cleavage mediated by the γ-secretase complex
preventing release of NICD and consequently, NICD-mediated transcriptional
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activation. First generation GSIs were chemically designed to mimic the transition
state of the γ-secretase substrate bound to the catalytic subunit, presenilin-1, such
as Notch or the amyloid precursor protein (APP) (Figure 7). Second generation
GSIs were designed as non-transition state analogs. These small molecule
inhibitors bind allosterically to γ-secretase and attenuate γ-secretase enzymatic
activity that is independent of direct competitive binding. Both types of GSIs
ultimately interfere with the ability of γ-secretase to cleave and activate the Notch
receptor (Clarke et al., 2006). There are several distinct GSIs including MRK-003,
DAPT, and Compound E as well as γ-secretase modulators (PF-03084014), which
are designed to specifically inhibit specific Notch paralogs (Zhang et al., 2012).
Role of Notch in breast cancer. There is a growing body of evidence
indicating that an increase in Notch expression or mutation results in a series of
events that enable breast cancer cells to: undergo EMT, become resistant to
targeted treatments, metastasize, and promote BCSC survival and self-renewal
(Reviewed in Nickoloff et al., 2003). Initial discovery of a role for Notch in breast
cancer was made by an observation from studies using the mouse mammary
tumor virus (MMTV) model of breast cancer. It was found that MMTV was inserted
in the in the Int3/Notch-4 locus of murine mammary tumors (Gallahan and
Callahan, 1987). The insertion of MMTV into the Notch-4 locus resulted in a Notch4 mutation that made it constitutively active. Further investigations revealed that
MMTV-driven NICD1 or NICD4 expression in the mammary gland induced
spontaneous mammary tumors in mice (Dievart et al., 1999). Aberrant activation
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of the Notch pathway has been shown to transform normal breast epithelial cells
into cancerous cells which can be inhibited by targeting Notch-1 (Stylianou et al.,
2006). Additionally, the expression of Numb is frequently lost in breast tumors
(Pece et al., 2004). Increased co-expression of Jagged-1 and Notch-1 in breast
tumors has been associated with worse overall survival in women with breast
cancer (Reedijk et al., 2005). Increased Notch-1 expression has been shown to
occur early in the development of HER2+ breast cancer (Zardawi et al., 2010) and
both Notch-1 and Notch-4 have been identified as prognostic markers for breast
cancer (Yao et al., 2012). Notch signaling has been shown to inhibit apoptosis by
activation of the Akt pathway via an autocrine loop in breast cancer cells (Meurette
et al., 2009). Notch-1, -3, and -4 are bonafide oncogenes in T-cell acute
lymphoblastic leukemia (T-ALL) (Ellisen et al., 1991), cervical (Zagouras et al.,
1995), B-cell lymphoma (Fabbri et al., 2011), lung (Konishi et al., 2007), colon
(Akiyoshi et al., 2008), and ovarian (Rose et al., 2010) cancers. In contrast, Notch2 has tumor suppressive activity in some breast cancer subtypes (O'Neill et al.,
2007; Parr et al., 2004; Shimizu et al., 2002). Notch-3 has been shown to facilitate
proliferation and survival of HER2 negative tumors (Yamaguchi et al., 2008) as
well as promotion of BCSC survival and self-renewal in a hypoxic environment
(Sansone et al., 2007) (Figure 8). There are a number of studies suggesting that
Notch functions as a tumor suppressor in myeloid malignancies (Klinakis et al.,
2011) and skin cancer (Lefort et al., 2007). Research in melanoma indicates that
Notch-1 acts as a master regulator of several signaling pathways. Notch-1 has
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been shown to activate both Akt and MAPK pathways as well to induce expression
of the EMT marker, N-Cadherin, both in vitro and in primary melanoma tumors (Liu
et al., 2006). These data indicate that Notch acts as an oncogene or a tumor
suppressor in a cell and/or tissue-dependent context.
The Notch pathway has been referred to as the Notch-survival pathway due
to its ability to stimulate cell proliferation and growth. One of the Notch target genes
responsible for regulation of cell longevity is called survivin. Survivin is an inhibitor
of apoptotic protein (IAP) and functions to downregulate caspase 3, 7, and 9mediated apoptotic activities. Survivin has also been shown to regulate the cell
cycle by interacting with spindle microtubules during mitosis (Li et al., 1998).
Cyclin dependent kinase 1 (CDK1) phosphorylates the threonine 34 residue of
survivin to increase its protein stability (O'Connor et al., 2000) enabling survivin to
evade degradation arbitrated by the X-linked IAP-X-linked association factor-1
complex (XIAP-XAF1). The XIAP-XAF1 complex induces E3 ligase activity that
targets survivin for ubiquitinylation and subsequent proteasome-mediated
degradation. Prolonged survivin expression has been associated with breast
cancer survival through PI3K/Akt and MAPK/ERK pathway activities (Siddiqa et
al., 2008). There is a clear association between Notch-1 and survivin as women
with ER+ breast tumors that overexpress both Notch-1 and survivin have poorer
survival outcomes than women whose tumors do not co-express both transcripts
(Lee et al., 2008).
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Role of Notch in BCSCs. Notch plays a critical role in determining cell fate of
both normal SCs and cancer SCs. It was found that Notch-4 plays a critical role in
proper mammopoiesis suggesting that it directs normal breast SC and BCSC fate.
It has been demonstrated that Notch, particularly Notch-4, plays a prominent role
in BCSC self-renewal, survival, and cell fate, or differentiation (Dontu et al., 2004).
In particular, Notch-4 was found to promote BCSC self-renewal and promote side
branching of breast cells in vitro. Additionally, breast stem cells are hypothesized
to be at the tips of extending branches in the developing mammary gland.
Conversely, specific inhibition of Notch-4, or Notch-1, reduced BCSC enrichment
as well as tumor initiation in vitro and in vivo yet inhibition of Notch-4 had a greater
effect than inhibition of Notch-1 (Harrison et al., 2010) (Figure 5).
It has been shown that Notch-1 promotes HER2+ tumor recurrence post
trastuzumab treatment in dormant residual tumor cells (Abravanel et al., 2015)
suggesting that these dormant cells were BCSCs. It has been shown that Notch-1
expression in BCSCs is low compared to differentiated progenitor cells yet
particular expression of the Notch paralogues appears to vary by breast cancer
subtype (Grudzien et al., 2010). Inhibition of Notch signaling by a GSI, or a Notch
decoy, reduces BCSC mammosphere formation in vitro suggesting that blockade
of Notch signaling is a viable treatment option to eliminate BCSCs. One way Notch
may promote BCSC survival is by regulating the differentiation of mammary
progenitor cells to either myoepithelial cells or epithelial cells (Reviewed in Dontu
et al., 2003). Constitutive expression of Notch-1 was shown to promote the luminal

73
cell fate and inhibited side branching of the developing breast tissue in a
doxycycline regulated Notch-1 mammary tumor model in mice (Simmons et al.,
2012). In this model, inhibition of Notch-1 promoted tumor regression and
prevented tumor metastasis. Notch-1 was found to regulate the embryonic stem
cell marker Nanog which is suggested to be the mechanism by which Notch-1
regulates the BCSC population in vivo. An increase in Notch-1 was shown to
increase BCSC markers, ALDH1 and ABC transporters, which have been show to
facilitate excretion of chemotherapeutic drugs from the cancer cell. Notch-1 was
shown to facilitate the transcription of the embroyonic stem cell marker Sox2,
which establishes a Notch-1/Sox2 signaling axis that is critical for ovarian CSC
activity. Similar work has been done in TNBC BCSCs, demonstrating the ability of
Notch-1 to activate transcription of Sox2 resulting in post trastuzumab treatment
enrichment of the BCSC population (Azzam et al., 2013).
In an interesting study, Notch was shown to regulate HER2 expression
thereby possibly regulating the survival and differentiation of BCSCs (Chen et al.,
1997). Work in a HER2+ DCIS model showed that Notch inhibition reduced
mammosphere formation and acini size yet had no effect on the HER2- DCIS
model (Burchell et al., 2013). Conversely, gefitinib or lapatinib reduced
mammosphere formation and acini size in HER2- DCIS with no effect on the
HER2+ DCIS cell model. Notch-EGFR crosstalk has been implicated as a
paracrine mediator of estrogen action to increase ER-/ER low BCSC survival as
well as to promote proliferation of ER+ breast cancer cell lines (Harrison et al.,
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2013). Estrogen has been shown to increase expression of FGFR, EGFR, and
Notch ligands in ER+ bulk breast cancer cells to act in a paracrine manner to
regulate

expression

via

FGF/FGFR/Tbx3,

EGFR/MAPK/ERK,

and

DLL-

Jag/Notch/Pea3 pathways in the ER-/ER low BCSC population. Estrogenmediated BCSC regulation can be attenuated by blocking estrogen with tamoxifen,
EGFR with gefitinib, or Notch with a GSI to inhibit BCSC survival and early
progenitor cell differentiation, and possibly dedifferentiation, respectively.
Crosstalk between FGFR, EGFR, and Notch pathways are responsible for
estrogen induced changes to ER-/ER low BCSC population and may play a part in
endocrine resistance as well as offer possible therapeutic targets for the treatment
of ER+ breast tumors.
Notch-1-HER2 crosstalk in trastuzumab resistance. Notch-HER2 crosstalk
was initially observed in HER2+ breast cancer cells treated with trastuzumab which
resulted in an increase in Notch-1 expression and activation (Osipo et al., 2008).
Similarly, chronic trastuzumab treatment of HER2+ breast cancer cells to induce
trastuzumab resistance resulted in an increase in Notch-1 as well as upregulation
of genes transcribed by Notch-1. Targeted inhibition of Notch-1, or pan-inhibition
of Notch by a GSI, enhanced trastuzumab sensitivity and reversed trastuzumab
resistance in vitro. Combinatorial targeting of HER2 by trastuzumab and Notch by
a GSI inhibited trastuzumab resistant HER2+ tumor growth as well as tumor
recurrence (Pandya et al., 2011). Together, these data suggest an inverse
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relationship between Notch-1 and HER2 in breast cancer in which inhibition of
HER2 upregulates Notch-1 expression.
Interestingly, there is evidence that Notch-HER2 crosstalk can be
stimulatory rather than inhibitory. The HER2 promoter contains a CBF-1 binding
site and overexpression of NICD1 was shown to induce transcription of the HER2
gene indicating that Notch-1 positively regulates HER2 expression (Chen et al.,
1997). HER2 overexpression in DCIS increased Notch-3-mediated transcription of
Notch target genes (Pradeep et al., 2011). In the HER2+ DCIS model, effectors of
the Notch pathway: ADAM17, Jag-1, DLL-1, presenilin-1, and Notch-1 were
increased upon Notch-3 nuclear localization. Notch-3 inhibition resulted in reduced
spheroid formation, cell proliferation, and luminal spheroid filling indicating that
HER2-mediated upregulation of Notch-3 promotes HER2+ DCIS survival and cell
proliferation. In addition to these studies, others have demonstrated that HER2
may enable increased expression of effectors of the Notch pathway such as Notch
activating matrix metalloproteinases (presinilin-1, ADAM) or Notch ligands (DLL-1,
Jag-1, -2).
Notch-1-HER2 crosstalk through the MAPK pathway. HER2 is a potent
activator of the Ras-MAPK pathway and communication between the Notch and
MAPK pathway has been investigated. TNBC cell lines use the MAPK/ERK
pathway to promote upregulation of Jagged-1 to activate Notch. TGFα-mediated
EGFR activation of the MAPK pathway has been shown to enhance Jagged-1
expression in breast cancer cells to promote metastasis in the bone (Sethi et al.,
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2011). The pseudokinase Tribble-3 (TRB3) was identified to activate both TGF-β
and MAPK/ERK pathways (Izrailit et al., 2013). Inhibition of TRB3 reduced TNBC
(MDA-MB-231) cell proliferation while Jagged-1 overexpression in TRB3-silenced
cells rescued cell proliferation. TRB3 knockdown was found to reduce tumor
growth in TNBC tumor xenografts in mice in vivo. These results indicate that TRB3
elevates Jagged-1 expression through the MAPK/ERK pathway and is critical for
TNBC cell proliferation and tumorigenesis.
Notch-1-HER2 crosstalk through the Akt pathway. It is well established
that HER2 activates a multitude of signal transduction pathways including
PI3K/Akt/mTOR signaling. This is critically important as most of the work to date
has focused on mechanisms of crosstalk between the PI3K/Akt pathway and
Notch. Hyperactivation of mTOR signaling has been associated with elevated
Notch signaling in poorly differentiated breast cancers as well as a poor clinical
outcome for women with mTOR/Notch overexpressing tumors (Ma et al., 2010).
The correlation between hyperactivation of mTOR and Notch pathways revealed
that RTK activation of PI3K/mTOR pathway promoted upregulation of several
mTOR targets: p63 (a member of the p53 family), signal transducer and activator
or

transcription

3

(STAT3),

Notch,

Jagged-1,

and

HES-1.

Aberrant

RTK/PI3K/Akt/mTORC1 signaling was found to increase Stat3 expression and
activation resulting in an increase in p63 transcription. This increase in p63
expression was found to induce Jagged-1-mediated Notch activation and
consequently HES-1 expression. This study demonstrates the mechanism by
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which the upregulation of the RTK/PI3K/Akt/mTOR signaling axis activates the
STAT3/Jag-1/Notch signaling cascade to promote breast tumorigenesis.
Conversely, Notch can activate the PI3K/Akt/mTOR pathway in T-ALL (Calzavara
et al., 2008; Palomero et al., 2007), indicating that Notch and mTOR may
cooperate in a positive regulatory loop to promote cancer cell proliferation or
differentiation.
Investigators have elucidated crosstalk between the PI3K/Akt/mTOR and
Notch pathways in several different cancer cell lines including a chemoresistant
ER+/HER2-, MCF-7 cell line, which displayed elevated Notch-1 expression and
activity (Mungamuri, 2006). Notch-1 activation inhibited p53 nuclear localization
and prevented phosphorylation of p53 at Ser15, Ser20, and Ser392 residues. This
Notch-1-mediated blockade of p53 activity was found to be dependent on the
mTOR/eIF4E signaling axis as the mTOR inhibitor, rapamyacin, reversed
chemoresistance in these cells and restored p53 activity. These studies reveal an
important role for the PI3K/mTOR pathway on Notch-1-mediated regulation of drug
resistance and p53-dependent apoptosis.
PTEN.
Role of PTEN in breast development and tumorigenesis. The PTEN gene
is located on chromosome 10 in the 10q23 region. PTEN expression is frequently
lost in a variety of cancers including breast cancer. To better understand the role
of PTEN in mammary gland development, mice with a conditional PTEN knockout
were bred (MMTVCrePTENflox/flox) and assessed for development of mammary
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tumors (Li et al., 2001). PTEN null mice displayed hyperplastic mammary gland
ducts, an increase in side branching, and amplified lobulo-aveolar budding
compared to the mammary tissue of control mice. Such developmental changes
were also observed at puberty and during pregnancy as the PTEN deficient mice
also had defective mammary gland involution after pregnancy. In addition to
defects in mammary gland development, the PTEN knockout mice developed
cancer earlier as well as benign lesions compared to control mice. Interestingly,
the PTEN null mice displayed increased staining for cytokeratins 5 and 6 (Li et al.,
2002), markers for the basal subtype of breast cancer (Sørlie et al., 2001).
Furthermore, mammary tumors from the PTEN null mice showed similar
characteristics to breast cancers containing BRCA-1 mutations (Saal et al., 2008).
Loss of PTEN is associated with Cowden syndrome which is an uncommon
autosomal dominant, inherited disorder and is categorized by the growth of noncancerous hamartomas. Cowden syndrome is associated with PTEN mutations
which results in an increase in mTOR activity and a predisposition to cancers,
including breast cancer. These data present the role for PTEN in proper mammary
gland development as well as the development of breast cancer when PTEN
expression is lost.
Role of PTEN in HER2+ breast cancer and trastuzumab resistance. Loss
of PTEN has been associated with worse overall outcome for women with HER2+
breast cancer (Stern et al., 2015). Loss of PTEN occurs in approximately 12% to
22% of HER2+ breast cancer patients (Esteva et al., 2010) while mutation of PTEN
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occurs in only 3.5% of breast cancers (Rexer et al., 2013; TCGA, 2012). Detection
of PTEN mutations in breast cancers had little overlap with HER2 amplification
indicating that a majority of the PTEN mutations do not occur in the HER2+
subtype. Transcription of the PTEN gene is regulated by a number of different
mechanisms and pathways, particularly during development and tumorigenesis.
PTEN transcription is regulated by p53, SMADs, and NFκB for proper
organogenesis and immune function (Knobbe et al., 2008; Luyendyk et al., 2008).
Loss of PTEN expression can occur a number of ways besides loss-of-function
mutations such as: loss of heterozygosity, RNA degradation, miRNA-mediated
transcriptional inhibition, epigenetic modification, or post translational modification
of PTEN. Additionally, transcriptional repression of PTEN could be due to the loss
of other tumor suppressors critical to breast cancer located in the vicinity of the
PTEN locus (Feilotter et al., 1999).
Trastuzumab treatment has been shown to increase expression of the
tumor suppressor, PTEN. PTEN loss and the resulting increase in PI3K/Akt activity
is a fairly good predictor of trastuzumab resistance and is improved when
combined with PIK3CA activating mutation status in women with HER2+ breast
cancer (Berns et al., 2007; Loibl et al., 2016). Women with tumors expressing low
PTEN were less likely to achieve pCR when treated with trastuzumab compared
to women with tumors expressing elevated PTEN (Dave et al., 2010). There are
many reports showing that loss of PTEN’s tumor suppressive activity results in
increased Akt signaling, trastuzumab resistance, poor prognosis, and decreased
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overall survival in women with HER2+ breast cancer (Fujita et al., 2006; Nagata et
al., 2004).
Trastuzumab-mediated activation of PTEN. Trastuzumab can increase
PTEN activity by disrupting the association between HER2 and Src (Nagata et al.,
2004). Trastuzumab treatment of HER2+ breast cancer cells, such as BT474 and
SkBr3, resulted in activation of PTEN. Trastuzumab was shown to inhibit
phosphorylation of tyrosine residues (Y240 and Y315) on the C2 domain of PTEN
(Figure 9). This blockade of tyrosine phosphorylation resulted in PTEN
translocating to the cell membrane where it is positioned to dephosphorylate PIP 3
to PIP2. The non-receptor tyrosine kinase Src has been shown to bind to and
activate HER2 (Belsches-Jablonski et al., 2001) as well as increase tyrosine
phosphorylation of PTEN (Lu et al., 2003) in HER2+ breast cancer cells.
Trastuzumab-mediated inhibition of Src kinase activity resulted in reduced
phosphorylation of PTEN as well as decreased phosphorylation of Akt. Inhibition
of Src kinase activity was found to be a major contributor to the anti-proliferative
effect of trastuzumab in HER2+ breast cancer in vitro as well as reducing tumor
growth in vivo. Importantly, reduced PTEN expression in HER2+ tumors, by PTEN
siRNA, promoted HER2+ cell proliferation in vitro as well as tumor growth in vivo,
regardless of trastuzumab or paclitaxel treatment. HER2+ cell proliferation and
tumor growth can be inhibited by a PI3K inhibitor, LY294002, thereby re-sensitizing
PTEN deficient tumors to trastuzumab treatment. PTEN deficient tumors from
women with HER2+ metastatic breast cancer showed the least clinical benefit from
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trastuzumab treatment compared to PTEN expressing tumors, making PTEN
deficiency a potential predictor of trastuzumab resistance.

Figure 9: PTEN.
The PTEN protein is composed of two domains, the phosphatase and C2 (Cterminal) domains. The N-terminus contains a PIP3 binding domain followed by a
nuclear localization signal (NLS1), a cytoplasmic localization sequence (CLS), and
a second nuclear localization signal (NLS2). The phosphatase domain is
responsible for lipid and protein phosphatase activity. The catalytic core binds PIP 3
to facilitate its dephosphorylation. The C2 domain binds to lipids and contains
NLS3 and 4, two proline/glutamic acid/serine/threonine-rich motifs (PEST), and the
PDZ domain. Monoubiquitylation can occur at residue K289 as well as residues
S370-S385. Phosphorylation can occur at residues Y240 and Y315.
Mechanisms of Notch-1-mediated inhibition of PTEN. Notch-1 has
demonstrated the ability to regulate the PI3K/Akt pathway through repression of
PTEN in several different cancers. Aberrant activation of Notch-1 is common in TALL (Reviewed in Grabher et al., 2006). Thus, GSI treatment was proposed as a
possible therapeutic for T-ALL, but half of T-ALL cells failed to respond to GSI
treatment (Palomero et al., 2007). Interestingly, GSI effectively reduced NICD1
levels and Notch target gene expression suggesting that compensatory signaling
pathways may be responsible for continued T-ALL cell growth. Palomero et al.
analyzed GSI sensitive and resistant T-ALL cell lines to find decreased expression
of PTEN in both cell types. GSI resistant cells were found to have a loss-of-function
PTEN mutation that resulted in hyperactivation of Akt and T-ALL cell growth.
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Notch-1 activity in GSI sensitive cells was found to indirectly represses PTEN. In
the GSI sensitive cells, constitutive activation of Notch-1 increased transcription of
the transcriptional repressor, and Notch-1 target gene, HES-1. HES-1 is directly
recruited to the PTEN promoter where it is able to inhibit transcription of PTEN.
These data demonstrate a parallel relationship between the Notch-1 and PI3K/Akt
pathway in which they both promote T-ALL cell growth. Accordingly, the inverse
relationship of Notch-1 and PTEN in T-ALL predicts a worse overall outcome for
T-ALL patients.
Repression of PTEN by Notch-1 has been shown to occur in melanoma cell
lines. Pan Notch inhibition by GSI (RO4929097) resulted in elevated PTEN
expression, reduced Akt pathway activity, and an increase in senescence and
apoptosis in PTEN wild type expressing melanoma cancer cells (Nair et al.,
2013b). PTEN null or mutant melanoma cell lines did not enter apoptosis or
senesce when treated with GSI suggesting that PTEN status dictates sensitivity to
GSI. As such, wild type PTEN is inhibited by Notch-1 and is sensitive to GSI
treatment but neither mutant nor PTEN null cells are dependent on Notch-1mediated repression of PTEN and are therefore, resistant to GSI. Additionally, in
wild-type PTEN expressing melanoma cells, GSI treatment improved the effect of
chemotherapeutic temozolomide treatment both in vitro and in vivo. These studies
highlight the importance of Akt pathway activity in dictating melanoma tumor
susceptibility to GSI alone or in combination with chemotherapy.
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Notch-1-mediated repression of PTEN can occur through post translational
modification of PTEN. In gastric cancer, Notch-1 inhibition results in increased
PTEN activity, cell cycle arrest at the G2/M checkpoint, and reduced tumor growth
in vivo (Kim et al., 2015). Notch-1 was shown to induce phosphorylation of the
PTEN C-terminus to promote accumulation of PTEN in the nucleus. Nuclear PTEN
accumulation resulted in cell apoptosis through interaction with the cyclin-1/CDK1
complex. Increased Akt activation through PTEN inhibition was also found to be
important in other cancer models such as mesothelioma, in which Notch-1 and
Notch-2 were found to have contrasting effects (Graziani et al., 2008).
Interestingly, Notch-1 was required for PTEN downregulation, Akt activation, and
DNA synthesis in mesothelioma cell models. However, Notch-2 had the opposite
effect by increasing PTEN expression, Akt inhibition, reduced DNA synthesis, and
cell death. Interestingly, Notch-1 was found to directly bind to CBF-1 at the PTEN
promoter thereby directly inhibiting PTEN transcription in mesothelioma cells.
Together, these data suggest several mechanisms in which Notch can inhibit
PTEN activity to regulate cancer cell growth and survival as well as tumorigenesis
in vivo.
Role of PTEN in BCSCs. Given the frequency of PTEN loss or downregulation
in breast cancer, it is probable that changes in PTEN activity can affect the BCSC
population. PTEN has been shown to regulate self-renewal of neuronal and
hematopoietic stem cells (Figure 5). Case in point, PTEN is an acute regulator of
FOXO transcription factors which control hematopoietic stem cell proliferation and
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survival (Sengupta et al., 2011). Inhibition of PTEN in malignant and normal
BCSCs from HER2 negative / ER+ cell lines activates the Akt pathway and
phosphorylation of GSK-β resulting in activation of the Wnt/β-catenin pathway
(Jordan et al., 2009). The PTEN/Akt/GSK-β/Wnt/β-catenin signaling pathway is
involved in enrichment of the mammary stem/progenitor cell population. Targeted
inhibition of Akt activity, by perifosine and not the mTOR inhibitor rapamycin,
reduces the BCSC population in vitro as well as tumor growth and recurrence in
vivo.
MicroRNAs have been shown to play a role in regulating PTEN expression
and consequently effecting enrichment of the BCSC population. Elevated miR-205
expression increased the mouse mammary epithelial progenitor cell population
and the CSC population through regulation of Zeb-1, -2, and PTEN expression
(Greene et al., 2010). Interestingly, it has been shown that overexpression of
HER2 attenuates miR-205 and may be essential for HER2-driven tumorigenesis
(Adachi et al., 2011). miR-10b is capable of increasing BCSC stemness, selfrenewal, and EMT markers by sustaining Akt pathway activation through PTEN
inhibition in MCF-7 cells (Bahena‐Ocampo et al., 2016). The BCSC population and
EMT have been shown to be dependent on miR-21 activity as inhibition of miR-21
reverses EMT. This reversal of EMT was shown to require both the PI3K/Akt and
MAPK/ERK pathway inactivation through upregulation of PTEN (Han et al., 2012).
Together these data indicate that PTEN attenuates both the Akt and MAPK
pathways to limit the BCSC population.
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Subcellular location of PTEN determines its phosphatase activity. Lipid or
protein phosphatase activity of PTEN depends on its location within the cell.
Canonically, PTEN acts as a lipid phosphatase by dephosphorylating the D3
position of PIP3 reversing PIP3 to PIP2. PTEN attenuation of PI3K signaling
occurs in the cytoplasm. Noncanonically, PTEN has been shown to act as a protein
phosphatase

in

the

nucleus

by

regulating

MAPK

activity

through

dephosphorylation of ERK1/2. In MCF-7 cells, expression of a mutant PTEN that
is localized in the nucleus resulted in cell cycle arrest in the G0/G1 phase through
downregulation of cyclin D1 (Chung et al., 2005b). Whereas, expression of a wild
type PTEN, that localized in the cytoplasm, resulted in a higher G1/S ratio of cells
compared to nuclear PTEN expressing cells (Figure 10). Cytoplasmic PTEN was
found to be pro-apoptotic while nuclear PTEN promoted cell cycle arrest. The
diversity of PTEN phosphatase activity makes it an attractive target for suppression
in cancer cells.
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Figure 10: Subcellular Phosphatase activity of PTEN.
The phosphatase functionality of PTEN can change by its location within the cell.
Cytoplasmic PTEN dephosphorylates Akt resulting in upregulation of p27 Kip1 and
apoptosis of the cell. Nuclear PTEN dephosphorylates ERK1/2 resulting in
downregulation of cyclin D1. Reduced cyclin D1 results in arrest of the cell cycle
at the G0-G1 phase and the cell to enter quiescence.
Nuclear PTEN acts as a protein phosphatase in which it regulates ERK1/2
phosphorylation and cyclin D1 expression (Weng et al., 2001). Ras mutations are
infrequent in breast cancer but increased Ras activation can occur through
overexpression of EGFR or HER2 amplification in HER2+ breast cancer (von Lintig
et al., 2000). Hyper-activation of the MAPK pathway through Ras correlates with
increased cancer stem cell enrichment and poor patient survival in TNBC (Mittal
et al., 2014). Recently it has been reported that a loss of PTEN in HER2+ breast
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cancer promotes dependency on the MAPK pathway through elevated MEK/ERK
activity (Ebbesen et al., 2016).
The mechanism of PTEN entry into the nucleus remains controversial.
There are examples of PTEN entering the nucleus by simple transport (Li et al.,
2005). However, PTEN binding to a major vault protein (MVP) has been shown to
transport PTEN from the cytoplasm into the nucleus in MCF-7 cells (Chung et al.,
2005a). Further assessment of PTEN nuclear translocation revealed 4 putative
nuclear localization signal (NLS)-like sequences (NLS-1, -2, -3, -4) (Figure 9).
PTEN localization was not affected by the mutation of one of these sequences but
mutation of a pair of the NLS sequences (NLS-2 and -3; NLS-3 and -4) inhibited
binding to MVP as well as entry into the nucleus. Calcium ions were found to
positively regulate MVP binding to PTEN (Minaguchi et al., 2006). PTEN entry into
the nucleus may also be regulated by the E 3 ligase, Neural precursor cell
Expressed

Developmentally

Downregulated

4

-1

protein

(NEDD4-1).

Monoubiquitinylation prevents PTEN nuclear entry whereas polyubiquitinylation by
NEDD4-1 results in PTEN degradation and loss of its tumor suppressive activity
(Wang et al., 2007). Together these data present the hypothesis that PTEN
functionality changes based on its location within the cell and that nuclear PTEN
may play a role in breast cancer.
The MAPK Pathway.
Role of the MAPK pathway in breast development. The MAPK pathway
plays a role in mammary gland development as well as tumorigenesis. Particular
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effectors of the MAPK pathway have been implicated in mammary gland
development, specifically ERK1/2, c-Jun N-terminal kinase (JNK), and p38
(Reviewed in Whyte et al., 2009). As described above, the phosphorylation
cascade of Raf/MEK/ERK results in translocation of ERK1/2 into the nucleus to
phosphorylate a number of targets including hormone receptors as well as
regulators of apoptosis and transcription. Biologically, ERK1/2 phosphorylation of
target substrates encourages cell proliferation, survival, differentiation (Reviewed
in Pearson et al., 2001), angiogenesis (Zeng et al., 2005), invasion, and motility
(Joslin et al., 2007). MAPK/ERK1/2 is involved in a number of cellular functions
important to organogenesis making activation of the MAPK pathway necessary for
proper mammary gland development as well as induction of breast cancer if
dysregulated. For example, normal mammary epithelial cells form spherical acini
that organize into branching alveolus structures when supported by a healthy
ECM. Alveolar structuring by breast epithelial cells can be recapitulated in vitro by
three dimensional culturing techniques (Blatchford et al., 1999). ERK1/2 signaling
is necessary for bidirectional crosstalk between β1-integrins and EGFR for the
proper polarization and placement of mammary epithelial cells in acinar formation
(Wang et al., 1998). Conversely, previous work has shown that HER2, and not
EGFR, plays an important role in acinar development in the early stages of breast
cancer disease progression (Muthuswamy et al., 2001). Inhibition of ERK1/2,
EGFR, or β1-integrins resulted in malformation of spherical acini as well as
inhibition of PI3K indicating that both MAPK/ERK1/2 and PI3K/Akt pathways play
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important roles in the proper mammary gland formation. Together these data
present the importance of the MAPK/ERK1/2 pathway in proper mammary gland
development and tumorigenesis.
Role of the MAPK pathway in HER2+ breast cancer. Increased HER2 activity
in HER2+ breast cancer cells upregulate both downstream PI3K/Akt and MAPK
pathways. Downstream effects of trastuzumab treatment on MAPK pathway
activity have been controversial. One study shows that trastuzumab treatment
does not affect downstream MAPK activity in HER2-positive SKBr3 and MDA-MB453 cell lines (Cuello et al., 2001). The trastuzumab treatment concentration for
this study, 1 μM, and length of treatment, 4 days, was very low. In vitro trastuzumab
treatment is typically between 10 and 20 μM in order to mimic physiological
treatment conditions. Conversely, a three-day course of 10 μM trastuzumab
treatment resulted in inhibition of MAPK phosphorylation and activation in BT474
and SkBr3 cells (Yakes et al., 2002) as well as in metastatic breast cancer patient
samples (Gori et al., 2009). These data suggest that trastuzumab affects
downstream MAPK pathway activity when given at the proper dose.
MAPK pathway activation has been shown to be the central node in a
variety of breast cancer subsets under varying treatment conditions. For instance,
alcoholism has been shown to increase the risk of breast cancer. Alcohol exposure
was shown to increase HER2+ cell migration and invasion (Xu et al., 2016).
Increased aggressiveness of HER2+ cells exposed to alcohol occurred through
the phosphorylation of p38γ (P-p38γ), a MAPK effector that typically responds to
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DNA damage and cell stress. Activation of p38 interacted with downstream
synapse associated protein 97 (SAP97) to promote cell migration and invasion as
well as enrichment of the BCSC population in a HER2+ MMTV mouse model.
Similarly, in a TNBC cell and mouse xenograft model, p38γ-MAPK inhibition was
found to reduce the BCSC population as well as downregulate Nanog, Sox2, and
Oct 3/4 cancer stem cell drivers (Qi et al., 2015). MAPK phosphatases
(DUSP/MKP1) are overexpressed in HER2+ breast cancers (Candas et al., 2014).
MKP1 attenuates MAPK activity by removing phosphate groups necessary to
progress the MAPK phosphorylation cascade. MKP1 has been shown to induce
chemoresistance and radioresistance by preventing apoptosis in HER2+ bulk and
cancer stem cells. These data represent how the MAPK pathway can contribute to
expansion of the BCSC population, resistance, and metastasis of HER2+ breast
cancer.
Notch-1- MAPK crosstalk in breast cancer. Here we assess bi-directional
crosstalk between Notch-1 and MAPK pathways in an effort to better understand
their involvement in mechanisms of cancer bulk and stem cell proliferation as well
as drug resistance in breast cancer. Ras (specifically H-Ras) can activate Notch-1
signaling in both in vitro and in vivo cancer models (Weijzen et al., 2002). Notch-1
activation by Ras was necessary to maintain the abnormal tumor phenotype in
Ras-transformed cells. Aberrant activation of Ras signaling through p38-MAPK
was found to upregulate proteins involved in Notch signaling, specifically
presanilin-1 and DLL-1. Inhibition of Notch-1 reduced proliferation and tumor
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growth of Ras transformed cells and tumor xenografts, respectively. Interestingly,
in cells with null or low Ras expression (human foreskin fibroblasts and HER2negative MCF-7 cells) overexpression of Notch-1 was unstable and toxic to these
cells. Additionally, NICD1 overexpression in hTERT/SV40 immortalized fibroblasts
was found to increase cell proliferation and anchorage independent growth
compared to the vector control but not to level of Ras transformed cells. This result
suggesting that oncogenic Ras allows cells to tolerate elevated Notch-1
expression. Together these data present a potential mechanism for Ras-mediated
upregulation of Notch-1 to drive and maintain the neoplastic phenotype in breast
cancer.
Immunohistological assessment of Notch in progressive stages of breast
carcinogenesis revealed that Notch-1, and downstream Notch targets, were
increased in approximately 75% of breast cancer tissue samples compared to
normal breast tissue samples (Mittal et al., 2009). Furthermore, aberrant activity of
Notch was apparent in DCIS and hyperplasia suggesting that abnormal Notch
activity occurs early in breast cancer progression. HMLE (Human Mammary
Epithelial cells overexpressing hTERT and SV40 large and small T antigens) cells
have low Notch-1 and Ras expression. Transformation of HMLE cells with Notch1 failed to form mammospheres in vitro or tumors in vivo. Conversely, NICD1
overexpression in Ras transformed cells (HMLER) increased mammosphere
formation in vitro and tumor growth in a mouse xenograft model compared HMLE
or HMLE with NICD1 overexpression alone. Inhibition of either Notch by GSI or
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Ras/MAPK pathway by the MEK inhibitor PD 98059 reduced BCSC survival and
self-renewal. Positive staining for both Notch and/or HES-5 as well as nuclear PERK1/2 in breast tumor tissues correlated to aggressive grade III carcinomas with
a high risk of metastasis. These results suggest an important role for the coexpression of Notch-1 and Ras/MAPK to promote BCSC survival and self-renewal
as well as tumor progression.
Conclusion.
These data presented here begin to reveal the complexity of the Notch1/PTEN/MAPK signal transduction pathway. As described above there are
numerous interactions between Notch-1 and PTEN, as well as downstream
PI3K/Akt and MAPK/ERK1/2 pathways. Being that both Notch-1 and PTEN are
context dependent we have limited our scope to trastuzumab resistant HER2+
breast cancer which may draw from more aggressive cancer models such as
TNBC or endocrine resistant ER+ breast cancer. However, little work has been
done on the role of Notch-1, PTEN, and the MAPK/ERK pathway in trastuzumab
resistant breast cancer. The results presented here may shed some light on the
mechanics of more aggressive cancers by presenting a novel role for Notch-1 in
PTEN regulation and MAPK activation in trastuzumab resistant HER2+ breast
cancer.

CHAPTER 2
MATERIALS AND METHODS

Cell Culture.
BT474TS and HCC1954 breast cancer cells were purchased from
American Type Culture Collection (ATCC). BT474TR, trastuzumab resistant, cells
were generated in vitro by treating parental BT474TS, trastuzumab sensitive, cells
with increasing concentrations of trastuzumab for 6 months till the cells could
survive under constant trastuzumab treatment of 10μg/mL in PBS (Osipo et al.,
2008). Cells were cultured in Dulbecco’s minimal essential media with high glucose
[1x DMEM (Fisher Scientific, Hampton, NH)] 10% fetal bovine serum (FBS),
100μM L-Glutamine, and 100μM nonessential amino acid. Cells were maintained
at 37⁰C with 5% CO2 and 95% O2. Cells were authenticated by STR allelic profiling
(DCC Medical).
Drugs.
Trastuzumab is a humanized monoclonal antibody against extracellular
domain IV of the HER2 receptor (Carter et al., 1992). Lyophilized trastuzumab was
resuspended in sterile PBS for a concentration of 22mg/mL. Cells in culture were
maintained at 7 to 10μg/mL in media. Experimental trastuzumab treatments were
20μg/mL. U0126 inhibits MAPK pathway activity by noncompetitive inhibition of the
dual specific kinases (threonine and tyrosine) MEK1 and MEK2. U0126-mediated
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inhibition of MEK1/2 results in reduced phosphorylation of the MEK1/2 kinase
substrate, ERK1/2. U0126 was resuspended in DMSO for a concentration of
20mg/mL and used in treatments at concentration of 10μg/mL in vitro.
Expression Vectors.
The pcDNA and pcDNA-NICD1 expression vectors were kindly provided by
Dr. Lucio Miele (Department of Genetics, Louisiana State University, New Orleans,
LA). The MEK1 S218D/S222D phosphomutant pEXP304-MEK1DD/V5, and
control vector pEXP304-LacZ/V5, were kindly provided by Dr. Takeshi Shimamura
(Department of Molecular Pharmacology and Therapeutics, Maywood, IL). The
pUSEamp and N-terminal Myrstoylated-Akt1 expression vectors were purchased
from Upstate Cell Signaling Solutions (Lake Placid, NY).
RNA Interference and Transfection Reagents.
Notch-1, PTEN, and HES-1 siRNAs were purchased from Santa Cruz
Biotechnology (Dallas, TX). Secondary Notch-1 siRNA (Notch-1i #2) was
purchased from Thermo Fisher Scientific [Dharmacon (Waltham, MA)] and
scrambled siRNA (SCBi) was purchased from Qiagen (Hilden, Germany).
Transfection reagents, Lipofectamine 2000, Lipofectamine 3000, and RNAiMax
were purchased from Invitrogen (Carlsbad, CA) as well as Polyethylenimine (PEI)
form PolySciences (Niles, IL).
BT474 (3 x 105) or HCC1954 (1 x 105) cells per well were seeded into a 6
well tissue culture treated plate. The following day, 1μg of vector DNA was mixed
with 250μL of Opti-MEM (Life Technologies, Carlsbad, CA) in a 15mL tube. In a
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separate microcentrifuge tube, 4μL of Lipofectamine 2000 or PEI were mixed with
250μL of Opti-MEM. The two tubes were incubated for 5 minutes at room
temperature then mixed together and incubated for an additional 20 minutes at
room temperature. The total volume of the transfection reaction was 500μL. The
cells were washed with PBS. 1.5mL of media was added to the transfection
reaction and then added to the washed cells. Similarly, transfections using
Lipofectamine 3000 in a 6 well plate, mixed 5μg of vector DNA, 5μL of P3000, and
250μL of Opti-MEM in one tube. 3.75μL of Lipofectamine 3000 and 250μL of OptiMEM were mixed in a separate tube followed by incubation and mixing in the same
manner as Lipofectamine 2000. siRNA transfections using RNAiMax were
performed in a similar manner. In a 6 well plate, 10μM of siRNA was added to
250μL of Opti-MEM in a 15mL tube. 10μM of RNAiMax was added to 250μL of
Opti-MEM in a separate tube. Both tubes were mixed, incubated, and added to the
cells in the same manner as previous transfections. Co-transfections used halved
ratios of siRNA and RNAiMax, 5μM and 5μL, respectively. The siRNA sequences
released by their respective companies are shown in Table 1.

96
siRNA

Company

Catalog #
Sc-36095A

Notch-1

Santa Cruz

Sc-36095B
Sc-36095C

Notch-1

Thermo
Fisher
(Dharamcon)

HSS107248

Sc-29459A
PTEN

Santa Cruz

Sc-29459B
Sc-29459C

Scrambled
Control
(SCBi)

Qiagen

1027281

Sense Sequence
(5’ – 3’)
CACCAGUUUGAA
UGGUCAAtt
CCCAUGGUACCA
AUCAUGAtt
CCAUGGUACCAA
UCAUGAAtt

Antisense
Sequence (5’ – 3’)
UUGACCAUUCAA
ACUGGUGtt
UCAUGAUUGGUA
CCAUGGGtt
UUCAUGAUUGGU
ACCAUGGtt

ACGAAGAACAGA
AGCACAAAGGCG
G

CCGCCTTTGTGC
TTCTGTTCTTCGT

CAGUGGCACUGU
UGUUUCAtt
GUGUGGUGAUAU
CAAAGUAtt
GAAGAUCAGCAU
ACACAAAtt

UGAAACAACAGU
GCCACUGtt
UACUUUGAUAUC
ACCACACtt
UUUGUGUAUGCU
GAUCUUCtt

Sequence held by Qiagen

Table 1: siRNA sequences
Antibodies.
PTEN (9559S), Phosphorylated Akt1 (Ser473, 9271S and Thr308, 9275S),
Pan Akt (4691S), Total p44/42 ERK1/2 (4695), Histone H3 (4620) and
Phosphorylated p44/42 ERK1/2 (Tyr202/Tyr204, 4370) were purchased from Cell
Signaling Technologies (Danavers, MA). Notch-1 (C-20, sc-6014), MEK-1 (C-18,
sc-219), and normal rabbit IgG (sc-2027) were purchased from Santa Cruz
Biotechnologies (Santa Cruz, CA). Total HER2 [(ErbB2) MS0730-P] was
purchased from Thermo Fisher Scientific (Waltham, MA). Phosphorylated HER2
at tyrosine 1248 [PY1248-ErbB2 (AF1768)] was purchased from R and D Systems
(Minneapolis, MN). β-Actin (A5441) was purchased from Sigma Aldrich (St. Louis,
MO) and used as an endogenous control for all Western blots. Secondary
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antibodies used include donkey anti-rabbit (1:1000, sc-2313) and donkey antimouse (1:5000, sc-2314) purchased from Santa Cruz Biotechnologies (Santa
Cruz, CA).
Reverse Transcription Real-Time Polymerase Chain Reaction (RT-PCR).
BT474 (3 x 105) or HCC1954 (1 x 105) cells were plated in a 6-well tissue
culture treated dish. The next day, the cells were transfected using the appropriate
transfection reagents and incubated at 37 ⁰C with 5% CO2 and 95% O2 for 2 days.
Similarly, co-transfections combining siRNA and expression vectors were
staggered meaning that one transfection was done in the morning and one in the
evening. 2 days later, the cells were harvested in TRIzol® (Thermo Fisher
Scientific, Waltham, MA). The cells were harvest on ice, by scraping the cells into
the TRIzol® (500μL) solution. Total RNA was extracted from the harvested cells
using the RiboPureTM Kit (Thermo Fisher Scientific). The cells in TRIzol® were
incubated at room temperature for 5 minutes then 50μL of 1-bromo-3chloropropane [(BCP) Sigma Aldrich, St. Louis, MO] was added to each sample.
The sample was vortexed and incubated for 5 minutes at room temperature. Next,
the samples were centrifuged at 15,000 RPM for 10 minutes at 4⁰C. On ice, the
clear aqueous phase was transferred to a new tube to which 200μL of 100%
ethanol was added and mixed immediately. The sample was passed through a
filter cartridge by centrifugation at 12,000 RPM for 30 seconds at room
temperature. Each sample was washed twice with 250μL of wash buffer and spun
at 12,000 RPM for 30 seconds at room temperature. After the second wash, the
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tubes were spun one more time at 12,000 RPM to discard any access
ethanol/wash buffer. Each filter cartridge was added to a new tube and 100μL of
elution buffer was added. The tubes were incubated in a 37 ⁰C water bath for 5
minutes then the RNA was extracted from the filter cartridge into a new
microcentrifuge tube via centrifugation at 12,000 RPM for 30 seconds at room
temperature. Total RNA quality and quantity was determined by measuring the UV
absorbance at 260 nm using the NanoDrop 1000 Spectrophotometer (Thermo
Fisher Scientific).
The harvested total RNA was reverse transcribed (RT) into total cDNA using
the TaqMan Reverse Transcriptase Kit (Applied Biosystems, Ford City, CA). 1μg
of total RNA was reverse transcribed into cDNA in a total volume of 100μL
containing: 1x RT buffer, 5.5mM MgCl2, 500μM dNTPs, 2.5μM random hexamers,
0.4 U/μL RNase inhibitors, and 1.25 U/μL RT enzyme (Multiscribe TM Reverse
Transcriptase Kit, Applied Biosystems). The RT reaction was incubated in a
thermal cycler under the parameters:10 minutes at 25 ⁰C, 30 minutes at 48 ⁰C, 5
minutes at 95 ⁰C, 60 minutes at 25 ⁰C, and held at 4 ⁰C until use.
Real time PCR was performed using iTaqTM SYBR® Green Supermix with
ROX (BioRad, Hercules, CA) in a 96-optical PCR plate. A mastermix solution of
22.5μL per sample was made of: 50μM forward and reverse primers, and 2x
SYBER® Green Universal Master Mix. 2.5μL of cDNA was added to 22.5μL of
mastermix in triplicate wells. Quantitative PCR was run using the StepOnePlus
thermocycler (Applied Biosystems, Foster City, CA) under the following
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parameters: initial denature at 95 ⁰C for 10 minutes, PCR cycling for 10 seconds
at 95 ⁰C for 40 cycles, and annealing for 45 seconds at 60 ⁰C. Upon completion of
the PCR cycling, melt curves were recorded and analyzed to determine the
average cycle threshold (Ct) value. The Ct value is the number of cycles necessary
for the fluorescent signal to overcome the background level, or threshold, of
fluorescent signal. Ct values were normalized to the housekeeping gene
hypoxanthine-guanine

phosphoribosyltransferase

(HPRT),

an

endogenous

control, to discern ΔCt. ΔΔCt was calculated by normalizing the ΔCt values to a
control sample, such as the scrambled control siRNA treated cells. Relative
quantification (Rq) was calculated using the 2- ΔΔCt method to determine relative
fold increases or decreases in transcript compared to the control sample (Rao et
al., 2013). The PCR primers used for the detection of specific transcripts are shown
in table 2.
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Real Time PCR Primers
cDNA Primers

Forward Primer 5'-3'

Reverse Primer 5’-3’

Notch-1

ATCAACGCCGTAGATGACC

TTGTTAGCCCCGTTCTTCAG

PTEN

ACCAGGACCAGAGGAAACCT

GCTAGCCTCTGGATTTGACG

HEY-1

TCATTTGGAGTGTTGGTGGA

CTCGCACACCATGATCACTT

HPRT

ATGAACCAGGTTATGACCTTGAT CCTGTTGACTGGTCATTACAATA
ChIP Primers

PTEN

TTCTCCTGAAAGGGAAGGTG

GGAGGCAGTAGAAGGGGAGAG

HEY-1

AGCGTGGGAAAGGATGGTTG

CTCGCTTCATGCTGGCTCCC

Table 2: PCR Primer sequences
Western Blot Analysis.
BT474 or HCC1954 were plated in 10 cm2 (3 x 106 or 1 x 106) tissue culture
treated dish. The following day, the cells were transfected with plasmid DNA or
siRNA, treated with 20μg/mL trastuzumab or 10μg/mL U0126 and incubated at 37
⁰C with 5% O2 and 95% CO2 for 48 hours. After transfection, the plates were put
on ice, media was aspirated, and the cells were washed with cold PBS. Cells were
lysed by adding 300μL per 10 cm2 dish of Triton X-100 lysis buffer or
Radioimmunoprecipitation Assay (RIPA) buffer, scraped, and collected in
appropriately labeled microcentrifuge tubes. Triton X-100 buffer consists of: 50mM
HEPES (pH to 7.4), 1% Triton X-100, 150mM NaCl, 5mM EDTA, 1mM Na3VO4,
10mM NaF, 1mM PMSF, 1 protease inhibitor cocktail tablet. RIPA buffer consists
of: [0.1 % SDS, 50mM Tris-HCl, 1% NP-40, (pH to 7.0)] 0.5% Na deoxycholate,
1mM Na3VO4, 1mM NaF, 1mM PMSF, 1 protease cocktail tablet. Little to no
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difference was observed between using Triton X-100 and RIPA buffer but both
were used. The harvested samples were vortexed for 5 seconds at a setting of 10
followed by incubation on ice for 20 minutes. After incubation, the samples were
sonicated two times for 10 seconds at 20% amplitude using the Sonic
Dismembrator (Thermo Fisher Scientific, Waltham, MA). 10μL of each sample
were plated into a 96-well plate, along with 0, 0.5, 1, 2, 4, 6, 8, and 10mM BSA
protein standards, to determine protein concentration by BCA protein assay [50:1
Reagent A:Reagent B (Thermo Fisher Scientific)]. The plate was incubated at 37
⁰C for 30 minutes then read on a 96-well plate fluorescent plate reader. Protein
concentrations were calculated [regression line from protein standard curve
(y=mx+b) used to calculate Average protein concentration – b / m)] and made into
10 – 20 μg aliquots in beta-mercaptoethanol (Fisher, Waltham, MA) and 2x lamelli
buffer (BioRad, Hercules, CA). Samples were heated for 5 minutes at 95 ⁰C.
Proteins were detected by Western blot using a 7% Tris-Acetate or 4-12%
Bis-Tris pre-cast gel (Invitrogen, Carlsbad, CA) as the proteins are detectable in
either gel. 10 to 40μg of prepared protein lysate as well as a pre-stained protein
ladder (SeeBlue® Plus 2, Thermo Fisher Scientific) were loaded into separate
lanes of an SDS-PAGE gel in 1x Tris-Acetate SDS running buffer (Invitrogen). The
7% Tris acetate gel was run at 150V for 1 hour or the 4-12% Bis-Tris gel was run
at 200V for 50 minutes using the XCell SureLock © MiniCell apparatus (Thermo
Fisher Scientific). The gel was transferred to a polyvinylidene fluoride (PVDF)
membrane using 1x transfer buffer [50 mL. of 10x NuPAGE © transfer buffer
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(Invitrogen), 200 mL methanol, 750 mL water] at 40 volts for 2 hours using the
XCell IITM Blot Module (Thermo Fisher Scientific). After completion of the gel
transfer, the PVDF membrane was hydrated in methanol for 30 seconds then
rinsed in deionized water. The membrane was blocked in 5% non-fat milk (BioRad) or Roche blocking solution [Roche buffer (Roche, Basel, Switzerland)] in 1x
Tris Buffered Saline with Tween 20 (TBST) [(10x TBST (12.1 g Tris Base, 87 g
sodium chloride, ph to 8.0 in 1 L) 0.2% Nonidet P-40, 0.05% Tween-20] or 1x Tris
Buffered Saline [(TBS) no Tween-20 added], respectively, for 1 hour at room
temperature under constant agitation. The membrane was incubated with a
primary antibody at 4⁰C overnight under constant agitation. The following day, the
membrane was washed 3 times in 1x TBST solution for 10 minutes while under
constant agitation at room temperature then the appropriate secondary antibody
conjugated to horseradish peroxidase was added. The secondary antibody was
diluted in the appropriate blocking solution for 1 hour at room temperature under
agitation. Membranes were washed 3 times in 1x TBST for 10 minutes. Proteins
were detected by adding Enhanced Chemiluminesence (Thermo Fisher Scientific)
or SuperSignal West Extended Duration substrate (Thermo Fisher Scientific) in a
1:1 volume, incubated for 1 or 5 minutes, respectively, at room temperature.
Stained bands were visualized by exposing the membrane to radiography film
(MedSci) in the dark room.
Membranes were regularly stripped and re-probed to detect additional
proteins. The membrane was washed once in 1x TBST. Stripping buffer (Thermo

103
Fisher Scientific) was added to cover the membrane and incubated for 30 minutes
at room temperature under constant agitation. After 30 minutes, the membrane
was hydrated in methanol for 30 seconds then rinsed in deionized water. The
membrane was washed 3 times for 10 minutes in 1x TBST then blocked in 5%
non-fat milk for 1 hour at room temperature. The appropriate primary antibody was
added and the procedure was continued as described previously.
Densitometry of Wester blots was done using ImageJ software to quantitate
protein amounts in three separate experiments (Rasband, 1997). Notch-1 and
PTEN proteins were normalized to the loading control, β-actin. Phosphorylation of
Akt at Serine473 was normalized to total Akt.
Chromatin Immunoprecipitation (ChIP).
Chromatin Immunoprecipitation (ChIP) assays were performed using the
SimpleChIP© Plus kit (Cell Signaling Technology, Danvers, MA). Specifications
for some of the components used in this kit would not be disclosed by Cell
Signaling Technology. BT474 (5 x 106) were seeded in 3x 15 cm2 tissue culture
treated dishes. The following day, BT474TS cells were transfected with NICD1
(7.5μg) or pcDNA3 using PEI (30μL) for 48 hours. After 2 days, the cells were
washed in cold PBS, trypsinized (2x trypsin), and the 3 plates were harvested into
one appropriately labeled 50mL canonical tube on ice. Cells were counted using
the Countess Automated Cell Counter (Life Technologies, Carlsbad, CA) by
Trypan Blue staining and 25 x 106 live cells were used for one ChIP sample. The
cells were cross-linked by adding 1% formaldehyde (Sigma Aldrich, St. Louis, MO)
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for 30 minutes at room temperature under constant agitation. After 30 minutes, the
cross-linking reaction was quenched with 1.25M glycine, swirled, and incubated
for 5 minutes at room temperature. The cross-linked cells were centrifuged at 1500
RPM for 5 minutes at 4⁰C then washed twice with ice cold PBS. The cells were
pelleted by centrifuged at 1500 RPM for 5 minutes at 4⁰C. Untransfected BT474TS
and BT474TR cells were seeded and harvested in the same manner.
The cells were resuspended in 1mL of ice cold Buffer A (750μL deionized
water, 250μL 4x Buffer A, 0.5μL (1M) DTT, 5μL (200x) PIC) for each
immunoprecipitation (IP) and incubated on ice for 10 minutes. The cells were
mixed by inversion and lightly vortexed every 3 minutes during the 10-minute
incubation period. The nuclei were pelleted by centrifugation at 3000 RPM for 5
minutes at 4⁰C. The supernatant was aspirated from the pelleted nuclei and
resuspended in 1mL of ice cold Buffer B (825μL deionized water, 275μL 4x buffer
B, 0.55μL (1M) DTT). Centrifugation was repeated at 3000 RPM for 5 minutes at
4⁰C, supernatant was aspirated, and 100μL of buffer B was added. 1μL of
micrococcal nuclease (4000 gel units/μL) was added to the nuclei for chromatin
digestion and incubated at 37 ⁰C for 20 minutes with intermittent mixing by
inversion every 3 to 5 minutes. After 20 minutes, the digestion was stopped by the
addition of 10μL of 0.5M Ethylenediaminetetraacetic acid (EDTA). The nuclei were
pelleted by centrifugation at 13,000 RPM for 1 minute at 4 ⁰C. The supernatant
was aspirated and the pellet was resuspended in 100μL of 1x ChIP Buffer (90μL
deionized water, 10μL 10x ChIP buffer, 0.5μL 200x PIC) and incubated on ice for
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10 minutes. After 10 minutes, the sample was sonicated 3 times for 20 seconds
(pulse 20 seconds on, 30 seconds off) at 20% amplitude. The chromatin was
centrifuged for 10 minutes at 10,000 RPM at 4 ⁰C and transferred to a fresh
microcentrifuge tube. 10μL of digested chromatin was put aside at -20 ⁰C to be
used as a 2% input control. This method of digestion should yield chromatin
fragments of 150 – 900 base pairs (bp). 3 antibodies were used for chromatin
immunoprecipitation: C-terminal Notch-1 (C-20), normal rabbit IgG, and Histone
H3 meaning that the prepared chromatin is immunoprecipitated by 3 different
antibodies in 3 separate microcentrifuge tubes. 100μL of chromatin was diluted in
400μL of 1x ChIP buffer for each ChIP. 10μL of Notch-1 (200 g/mL), 1μL of
normal rabbit IgG (200 g/0.5 μL), or 10μL of Histone H3 antibody was added to
the diluted chromatin. The antibody:chromatin mixture was rotated overnight at 4
⁰C to facilitate chromatin immunoprecipitation.
The next day, condensation in the ChIP sample was lightly spun down to
get all of the antibody:chomatin mixture to the bottom of the microcentrifuge tube.
The ChIP sample was placed in a magnetic rack. The tube was left in the rack for
1 to 2 minutes until the beads visibly gathered on one side of the tube allowing
aspiration of the supernatant from the tube. The ChIP sample was washed with
low salt buffer (1x ChIP Buffer) 3 times then high salt buffer [(1x ChIP Buffer and
5M NaCl] one time. 150μL of ChIP elution buffer (2x ChIP Buffer) was added to
the ChIP sample in a fresh screw top microcentrifuge tube and put in a shaker at
300 RPM at 65 ⁰C for 30 minutes. Condensation was lightly spun down in the ChIP
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sample and placed in the magnetic rack. The supernatant contains the
immunoprecipitated DNA which is placed in a new screw top microcentrifuge tube.
150μL of ChIP elution buffer was added to the 2% Input samples. 6μL of 5M NaCl2
and 2μL of proteinase K (20 mg/mL) was added to both the ChIP and 2% input
samples followed by incubation at 65 ⁰C for 2 hours.
After the 2 hour incubation, 600μL of DNA binding reagent A was added at
a 4:1 ratio to each sample. The mixture was transferred to a DNA purification
column in a microcentrifuge tube and centrifuged for 30 seconds at 14,000 RPM.
The supernatant was discarded and the DNA in the purification column was
washed twice with 700μL of wash reagent B. The spin column was put in a new,
properly labeled microcentrifuge tube. 50μL of DNA elution reagent C was added
to the DNA and spun down again for 30 seconds at 14,000 RPM. The DNA was
diluted in deionized water at a 1:5 ratio. Quantitative PCR was performed as
described in section 6, Reverse Transcription Real-Time Polymerase Chain
Reaction (RT-PCR), using HEY-1 and PTEN ChIP primers that were designed to
flank CBF-1 binding elements (Persson et al., 2010) (Table 2) to quantitate NICD1
enrichment of the PTEN and HEY-1 promoters.
Mammosphere Assay.
BT474 or HCC1954 were plated in a 6-well (3 x 105 or 1 x 105) tissue culture
treated dish. The following day, the cells were transfected with plasmid DNA or
siRNA and incubated at 37 ⁰C with 5% O2 and 95% CO2 for 48 hours. After 2 days,
the cells were trypsinized and harvested in PBS. Live cells were counted using the
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Countess Automated Cell Counter (Life Technologies, Carlsbad, CA) by Trypan
Blue staining. 1.0 x 106 cells were suspended in 1 ml of PBS. 1.0 x 10 5 BT474 or
5.0 x 104 HCC1954 cells were seeded in mammosphere forming media [(196mL
DMEM/F12 (Life Technologies), 4g methyl cellulose (Sigma Aldrich, St. Louis,
MO), 10mL B27 (Life Technologies), 1μL recombinant EGF (Sigma Aldrich)] on
low attachment 6 well plates (Dot Scientific, Burton, MI). Mammosphere media
was pretreated with PBS, trastuzumab (20μg/mL in PBS), dimethylsulfoxide
(DMSO), or U0126 (10µg/mL in DMSO) per well. Mammosphere media was added
to the well followed by the cells on top of the media then vigorously swirled to
assure cell individualization in the mammosphere media. The BT474
mammospheres were incubated at 37 ⁰C with 5% O2 and 95% CO2 for 10 days
and the HCC1954 mammospheres for 7 days.
After incubation, pictures of the mammospheres were taken at 20x
magnification using a Nikon Diaphot TMD Fluorescence Phase Contrast Inverted
microscope (Nikon, Tokyo, Japan). 2mL of PBS were added to the well and
incubated at 37 ⁰C for 30 minutes to dissolve the mammosphere media. After 30
minutes, the PBS:mammosphere solution was put in a properly labeled 50mL tube.
Care was taken not to disrupt the mammospheres during collection. Addition of
PBS to the mammospheres was repeated a total of three times to completely
remove all mammospheres from the well. The harvested mammospheres were
centrifuged at 1200 RPM for 2 minutes at 4 ⁰C. Care was taken to only aspirate off
the mammosphere media:PBS mixture leaving the mammospheres pelleted at the
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bottom of the 50mL tube. BT474TS mammospheres were resuspended in 3mL of
PBS and BT474TR or HCC1954 in 5 mL of PBS. 50μL of the mammosphere:PBS
mixture was plated in a flat bottom, 96 well plate. 4 to 5 pictures at 4x magnification
were taken of the of the mammospheres. These pictures were used to count the
number of mammospheres/50μL. Mammospheres larger than 50 μmicrons were
counted as such. Percent mammosphere forming efficiency (%MFE) was
calculated as follows: number of mammospheres counted/number of cells seeded
x 100.
After the pictures were taken, 300μL of trypsin was added to the primary
mammospheres. The mammospheres were incubated at 37 ⁰C for 5 minutes then
disaggregated

by

vigorous

pipetting.

Once

the

mammospheres

were

disaggregated into single cells, media was added to deactivate the trypsin and the
cells were washed twice in PBS. 1.0 x 106 live cells from primary mammospheres
were resuspended in 1mL of PBS. The live cells were plated in mammosphere
media and incubated to form secondary mammospheres. The secondary
mammospheres were harvested, counted, and secondary %MFE was calculated
in the same manner as primary mammospheres.
Trastuzumab Resistant BCSC Tumor Xenograft Growth.
3 x 106 BT474TR cells were seeded in a 10 cm2 tissue culture treated dish.
The following day, the cells were transfected with scrambled control, Notch-1,
PTEN, or Notch-1 and PTEN siRNA for 2 days. After transfection, the cells were
trypsinized (2x trypsin), counted, and 1 x 10 5 live cells were seeded in
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mammosphere media as described in section 9, mammosphere assay. After a 10
day incubation period, the mammospheres were harvested and disaggregated. 1
x 104 live cells in 50μL of PBS were mixed in 50μL of Matrigel (Corning, Corning,
NY). The Matrigel:PBS suspension of cells was injected bilaterally into the
mammary fats pads of 5 to 6 week old, ovariectomized, FoxN1nu/nu athymic, nude
female mice (Charles River, Chicago, IL) along with implantation of a 17βestradiol-containing silastic release capsule of 0.3cm in length for a constant
release of 83-100pg/mL as previously described (O’Regan et al., 1998). Each
mouse was tagged with an ear tag to identify their treatment group (SCBi, N-1i,
PTENi, N1i + PTENi) as well as record their tumor take and growth. Tumor growth
was measured weekly as area (length x width) using Vernier calipers. Some
tumors reached the maximum cross sectional area [(l x w)π/4)] allowed (0.5cm 2)
by week 12. On week 12, mice were sacrificed, tumors were harvested, and frozen
at -80 ⁰C. Percent tumor take as well as tumor growth was calculated and graphed.
All animal study protocols were approved by Loyola University’s Institutional
Animal Care and Use Committee.
Statistical Analysis.
Statistical analysis of at least 3 independent experiments was performed.
Means plus or minus standard deviations were calculated using Excel software
(Microsoft). A two-sided student’s t-test was used to compare 2 groups. A one-way
ANOVA with Tukey’s range test was used to compare multiple groups. Asterisk (*)
represents statistical significance between control groups and sensitive cells and
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(**) represents statistical significance between Notch-1 inhibition compared to
other treatment groups. We performed power analysis to determine the
appropriate number of mice needed per treatment group for the in vivo study.
Based on previous experience, we determined the number of mice required for
each treatment group was 6. A Kaplan-Meier curve for tumor formation was
generated by Prism Version 6 (GraphPad Software). P-values <0.05 were
considered statistically significant.
Meta-Analysis of microarray cohorts. The Hatzis, Bonnefoi, and Curtis
breast cancer microarray cohorts were acquired from oncomine (oncomine.org).
Dr. Jun Li from the University of Notre Dame analyzed the cohorts with a log rank
(Mantel-Cox) test.

CHAPTER 3
HYPOTHESIS AND SPECIFIC AIMS

Resistance to anti-ErbB-2 (HER2)-targeted therapy remains a clinical
problem for women with HER2+ breast cancer. Resistance has been shown to
lead to enrichment of cancer stem cells, tumor recurrence, disease progression,
and ultimately death. There is an immediate need to elucidate mechanisms
responsible for drug resistance and breast cancer stem survival and self-renewal.
Discerning these mechanisms will identify actionable targets to combat breast
cancer progression. Several markers of trastuzumab resistance are known
including downregulation of the tumor suppressor, PTEN. Canonically, PTEN acts
as a lipid phosphatase to reduce the PI3K/Akt pathway and non-canonically as a
protein phosphatase to dephosphorylate nuclear ERK1/2 resulting in diminished
MAPK signaling. Women with HER2+ breast tumors expressing less PTEN and
increased PI3K/Akt or MAPK activity have worse overall outcome. Our lab has
previously shown that trastuzumab resistant cells have increased expression of
Notch-1 which drives cell proliferation in vitro as well as tumor recurrence in vivo.
Yet, we do not know the mechanism by which Notch-1 represses PTEN to increase
downstream signaling and trastuzumab resistance. Initial characterization of
trastuzumab resistant cells (BT474TR) display an increase in Notch-1 and a
decrease in PTEN protein expression as well as upregulation of Akt and MAPK
111
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pathway activity as measured by phosphorylation of Akt (Ser473-Akt1 and Thr308Akt1) and ERK1/2 compared to trastuzumab sensitive cells (BT474TS) (Figure
11A). Preliminary results demonstrate an increase in PTEN protein (Figure 11B)
and transcript (Figure 11C) expression upon Notch-1 knockdown. Additionally,
Notch-1 knockdown results in downregulation of ERK1/2 phosphorylation (Figure
11B) indicating reduced MAPK pathway activity. Taken together, these results
suggest the following hypothesis (Figure 12).
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Figure 11: Characterization of the trastuzumab resistant (BT474TR) cell
line.
A. Total protein lysates from BT474TS [Trastuzumab Sensitive (Sen.)] and
BT474TR [Acquired Trastuzumab Resistant (Res.)] cells underwent Western blot
analysis to detect HER2, HER2 phosphorylation (PY-HER2), Akt phosphorylation
(PSer473-Akt1, PThr308-Akt1), Notch-1, PTEN, and β-Actin protein expression.
B. BT474TR cells were transfected with scrambled control (SCBi) or Notch-1
siRNA (N-1i) for 48 hours. Post transfection, total cellular Notch-1, PTEN, and βActin protein expression was analyzed by Western blot.
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Figure 12: Notch-1 mediated inhibition of PTEN in trastuzumab resistant
cells promotes activation of the MAPK/ERK1/2 pathway.
The role of Notch-1-mediated repression of PTEN in HER2+
trastuzumab resistant breast cancer
We will address this hypothesis with the following specific aims:
Specific Aim 1: Determine if Notch-1 directly binds to the PTEN
promoter in trastuzumab resistant cells.
Specific Aim 2: Determine the biological significance of Notch-1mediated downregulation of PTEN in trastuzumab resistant cells.
Specific Aim 3: Determine if Notch-1-mediated repression of PTEN is
necessary for trastuzumab resistant tumor initiating potential in vivo.

115
Our studies will elucidate the mechanism by which Notch-1 inhibits PTEN in
HER2+ breast cancer cells. Upregulation of Notch-1 in trastuzumab treated, as
well as trastuzumab resistant, cells through inhibition of HER2 has been
established. However, the role of Notch-1 in driving trastuzumab resistance
remains unknown. PTEN is a well-established suppressor of the PI3K/Akt pathway
which has been associated with drug resistance and a more aggressive breast
cancer phenotype. A majority of work focuses on PTEN-mediated downregulation
of the Akt pathway but PTEN-mediated inhibition of the MAPK pathway has not
been well characterized in trastuzumab resistant HER2+ breast cancer. Here, for
the first time, we demonstrate the ability of Notch-1 to mediate PTEN inhibition
which results in increased MAPK activity in HER2+ trastuzumab resistant cells.
Furthermore, Notch-1-mediated inhibition of PTEN promotes trastuzumab
resistant cell proliferation as well as breast cancer stem cell survival and selfrenewal in vitro. Additionally, Notch-1 repression of PTEN promotes tumorigenesis
in a trastuzumab resistant tumor xenograft model. Together, these results
demonstrate the functional relevance of Notch-1 regulation of PTEN in HER2+
breast cancer. These studies present a mechanism by which Notch-1 regulation
of the PTEN-ERK1/2 signal transduction pathway promotes resistance to
trastuzumab treatment. Furthermore, these studies establish combined low PTEN
and high Notch-1 activity as good prognostic indicators of trastuzumab resistance
in HER2+ breast cancer patients. This data presents a new perspective on the role
of Notch-1 in trastuzumab resistant breast cancer and further promotes Notch-1
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as a therapeutic target for women who confront resistance to first line anti-HER2
therapies such as trastuzumab.

CHAPTER 4
RESULTS

Specific Aim 1. Determine if Notch-1 Directly Binds to the PTEN Promoter
in Trastuzumab Resistant Cells.
The goal of specific aim 1 is to test the following hypotheses:
Aim 1A: Discern if Notch-1 is necessary to inhibit PTEN expression in
trastuzumab resistant cells.
Aim 1B: Determine if Notch-1 is sufficient to repress PTEN expression in
trastuzumab sensitive cells.
Aim 1C: Ascertain if Notch-1 is directly recruited to the PTEN Promoter.
Aim 1A: Discern if Notch-1 is Necessary to Inhibit PTEN Expression in
Trastuzumab Resistant Cells.
Rationale. We wanted to determine the mechanism by which Notch-1
maintains trastuzumab resistance in HER2+ breast cancer cells, specifically
through the PI3K/Akt pathway. Previous work by our laboratory has demonstrated
that resistant cells depend on the Notch pathway to promote HER2+ breast cancer
cell proliferation in vitro and tumor growth and recurrence in vivo (Osipo et al.,
2008;
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Pandya et al., 2011). Additionally, our preliminary data shows that trastuzumab
resistant cells have an increase in Notch-1 protein expression and Akt-1
phosphorylation as well as a decrease in PTEN protein expression when
compared to trastuzumab sensitive cells (Figure 11A). Moreover, both sensitive
and resistant cells have similar levels of tyrosine phosphorylated HER2 (PYHER2), suggesting that continued proliferation of trastuzumab resistant cells is
likely independent of HER2 activity. Importantly, upon Notch-1 knockdown, we
observed an increase in PTEN protein expression as detected by Western blotting
(Figure 11B). Together, these preliminary data suggest that Notch-1 is necessary
for inhibition of PTEN expression in trastuzumab resistant cells. However, the
exact mechanism by which Notch-1 represses PTEN in HER2+ breast cancer is
unknown. The goal of aim 1A is to determine if Notch-1 is necessary to repress
PTEN expression at the mRNA level.
Notch-1

inhibition

increases

PTEN

RNA

transcript

and

protein

expression. Initial investigation into the mechanism of trastuzumab-mediated
inhibition of HER2+ breast cancer demonstrated an upregulation of PTEN protein
expression upon trastuzumab treatment. Trastuzumab-mediated upregulation of
PTEN is hypothesized to decrease downstream PI3K/Akt pathway activation
resulting in reduced HER2+ tumor growth. Our model of acquired resistance to
trastuzumab include cell lines (BT474TR) that display both a decrease in PTEN
protein and an increase in downstream Akt activity as measured by increased
levels of P-Thr308 and P-Ser473 Akt by Western blotting compared to the parental,
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trastuzumab sensitive cell line (BT474TS). These results are consistent with
findings from other laboratories demonstrating similar characteristics in resistant
cells as those previously described (Figure 11A) (Chan et al., 2005). Moreover, we
discovered that our BT474TR cells also have an increase in Notch-1 protein
expression and activity compared to trastuzumab sensitive cells (Figure 11A)
(Osipo et al., 2008).
Our preliminary data demonstrated that inhibition of Notch-1 promoted
PTEN protein expression (Figure 11B). In order to determine if this effect occurs
at the transcript level, we asked the question: does Notch-1 inhibit PTEN RNA
expression? To answer this question, we measured Notch-1 and PTEN transcript
levels using real-time PCR in acquired resistant cells (BT474TR) upon Notch-1
knockdown compared to control. The results showed that inhibition of Notch-1
resulted in an increase in PTEN RNA transcripts (Figure 13A). This result suggests
that Notch-1 is required for PTEN expression at the RNA transcript level. To
determine if Notch-1 repression of PTEN was reproducible in other cell lines,
protein and transcript levels of PTEN were measured post Notch-1 knockdown in
inherently resistant HCC1954 cells by Western blot and real time PCR analysis,
respectively. In agreement with results from acquired resistant BT474 cells, Notch1 knockdown also resulted in an increase in PTEN RNA transcript (Figure 13B)
and protein (Figure 13C) levels.
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Figure 13: Notch-1 represses PTEN expression in trastuzumab resistant
cells.
A. BT474TR cells were transfected with scrambled control (SCBi) or Notch-1
siRNA (N-1i) for 48 hours. Post transfection, relative expression of Notch-1 (top)
or PTEN (bottom) was measured by RT-PCR. B. Similarly, intrinsically resistant
HCC1954 were transfected with SCBi or Notch-1i and relative expression of Notch1 (top) or PTEN (bottom) was measured by RT-PCR. C. Post transfection of
HCC1954 cells, total cellular Notch-1, PTEN, and β-Actin protein expression was
analyzed by Western blot. D. BT474TR cells were transfected with SCBi, N-1i, and
a second Notch-1 siRNA (N-1i#2) for 48 hours. Post transfection, total cellular
Notch-1, PTEN, and β-Actin protein expression was analyzed by Western blot.
Asterisk (*) represents statistical significance compared to SCBi from three
independent experiments using a Student’s t-test.
Taken together, these results indicate that Notch-1 is necessary for PTEN
inhibition at the transcript level in HER2+ trastuzumab resistant cells.
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Notch-1-mediated inhibition of PTEN is not due to an off target effect by
Notch-1 siRNA. It has become a common practice to validate effects of siRNAs
using a second, distinct siRNA targeting the same transcript. This is now standard
due to siRNAs having off target effects (Jackson et al., 2010). To ensure that
knockdown of Notch-1 by the first siRNA resulting in an increase in PTEN
expression was not due to an off target effect, we repeated the previous studies
using a distinct Notch-1 siRNA (#2). The results using the second Notch-1 siRNA
(#2) were similar to findings using the first Notch-1 siRNA (#1). Knockdown of
Notch-1 using either siRNA (#1 or #2) resulted in upregulation of PTEN protein
expression (Figure 13D). Notch-1 siRNA #1 is used throughout this manuscript
unless otherwise noted. This result confirms that Notch-1 is necessary for inhibition
of PTEN in our trastuzumab resistant cell models.
Aim 1B: Determine if Notch-1 is Sufficient to Repress PTEN Expression in
Trastuzumab Sensitive Cells.
Aberrant expression of Notch-1 has been shown to regulate PTEN in T-ALL
(Palomero et al., 2007) and gastric cancers (Kim et al., 2015). Similarly,
trastuzumab resistant cells display an increase in Notch-1 and a decrease in PTEN
expression compared to trastuzumab sensitive cells. Thus far, our results
demonstrate that Notch-1 is required for PTEN inhibition in both acquired and
inherently resistant HER2+ breast cancer cells. However, Notch-1 is elevated in
trastuzumab resistant cells compared to trastuzumab sensitive cells (Figure 11A)
suggesting that upregulation of Notch-1 may be necessary for attenuating PTEN
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transcription. Under this assumption, an inverse relationship exists between
Notch-1 and PTEN in which high Notch-1 expression results in PTEN inhibition
and low Notch-1 expression allows increased PTEN expression. Thus, the goal for
aim 1B is to determine if Notch-1 is sufficient to inhibit PTEN expression in
trastuzumab sensitive cells.
Overexpression of Notch-1 results in decreased PTEN expression. Given
our initial data demonstrating that Notch-1 is required to attenuate PTEN transcript
and protein expression in resistant cells, we asked if Notch-1 overexpression
downregulates PTEN in trastuzumab sensitive cells. To address this question, we
measured PTEN protein and transcript levels expression in BT474 sensitive cells
transfected with a control plasmid (pcDNA3) or a plasmid harboring cDNA for the
Notch-1 Intracellular Domain 1 (pcDNA3-NICD1) by Western blot and real time
PCR analysis. The results showed that NICD1 overexpression in trastuzumab
sensitive, BT474 cells resulted in a significant decrease in PTEN transcript (Figure
14A) and protein (Figure 14B) expression compared to the vector control.
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Figure 14: Notch-1 overexpression represses PTEN in trastuzumab
sensitive cells.
A. BT474TS cells were transfected with a vector control (pcDNA3) or NICD1
expression vector (NICD1) for 48 hours. Post transfection, Notch-1 (left) or PTEN
(right) mRNA expression was measure by RT-PCR. B. Total cellular Notch-1,
PTEN, and β-Actin protein expression was analyzed by Western blot post
transfection. Asterisk (*) represents statistical significance compared to pcDNA
from three independent experiments using Student’s t-test.
Taken together, these data suggest that Notch-1 is sufficient to regulate
PTEN expression at the transcript and protein levels in trastuzumab sensitive,
HER2+ breast cancer cells.
Aim 1C: Ascertain if Notch-1 is Directly Recruited to the PTEN Promoter.
Recruitment of Notch-1 to a CBF-1 element on a gene promoter
canonically activates transcription of the target gene. Previous work reported that
Notch-1 activated PTEN transcription in an embryonic kidney cell model (293T)
(Whelan et al., 2007). In contrast, Notch-1 was shown to repress PTEN
expression in T-ALL (Palomero et al., 2007). Canonically, Notch-1 is a
transcriptional activator of CBF-1-driven gene targets. In T-ALL, Palomero et al.
demonstrated that Notch-1 indirectly represses PTEN through upregulation of the
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transcriptional repressor HES-1, which is recruited to the PTEN promoter to
repress transcription of PTEN. Thus far, our results show that Notch-1 is both
necessary and sufficient to downregulate PTEN at the transcript level. To
determine if Notch-1 enrichment at the PTEN promoter correlates with reduced
PTEN transcript RNA expression, we performed a series of chromatin
immunoprecipitation (ChIP) assays to measure direct recruitment of NICD1 to a
CBF-1 site on the PTEN promoter. The goal of aim 1C is to determine if aberrant
Notch-1 expression results in an increase in NICD1 recruitment to the PTEN
promoter in HER2+ breast cancer cells.
Trastuzumab resistant cells have increased recruitment of Notch-1 at
the PTEN promoter. The canonical role of Notch-1 is to activate transcription,
leading us to ask the question: Is there an increase in NICD1 recruitment at the
PTEN promoter in resistant cells compared to sensitive cells? We measured
endogenous NICD1 enrichment at CBF-1 sites on HEY-1 and PTEN promoters in
both trastuzumab sensitive and resistant cells through a series of ChIP assays.
Enrichment of NICD1 on the HEY-1 promoter was performed as a positive
control as HEY-1 is a canonical Notch-1 target gene (Katoh and Katoh, 2007).
NICD1 enrichment at the HEY-1 promoter was measured by ChIP followed by
quantitative PCR (qPCR). The DNA fragment from the HEY-1 promoter region 243 bps upstream of the transcriptional start site (maps above bar graphs, Figure
16A) was amplified using a pair of primers flanking this region. Similarly, primers
flanking a region -432 bps upstream of the transcriptional start site of the PTEN
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gene amplified a DNA fragment enriched by NICD1. The primer pairs used in this
study were shown to flank a canonical CBF-1 binding sequence (CTGGGAA)
(Persson and Wilson, 2010), in the PTEN promoter as previously described by
Graziani et al. (Graziani et al., 2008). Analysis of the PTEN and HEY-1
promoters revealed 5 to 6 putative CBF-1 sites and we found that putative site #4
(CTGGGAA) was the most highly enriched for NICD1 in our HER2+ breast
cancer cell model (Figure 15). We detected more than a 3-fold increase in
endogenous NICD1 enrichment at both the HEY-1 and PTEN promoters in
resistant cells compared to sensitive cells (Figure 16B).
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Figure 15: PTEN promoter region.
The PTEN promoter region includes the transcription initiation site [ATG(+1)],
forward (-585 to -610) and reverse (-389 to -410) ChIP pimers, CBF-1 (olive green)
#4 (-425 and -1160), #5 (-1930), #1 (-2210), #10 (-2566), c-Ets (pink), GATA-1
(agua blue), c-Fos (blue-green), AP-1 (Yellow), RUNX-1 (blue with white letters),
NF-κB (purple), c-Myc (red), Oct-1 (blue), GATA-1/Oct-1 (Maroon with white
letters), and the HES-1 binding site (+118 to +319) (Palomero et al., 2007).

127

Figure 16: Notch-1 is directly recruited to the PTEN promoter.
A. HEY-1 (left) and PTEN (right) promoter maps showing CBF-1 binding sites
flanked by specific primer amplification sites. These primers were used to quantify
NICD1 enrichment of the HEY-1 or PTEN promoter by qPCR. B. BT474TR and
BT474TS cells were fixed, fragmented, and chromatin was immunoprecipitated by
a C-terminal Notch-1 (Santa Cruz Notch-1 Ab) or control IgG antibody. Purified
DNA from Notch-1 or IgG immunoprecipitated chromatin was used to quantify
NICD1 enrichment of HEY-1 or PTEN promoters by qPCR using the primers
shown in A. C. BT474TS cells were transfected with NICD1 or pcDNA3 expression
vectors for 48 hours. Post transfection, cells were harvested, fixed, fragmented,
immunoprecipitated by Notch-1 or IgG antibodies, and NICD1 enrichment of HEY1 or PTEN promoters was quantified by qPCR using the same HEY-1 or PTEN
primers as in B. Asterisk (*) represents statistical significance compared to
sensitive (B) or pcDNA3 (C) mean NICD1 enrichment from three independent
experiments using Student’s t-test.
These results are contrary to the canonical role of Notch-1 as a
transcriptional activator as we observe a decrease in PTEN transcripts in resistant
compared to sensitive cells. Yet, there is an increase in NICD1 enrichment at the
PTEN promoter in resistant compared to sensitive cells. This result suggests that
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Notch-1 is potentially acting as a direct inhibitor of PTEN transcript RNA
expression in trastuzumab resistant, HER2+ breast cancer cells.
Overexpression of Notch-1 increases Notch-1 enrichment at the PTEN
promoter in trastuzumab sensitive cells. Previous results indicated that Notch1 is sufficient to repress PTEN transcripts in trastuzumab sensitive cells (Figure
14). Given this result, and the enrichment of NICD1 at the PTEN promoter in
resistant cells, lead us to ask the question: is NICD1 directly recruited to the PTEN
promoter in trastuzumab sensitive cells? We addressed this question by
performing the same ChIP assays used to determine endogenous enrichment of
NICD1 at the PTEN promoter in resistant and sensitive cells. Similar to the
previous results, we observed a 3-fold increase in NICD1 enrichment at CBF-1
sites on the HEY-1 and PTEN promoters in sensitive cells-overexpressing NICD1
as compared to the vector control (pcDNA3)-transfected cells (Figure 16C).
Taken together, these data presented in aim 1C suggests that Notch-1 is
directly involved in repression of PTEN expression in HER2+ breast cancer cells.
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Specific aim 2. Determine the Biological Significance of Notch-1-Mediated
Downregulation of PTEN in Trastuzumab Resistant Cells.
The goal of specific aim 2 is to test the following hypotheses:
Aim 2A: Determine if Notch-1-mediated repression of PTEN promotes cell
proliferation of trastuzumab resistant cells.
Aim 2B: Determine the role of the MAPK pathway in Notch-1-mediated
repression of PTEN in trastuzumab resistant cells.
Aim 2C: Deduce if Notch-1-mediated repression of PTEN promotes
trastuzumab resistant breast cancer stem cell survival and self-renewal.
Aim 2A: Determine if Notch-1-Mediated Repression of PTEN Promotes
Proliferation of Trastuzumab Resistant Cells.
Rationale. Notch-1 has been shown to promote tumorigenesis in a number of
different cancers. Additionally, PTEN is a well-known inhibitor of the PI3K/Akt
pathway which has presented itself as a central node in drug resistant, HER2+
breast cancer (Berns et al., 2007). Thus far, we have shown that Notch-1 is
required for the inhibition of PTEN expression potentially through direct recruitment
of NICD1 to the PTEN promoter. Moreover, we have shown that there is an
increase in Akt activation in resistant compared to sensitive cells. Thus, we wanted
to determine the biological significance of Notch-1-mediated repression of PTEN
on cell growth and the PI3K/Akt pathway in trastuzumab resistant cells. The goal
of aim 2A is to determine if Notch-1-mediated repression of PTEN is responsible
for proliferation of trastuzumab resistant cells in vitro.

130
Trastuzumab reduces trastuzumab sensitive cell proliferation yet has no
effect on resistant cell proliferation. First, we wanted to ensure that our
trastuzumab resistant cells were resistant to trastuzumab treatment and that our
trastuzumab sensitive cells remained sensitive to trastuzumab treatment. To
assess trastuzumab sensitivity, we measure cell proliferation of resistant and
sensitive cells treated with 0, 2.5, 5, 10, 20, or 40 μg/ml of trastuzumab for 10 days.
The results demonstrate that our resistant cells are able to proliferate under high
doses of trastuzumab treatment while our sensitive cells are unable proliferate
when exposed to low doses of trastuzumab (Figure 17). These data show that our
sensitive cells are indeed sensitive to trastuzumab treatment while our resistant
cells are able to proliferate in response to high doses of trastuzumab treatment.

131

Figure 17: Trastuzumab reduces trastuzumab sensitive cell proliferation
but has no effect on resistant cell proliferation.
100,000 BT474S and BT474TR cells / well were seeded in 6 well plates and
treated daily with 0, 2.5, 5, 10, 20, 30, or 40 μg/mL of trastuzumab for 10 days.
Mean cell proliferation was calculated as the number of live cells / number of cells
seeded from triplicate wells.
Notch-1-mediated inhibition of PTEN promotes trastuzumab resistant cell
proliferation regardless of trastuzumab treatment. Previous work showed that
Notch-1 was required for cell proliferation of trastuzumab resistant breast cancer
cells (Osipo et al., 2008). Thus far, we have shown that Notch-1 is directly recruited
to the PTEN promoter which associates with reduced PTEN transcript RNA
expression in the same trastuzumab resistance cells. Additionally, we have shown
that low PTEN expression in trastuzumab resistance cells correlated with
hyperactivation of Akt. What is not known is if Notch-1-mediated repression of
PTEN is responsible for cell proliferation and the increase in hyper-phosphorylation
of Akt. To assess the role of Notch-1-mediated inhibition of PTEN in resistant cells,
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we measured cell proliferation in resistant cells transfected with a scrambled
control, Notch-1, and/or PTEN siRNA treated with PBS or trastuzumab (20 μg/ml)
for 10 days. In the acquired resistant model (BT474TR), knockdown of Notch-1
reduced cell proliferation by more than 4 fold compared to the scrambled control
(Figure 18A and B). Additionally, simultaneous knockdown of Notch-1 and PTEN
rescued cell proliferation by 2-fold compared to Notch-1 knockdown alone.
Furthermore, these proliferations results were similar either in the absence or
presence of trastuzumab treatment. We repeated this assay using another
trastuzumab resistant, HER2+ breast cancer line, HCC1954, and observed similar
results (Fig 18C and D). It is important to note that combined knockdown of Notch1 and PTEN in HCC1954 cells completely rescued cell proliferation compared to
knockdown of Notch-1 alone.
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Figure 18: Notch-1-mediated inhibition of PTEN promotes trastuzumab
resistant cell proliferation.
A-B. BT474TR cells were transfected with SCBi, N-1i, and/or PTENi for 48 hours.
Post transfection, the cells were harvested and seeded at 100,000 cells/ well in a
6 well plate and treated daily with 20 μg/mL of PBS (A) or trastuzumab (B) for 10
days. After treatment, the cells were harvested and counted. Mean proliferation
was calculated as the number of live cells harvested / number of live cells seeded.
C-D. HCC1954 cells were transfected with SCBi, N-1i, and/or PTENi and treated
with PBS (C) or trastuzumab (D) in the same manner as A-B. Asterisk (*) denotes
statistical significance compared to SCBi or (**) Notch-1i mean proliferation as
calculated using a one-way ANOVA with an overall statistical significance of p <
0.0001 from three independent experiments.
Taken together, these results demonstrate that Notch-1-mediated
repression of PTEN promotes proliferation of trastuzumab resistant cells.
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Notch-1-mediated repression of PTEN is not responsible for hyperactivation of Akt. The results from the cell proliferation assays encouraged us to
assess downstream PI3K/Akt pathway activity to determine if Notch-1-mediated
inhibition of PTEN resulted in increased Akt activation. Western blotting was
performed to assess the efficiency of Notch-1 and PTEN protein knockdown as
well as to detect the activation of Akt as measured by phosphorylation of Akt at
serine 473 and threonine 308. Additionally, densitometric analysis using ImageJ
was used to quantitate Notch-1 and PTEN protein expression normalized to the
loading control, β-actin (Rasband, 1997). This was repeated for protein levels of
phosphorylated serine473 on Akt normalized to overall Akt expression (Figure 19A
below blot). The results show that we were consistently able to knockdown both
Notch-1 and PTEN in both the acquired [(BT474TR) left] and inherently
[(HCC1954) right] resistant breast cancer cell models. Additionally, Notch-1
knockdown consistently resulted in an increase in PTEN protein expression.
Interestingly, the increase in PTEN expression in response to Notch-1 knockdown
either slightly increased or had little effect on the phosphorylation status of Akt.
This result is contrary to our initial hypothesis as we anticipated that inhibition of
Notch-1 would increase PTEN which in turn would inhibit PI3K kinase activity
resulting in decreased phosphorylation of Akt. Moreover, trastuzumab treatment
of acquired resistant cells (BT474TR) reduced phosphorylation of Akt yet
trastuzumab had little to no effect on proliferation (Figure 19A). Similar results were
seen in inherently resistant cells (HCC1954) in which Notch-1 knockdown
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increased PTEN expression, yet slightly increased phosphorylation of Akt. This
result was again independent of trastuzumab treatment (Figure 19B).

Figure 19: Notch-1 mediated inhibition of PTEN has little to no effect on
phosphorylation of Akt.
A. BT474TR cells were transfected with SCBi, N-1i, and/or PTENi for 48 hours.
Post transfection, total cellular Notch-1, PTEN, Akt, β-Actin, phosphorylation of
Akt-1 at threonine308 (PThr308-Akt1) and serine473 (PSer473-Akt1) protein
expression from the transfected cells post 48 hour PBS (left) or trastuzumab (right)
treatment was analyzed by Western blot. Mean values from densitometric analysis
of Notch-1, PTEN, and PSer473-Akt1 normalized to β-Actin or Akt, respectively,
are displayed below their respective blots, and quantitated from three independent
experiments. B. HCC1954 cells were transfected, treated, and analyzed by
Western blot in a similar manner as in A.
Taken together, these data indicate that Notch-1-mediated repression of
PTEN is not promoting trastuzumab resistance due to activation of Akt. Contrary,
Notch-1-mediated repression of PTEN could be promoting cell proliferation by
activating another pathway.
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PTEN siRNA B inhibits trastuzumab resistant cell proliferation. We wanted
to validate the results of our cell proliferation assays by using the three individual
siRNAs that comprise the PTEN SmartPool siRNA. The results of our cell
proliferation assays displayed a decrease in resistant cell proliferation when
transfected with the PTEN SmartPool siRNA (Figure 18A and B). Therefore, we
asked the question: Is one of the individual siRNA oligonucleotides in the PTEN
SmartPool having an anti-proliferative effect on trastuzumab resistant cells? To
address this question, we measured cell proliferation of acquired resistant cells
(BT474TR) transfected with the three separate oligonucleotides (A, B, C)
compared to a control siRNA and the PTEN SmartPool siRNA.

The cell

proliferation studies revealed that PTEN siRNA B reduced resistant cell
proliferation (Figure 20A). Additionally, whole cell lysates from the cell proliferation
study were used to measure PTEN protein expression by Western blotting. The
three PTEN siRNAs were able to downregulate PTEN protein expression (Figure
20B). These results explain the decrease in resistant cell proliferation when
transfected with the PTEN siRNA SmartPool.
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Figure 20: Distinct Notch1 and PTEN siRNAs Produce Similar Effects.
A. BT474TR cells were transfected with SCBi, PTENi-A, PTENi-B, PTENi-C, or
the PTENi SmartPool for 48 hours. Post transfection, the cells were harvested and
100,000 live cells / well were plated into a 6 well plate and grown for 10 days. On
day 10, the cells were harvested and counted. Mean cell proliferation was
calculated as the number of live cells / number of cells seeded from triplicate wells.
B. Total cellular PTEN and β-Actin protein expression from samples in A was
analyzed by Western blot. C. BT474TR cells transfected with SCBi, Notch-1i #2
and/or PTENi-A for 48 hours. Post transfection, the cells were harvested and
100,000 live cells / well were seeded into 6 well plates and grown for 10 days.
Mean cell proliferation was calculated from triplicate wells in the same manner as
A. D. Total cellular Notch-1, PTEN, and β-Actin protein expression from samples
in C was analyzed by Western blot.
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Distinct Notch-1 and PTEN siRNAs have similar effects on the
proliferation of trastuzumab resistant cells. Given the off-target effects of one
of the PTEN SmartPool siRNAs, we wanted to validate the results of the Notch-1
siRNA in our cell proliferation studies. Thus, we asked the question: does a second
Notch-1 siRNA yield similar results when combined with an individual PTEN
siRNA? We addressed this question by performing the same cell proliferation
studies in which we transfected acquired resistant cells (BT474TR) with a
scrambled control, a second Notch-1 siRNA (#2), and/or a single PTEN siRNA A.
The cell proliferation study yielded similar results to the initial studies in which
combined knockdown of Notch-1 and PTEN partially rescued cell proliferation
compared to Notch-1 knockdown alone (Figure 20C). Western blotting confirmed
that the second, distinct siRNAs against Notch-1 and PTEN were efficient in
decreasing protein levels (Figure 20D). These results confirm that Notch-1 is
required to repress PTEN expression and this mechanism is responsible for
proliferation

of

trastuzumab

resistant,

HER2+

breast

cancer

cells.

Notch-1 is not sufficient to induce trastuzumab resistance. Thus far, we
have demonstrated that proliferation of trastuzumab resistant cells is dependent
on Notch-1-mediated repression of PTEN. Previous results have shown that
Notch-1 is sufficient to repress PTEN in sensitive cells. Thus, the critical aim now
is to determine if Notch-1 is sufficient to induce resistance in cells that are initially
sensitive to trastuzumab. To address this aim, we performed a series of cell
proliferation assays in which we overexpressed NICD1 or a vector control
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(pcDNA3) in trastuzumab sensitive cells and treated them with PBS or
trastuzumab (20 μg/ml) for 10 days. NICD1 overexpression modestly increased
cell proliferation of sensitive cells in response to trastuzumab treatment. Taken
together, these results suggest that Notch-1 overexpression alone is not sufficient
to promote trastuzumab resistance (Figure 21A and B). These results indicate that
prolonged exposure to trastuzumab treatment is necessary for upregulation of
Notch-1 and the development of resistance.

Figure 21: Notch-1 overexpression in trastuzumab sensitive cells modestly
increases proliferation in response to trastuzumab treatment.
A. BT474TS cells transfected with NICD1 or pcDNA3 expression vectors for 48
hours. Post transfection, the cells were harvested and 100,000 cells were seeded
/ well in a 6 well plate. Cells were treated daily with 20 µg/mL trastuzumab or PBS
for 10 days. On day 10, the cells were harvested and live cells were counted. B.
Cell proliferation of BT474TS cells transfected with pcDNA or NICD1 and treated
with trastuzumab from A. Mean cell proliferation rate was calculated by the number
of live cells / number of cells seeded. Asterisk (*) denotes statistical significance
between mean cell proliferation of PBS and trastuzumab treated cells (A) or
pcDNA3 and NICD1 transfected cells under trastuzumab treatment (B) from three
independent experiments using a Student’s t-test.
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Aim 2B: Determine the Role of the MAPK Pathway in Notch-1-Mediated
Repression of PTEN in Trastuzumab Resistant Cells.
Our results demonstrate that Notch-1 inhibition resulted in little to no effect
on the activation status of Akt in the resistant cell models. Previous work has
demonstrated that PTEN is able to attenuate phosphorylation of ERK1/2 in a
HER2-negative breast cancer cell model, MCF-7 (Chung et al., 2005b).
Additionally, MAPK pathway activity is inhibited by trastuzumab and has been
found to be upregulated in models of acquired resistance to trastuzumab (Chan et
al., 2005). The MAPK pathway is known for controlling cell death and proliferation
which leads us to hypothesize that Notch-1-mediated repression of PTEN is
promoting the activation of ERK1/2 to increase cell proliferation.
Trastuzumab resistant cells have increased ERK1/2 activity compared to
sensitive cells. If the ERK1/2 pathway is critical to promoting proliferation of
resistant cells, then these cells should have higher expression of phosphorylated
ERK1/2 than sensitive cells. To address this aim, we measured the
phosphorylation status of ERK1/2 in both sensitive and resistant whole cell lysates.
The results indicate that resistant cells have increased ERK1/2 phosphorylation
compared to sensitive cells (Figure 22A) (Rogowski, 2011). This result suggests
that proliferation of resistant cells could be dependent on increased ERK1/2
activity.
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Figure 22: Trastuzumab resistant cells have increased phosphorylation of
ERK1/2 mediated by Notch-1.
A. Total protein lysates from BT474TS (Sen.) and BT474TR (Res.) underwent
Western blot analysis to detect P-ERK1/2, ERK1/2, and β-Actin protein
expression. B. BT474TR cells were transfected with SCBi or N-1i for 48 hours.
Post transfection, total cellular P-ERK1/2, ERK1/2, and β-Actin protein expression
was analyzed by Western blot.
Notch-1 is required for ERK1/2 phosphorylation in trastuzumab resistant
cells. Our data demonstrate that the ERK1/2 pathway is upregulated in
trastuzumab resistant cells compared to sensitive cells, yet the role of Notch-1 in
regulating the ERK1/2 pathway has yet to be assessed. Therefore, we asked the
question: is expression of Notch-1 required for the increased phosphorylation of
ERK1/2 in trastuzumab resistant cells? To address this question, we measured
ERK1/2 phosphorylation in lysates from scrambled control or Notch-1 siRNA
treated cells by Western blot analysis. The results show that ERK1/2
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phosphorylation decreases upon Notch-1 knockdown compared to the scrambled
control (Figure 22B).
These data suggest that Notch-1 is necessary to activate or at least
maintain ERK1/2 activity in trastuzumab resistant cells.
Inhibition of the MAPK pathway reduces proliferation of trastuzumab
resistant cells. Proliferation of trastuzumab resistant cells depends on Notch-1.
This dependence may be due, in part, to the ability of Notch-1 to activate or
maintain the ERK1/2 pathway. To determine if proliferation of resistant cells is
dependent on the MEK1/2-ERK1/2 pathway, we used a MEK1/2 inhibitor, U0126,
in a series of cell proliferation assays. We transfected resistant cells with a
scrambled control, Notch-1, and/or PTEN siRNA and treated them with the vehicle,
dimethylsulfoxide (DMSO) or U0126 for 10 days. We found that treatment of
resistant cells with U0126 dramatically reduced proliferation of resistant cells
(Figure 23A). Importantly, Western blot analysis of cell lysates showed that the
decrease of ERK1/2 phosphorylation in response to Notch-1 knockdown was
rescued by knockdown of PTEN. The U0126 treatment almost completely
abrogated ERK1/2 phosphorylation under all conditions (Figure 23B).
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Figure 23: Notch-1 mediated repression of PTEN activates ERK1/2 which is
necessary for resistant cell proliferation.
A. BT474TR cells were transfected with SCBi, N-1i, and/or PTENi-A for 48 hours.
Post transfection, 100,000 cells/well were plated in a 6 well plate and treated daily
with 10 µg/mL U0126 (left) or DMSO (right) for 10 days. Post treatment, the cells
were harvested and counted. Mean cell proliferation was calculated as the number
of live cells harvested / number of cells seeded from triplicate wells. C. Total
cellular Notch-1, PTEN, P-ERK1/2, ERK1/2 and β-Actin protein expression from
the cells in A post 48 hours of DMSO (left) or U0126 (right) was analyzed by
Western blot.
Taken together, these results suggest that Notch-1-mediated repression of
PTEN maintains or activates ERK1/2 phosphorylation via MEK1/2 activity to drive
resistant cell proliferation.
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Constitutive MEK1/2 activation rescues trastuzumab resistant cell
proliferation from Notch-1 inhibition. Thus far, we have shown that MEK1/2
activity is required for proliferation of resistant cells. What is not known is whether
constitutive activation of MEK1/2-ERK1/2 activity can rescue the decrease in
resistant cell proliferation upon Notch-1 knockdown. To test this, we measured
proliferation of resistant cells transfected with a scrambled control or a Notch-1
siRNA in combination with a vector control (pEXP) or a constitutively active mutant
of MEK1/2 (pEXP-MEK1DD) (www.addgene.org/31202/). MEK1DD has been
reported to maintain phosphorylation of ERK1/2 (Yang et al., 2011). Protein
expression from cell lysates were measured by Western blotting. The results show
that constitutive ERK1/2 phosphorylation by MEK1DD partially rescued the growth
inhibitory effects mediated by Notch-1 knockdown by nearly 4-fold compared to
Notch-1 knockdown alone (Figure 24A). Importantly, the decrease in ERK1/2
phosphorylation by Notch-1 knockdown was prevented when MEK1DD was
expressed (Figure 24B).
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Figure 24: Notch-1 promotes ERK1/2 phosphorylation which is sufficient
for resistant cell proliferation.
A. BT474TR cells were transfected with SCBi or Notch-1i and MEK1DD or pEXP
expression vectors for 48 hours. Post transfection, cells were harvested and
seeded at 100,000 cells / well of a six well plate. After 10 days, the cells were
harvested and counted. Mean cell proliferation was calculated as number of live
cells harvested / number of cells seeded from triplicate wells. B. Total cellular
Notch-1, MEK1, P-ERK1/2, ERK1/2 and β-Actin protein expression from the cells
in A post transfection was analyzed by Western blot.
Together, these results indicate a novel mechanism in which Notch-1
maintains proliferation of trastuzumab resistant, HER2+ breast cancer cells by
repressing PTEN expression to increase the activity of the MEK1/2-ERK1/2
pathway.
Aim 2C: Deduce if Notch-1-Mediated Repression of PTEN Promotes
Trastuzumab Resistant, Breast Cancer Stem Cell Survival and Self-Renewal.
The discovery of the cancer stem cell population has garnered much
attention as it is hypothesized to promote cancer metastasis, recurrence, and drug
resistance (Liu et al., 2014). Previous work has shown that HER2 (Korkaya et al.,
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2014) and Notch-1 (Harrison et al., 2010) promote expansion and survival of the
BCSC population. Additionally, PTEN has been shown to increase BCSC
differentiation through inhibition of both PI3K/Akt and MAPK pathways (Jordan et
al., 2009; Han et al., 2012). Moreover, trastuzumab resistant breast cancer cells
have displayed an increase in BCSC enrichment through increased Akt pathway
activity (Korkaya et al., 2008). With data presented so far, we found it important to
determine the role of the Notch-1-PTEN-ERK1/2 signaling axis in survival and selfrenewal of our trastuzumab resistant cells. The goal of aim 2C is to determine the
effect of Notch-1-mediated activation of the downstream MAPK pathway through
PTEN inhibition on the survival and self-renewal of the trastuzumab resistant
BCSC population.
Trastuzumab resistant cells are enriched for BCSCs. Trastuzumab has
been shown to reduce the BCSC population in trastuzumab sensitive cells
(Magnifico et al., 2009). These data led us to assess the effect of trastuzumab on
the BT474 sensitive BCSC population. We assessed BCSC survival of BT474
sensitive cells by using an in vitro mammosphere forming assay (Shaw et al.,
2012) in response to a vehicle control (PBS) or trastuzumab (20 μg/ml) treatment.
We found that trastuzumab treatment significantly reduced the primary percent
mammosphere forming efficiency (%MFE) of the BT474 sensitive cells (Figure
25A). Moreover, we observed that the size of mammospheres from BT474
sensitive cells were smaller (<50m) in response to trastuzumab treatment (Figure
25B). Reduced size of mammospheres and a decrease in %MFE confirmed that
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trastuzumab inhibited the survival of the HER2- dependent BCSC population as
previously demonstrated by Magnifico et al.

Figure 25: Breast Cancer Stem survival effects in trastuzumab sensitive
and resistant cells.
A. 100,000 BT474TS cells were plated into PBS or trastuzumab (20 μg/mL)
inoculated mammosphere media. Mammospheres were grown for 10 days. On
day 10, mammospheres were harvested and counted to determine mean percent
mammosphere forming efficiency (%MFE) which is calculated as [(number of
mammospheres counted / number of cells seeded) X 100]. B. Representative
photographs of BT474TS mammospheres from A at 20x magnification before
harvest. C. 100,000 BT474TS or BT474TR cells were plated into mammosphere
media and incubated for 10 days. On day 10, mammospheres were harvest and
counted from three independent experiments in the same manner as A. D.
Representative photographs of BT474TS and BT474TR mammospheres from C
at 20x magnification before harvest. Scale bare = 50m. Asterisk (*) denotes
statistical significance between mean %MFE of PBS and trastuzumab treated cells
(A) or BT474TS and BT474TR mammospheres (C) from three independent
experiments using a Student’s t-test.
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Previously, trastuzumab resistant cells have been shown to be enriched for
BCSCs compared to sensitive cells (Korkaya et al., 2008). Given this information,
we wanted to assess the mammosphere forming potential of our resistant cells
compared to sensitive cells to characterize the BCSC population in our cell models.
We assessed %MFE of both BT474 sensitive and resistant cells and determined
that %MFE of trastuzumab resistant cells was significantly higher than %MFE of
trastuzumab sensitive cells by almost 8 fold (Figure 25C). It is important to note
that mammospheres from resistant cells were nearly twice the size of
mammospheres from sensitive cells (100m versus 50m) (Figure 25D).
Together, these data confirm findings from previous work and suggest that
long term treatment with trastuzumab enriches for BCSCs.
Notch-1-mediated repression of PTEN is necessary for breast cancer
stem cell survival and self-renewal. Notch has been shown to be a primary
driver of BCSC survival and self-renewal from studies performed on breast cancer
cells lines as well as patient tumor samples (Grudzien et al., 2010; Harrison et al.,
2010). Yet, the mechanism by which Notch-1 promotes BCSC survival and selfrenewal remains, for the most part, unknown. In order to investigate the role of
Notch-1-mediated repression of PTEN in the BCSC population in vitro, we
performed both primary and secondary mammosphere forming assays from
trastuzumab resistant cells transfected with a scrambled control, Notch-1, and/or
PTEN siRNAs in response to PBS or trastuzumab. Measurement of primary %MFE
determines the survival of the BCSC, while secondary %MFE determines self-
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renewal capacity of the BCSC (Shaw et al., 2012). The results showed that
knockdown of Notch-1 significantly reduced both primary and secondary %MFE
by nearly 5-fold compared to the scrambled control (Figure 26). Knockdown of
PTEN had little effect on primary or secondary %MFE compared to the control
(Figure 26). Importantly, knockdown of PTEN partially rescued the effects of
Notch-1 knockdown by more than 2-fold compared to Notch-1 knockdown alone.
These results were similar regardless of trastuzumab treatment (Figure 26,
compare right panels to left panels). Mammospheres were photographed at 20x
magnification with a 100m scale bar (Figure 26A and C). Similar results were
observed with the inherently resistant HCC1954 cell line. Simultaneous
knockdown of Notch-1 and PTEN almost completely recovered both primary and
secondary %MFE compared to Notch-1 knockdown alone (Figure 27A-D).
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Figure 26: Notch-1-mediated inhibition of PTEN promotes trastuzumab
resistant breast cancer stem cell (BCSC) survival and self-renewal of
BT474TR cells.
A and C. BT474TR cells were transfected with SCBi, Notch-1i, and/or PTENi for
48 hours. Post transfection, the cells were harvested and 100,000 cells/well were
seeded into PBS (A) or trastuzumab (20 μg/mL) (C) inoculated mammosphere
media in a 6 well plate. The mammospheres were incubated for 10 days to form
primary (1⁰) mammospheres then harvested, disaggregated, and 100,000 live cells
from the primary mammospheres were seeded into PBS or trastuzumab inoculated
mammosphere media. The cells were incubated for 10 days to form secondary (2⁰)
mammospheres. Before harvesting, representative photographs of primary (top)
and secondary (bottom) mammosphere were taken on day 10 at 20x
magnification. B and D. Mammospheres were harvested in PBS and
mammospheres over 50 μm were counted as such. Primary percent
mammosphere forming efficiency (%MFE) (black bars) was calculated as:
[(number of mammospheres counted / well) / number of cell seeded X 100].
Secondary %MFE (white bars) was calculated in the same manner as primary
%MFE. Asterisk (*) denotes statistical significance compared to SCBi or (**) Notch1i mean %MFE as calculated using a one-way ANOVA with an overall statistical
significance of p < 0.01 from three independent experiments. Scale bar = 50m.
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Figure 27: Notch-1-mediated inhibition of PTEN promotes trastuzumab
resistant breast cancer stem cell (BCSC) survival and self-renewal of
HCC1954 cells.
A and C. HCC1954 cells were transfected with SCBi, Notch-1i, and/or PTENi for
48 hours. Post transfection, the cells were harvested and 50,000 cells/well were
seeded into PBS (A) or trastuzumab (20 μg/mL) (C) inoculated mammosphere
media in a 6 well plate. The mammospheres were incubated for 7 days to form
primary (1⁰) mammospheres then harvested, disaggregated, and 50,000 live cells
from the primary mammospheres were seeded into PBS or trastuzumab inoculated
mammosphere media. The cells were incubated for 7 days to form secondary (2⁰)
mammospheres. Representative photographs of primary (top) and secondary
(bottom) mammosphere were taken on day 7 before harvest at 20x magnification.
B and D. Mammospheres were harvested in PBS and mammospheres over 50
μm were counted as such. Primary percent mammosphere forming efficiency
(%MFE) (black bars) was calculated as: [(number of mammospheres counted /
well) / number of cell seeded X 100]. Secondary %MFE (white bars) was calculated
in the same manner as primary %MFE. Asterisk (*) denotes statistical significance
compared to SCBi or (**) Notch-1i mean %MFE as calculated using a one-way
ANOVA with an overall statistical significance of p < 0.01 from three independent
experiments. Scale bar = 50m.
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Taken together, these results indicate that Notch-1 is necessary for the
survival and self-renewal of trastuzumab resistant BCSCs at least partially through
repression of PTEN.
Inhibition of MEK1/2 (MAPKK) activity reduces trastuzumab resistant
BCSC survival. We showed that activation of MEK1/2-ERK1/2 signaling rescued
proliferation of bulk, trastuzumab resistant cells from knockdown of Notch-1. If the
bulk, resistant cell population is dependent on MEK1/2-ERK1/2 activity for
proliferation, then this pathway may be required for BCSC survival. To test this,
%MFE was measured from trastuzumab resistant cells transfected with a
scrambled control, Notch-1, and/or PTEN, siRNAs in response to a vehicle
(DMSO) or the MEK1/2 inhibitor (10M U0126). The results showed that %MFE of
control siRNA transfected, resistant cells was decreased by nearly 3 fold in
response to U0126 (Figure 28). Knockdown of Notch-1 almost completely inhibited
%MFE regardless of U0126 treatment. Importantly, %MFE of cells transfected with
the PTEN siRNA alone or PTEN plus Notch-1 siRNAs was inhibited to the same
degree as cells transfected with the Notch-1 siRNA alone when treated with U0126
(Figure 28). These data suggest that survival of BCSCs from the trastuzumab
resistant cell population are dependent on Notch-1-mediated activation of MEK1/2ERK1/2 signaling possibly through repression of PTEN.
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Figure 28: MEK1/2 inhibition reduces trastuzumab resistant BCSC survival.
A. BT474TR cells were transfected with SCBi, Notch-1i, and/or PTENi-A for 48
hours. Post transfection, cells were harvested and 100,000 live cells / well were
seeded into 10 μg/mL DMSO (left) or U0126 (right) inoculated mammosphere
media in a 6 well plate and incubated for 10 days. On day 10, mammospheres
were harvested in PBS and counted. Mean percent mammosphere forming
efficiency (%MFE) which was calculated as [(number of mammospheres counted
/ number of cells seeded) X 100] from triplicate wells. B. Representative
photographs of BT474TR mammospheres from A at 20x magnification before
harvest. Scale bare = 50m.
Constitutive MEK1/2 activity and ERK1/2 phosphorylation does not
rescue BCSC survival of trastuzumab resistant cells from Notch-1 inhibition.
Since the survival of BCSCs from the resistant cell population is dependent on
MEK1/2-ERK1/2 activity, we tested whether constitutive MEK1/2-ERK1/2 activity
is sufficient to rescue %MFE in response to Notch-1 knockdown. We assessed
%MFE of resistant cells transfected with a scrambled control or a Notch-1 siRNA
plus a vector control (pEXP) or the MEK1DD mutant. The results showed that
although knockdown of Notch-1 decreased %MFE, expression of MEK1DD did not
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rescue BCSCs from these inhibitory effects (Figure 29). Surprisingly, expression
of MEK1DD with the control siRNA inhibited %MFE similarly to Notch-1
knockdown. One main problem with this assay could have been that expression of
MEK1DD and increased ERK1/2 phosphorylation was not maintained in the
mammosphere culture up to 10 days. Alternatively, hyper-activation of ERK1/2
could potentially be detrimental to the survival of BCSCs. These studies need to
be repeated using stable cell lines in the future to confirm these results.
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Figure 29: Constitutive activation of ERK1/2 does not promote resistant
BCSC survival.
A. BT474TR cells were transfected with SCBi or Notch-1i and MEK1DD or pEXP
expression vectors for 48 hours. Post transfection, cells were harvested and
100,000 live cells / well were seeded into mammosphere media in a 6 well plate
and incubated for 10 days. On day 10, mammospheres were harvested in PBS
and counted. Mean percent mammosphere forming efficiency (%MFE) which was
calculated as [(number of mammospheres counted / number of cells seeded) X
100] from triplicate wells. B. Representative photographs of BT474TR
mammospheres from A at 20x magnification before harvest. Scale bare = 50m.
Notch-1 and PTEN siRNAs do not have off target effects on trastuzumab
resistant BCSCs. Previous work in the resistant bulk cell population demonstrated
than PTEN siRNA B has an off target effect on resistant cell proliferation. We
wanted to confirm that results from the Notch-1 and PTEN siRNAs on %MFE were

156
not due to off target effects. To address this issue, we transfected resistant cells
with a scrambled control, secondary Notch-1 (#2), and/or PTEN-A siRNAs and
performed mammosphere forming assay to assess %MFE (Figure 30A and B).
The %MFE results were similar to the previous results using distinct siRNAs
(Figure 30). These data confirm that Notch-1- mediated inhibition of PTEN is
necessary to promote survival and self-renewal of BCSCs from trastuzumab
resistant breast cancer cells.
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Figure 30: Distinct Notch1 and PTEN siRNAs Produce Similar Effects in
BCSCs.
A. BT474TR cells were transfected with SCBi, secondary Notch-1 siRNA (Notch1 #2) and/or PTENi-A for 48 hours. Post transfection, 100,000 live cells were
seeded / well into mammosphere media and incubated for 10 days. % MFE was
calculated as [(number of mammospheres counted / number of cells seeded) X
100] from triplicate wells. B. Representative photographs of BT474TR
mammospheres from E at 20x magnification before harvest. Scale bare = 50m.
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Specific Aim 3. Determine if Notch-1-mediated repression of PTEN is
necessary for trastuzumab resistant tumor initiating potential in vivo.
The goal of specific aim 3 is to test the following hypotheses:
Aim 3A: Determine if Notch-1-mediated inhibition of PTEN is necessary for
tumor initiation.
Aim 3B: Discern the co-expression profile of Notch-1 and PTEN and if this
co-expression predicts outcome in patients with breast cancer.
Aim 3A: Determine if Notch-1-Mediated Inhibition of PTEN is Necessary For
Tumor Initiation.
Rationale. The data from the mammosphere assays demonstrate that the
survival and self-renewal of resistant BCSCs are dependent on Notch-1-mediated
repression of PTEN. These results encouraged us to determine if Notch-1mediated inhibition of PTEN was necessary for tumor formation in a mouse tumor
xenograft model. Due to a lack of pharmacological means to specifically inhibit
Notch-1 and PTEN, we inhibited Notch-1 and PTEN using siRNAs as in our in vitro
studies which have demonstrated the ability to persistently inhibit target gene
expression for an extended period of time. Pandya et al. showed that GSI can
reduce BT474TR tumor xenograft growth and recurrence (Pandya et al., 2011).
However, GSI is a pan Notch inhibitor, and bulk BT474TR cells were used to create
resistant tumor xenografts in a nude mouse model. However, the specific role and
contribution of Notch-1 on trastuzumab resistant BCSC tumor xenografts remained
unknown. The goal of aim 3A is to determine if specific inhibition of Notch-1 can

159
reduce BCSC tumor xenograft formation and if this inhibition can be recovered by
combined knockdown of Notch-1 and PTEN in vivo.
Notch-1-mediated inhibition of PTEN promotes trastuzumab resistant
breast cancer stem cell tumor formation in vivo. Breast tumor xenografts were
generated from resistant BCSCs. BT474TR cells were transfected with a
scrambled control, Notch-1, and/or PTEN siRNAs and incubated in mammosphere
media for 10 days. The primary mammospheres were harvested and
disaggregated into single cells. 10,000 live, primary mammosphere-derived cells
in PBS were mixed at a 1:1 ratio with matrigel and subcutaneously injected into
the mammary fat pads of FOXN1-null, athymic, nude mice. Injection of the cells
was followed by implantation of an estrogen capsule to provide a constant release
of estrogen as BT474 cells express moderate levels of ER and require estrogen
for optimal growth. Tumors were allowed to grow for 12 weeks at which time some
tumors had reached the maximum cross sectional area (0.5cm2) allowed and all of
the tumors were harvested. The results demonstrate that Notch-1 knockdown
prevented tumor formation while the combined Notch-1 and PTEN knockdown
rescued tumor formation compared to Notch-1 or PTEN siRNA (Figure 31A – C).
Additionally, tumor growth rates and volumes were similar in the control, PTEN,
and combined Notch-1 and PTEN siRNA tumors (Figure 32A and B).
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Figure 31: Notch-1 mediated inhibition of PTEN promotes trastuzumab
resistant breast cancer stem cell xenograft tumor formation in vivo.
A. BT474TR cells were transfected with SCBi, N-1i, and/or PTENi for 48 hours.
Post transfection, the cells were harvested and seeded in mammosphere media
at 100,000 cells/ well in a 6 well plate for 10 days. After 10 days, the primary
mammospheres were harvested and trypsinized into single cells. 10,000 live cells
in 50 μl of PBS were mixed with 50 μl of Matrigel and subcutaneously injected
bilaterally into the mammary fat pads of athymic nude mice along with a 17βestradiol capsule. Mice were monitored for tumors weekly for 12 weeks. The
Kaplan-Meier curves and log rank test (<0.0001) displays percent tumor free mice
in SCBi, Notch-1i, PTENi, and Notch-1i combined with PTENi tumor-bearing mice.
B. Photographs of SCBi, Notch-1i and/or PTENi treated BCSC tumor formation
(red circles) in nude mice. C. SCBi, Notch-1i and/or PTENi treated BCSC tumors
excised from nude mice.
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Figure 32: Notch-1 is required for Trastuzumab resistant breast cancer
stem cell xenograft tumor growth in vivo.
A. BT474TR cells were transfected with SCBi, N-1i, and/or PTENi for 48 hours.
Post transfection, the cells were harvested and seeded in mammosphere media
at 100,000 cells/ well in a 6 well plate for 10 days. After 10 days, the primary
mammospheres were harvested and trypsinized into single cells. 10,000 live cells
in 50 μl of PBS were mixed with 50 μl of Matrigel and subcutaneously injected
bilaterally into the mammary fat pads of athymic nude mice along with a 17βestradiol capsule. Tumors in mice were measured (l X w) weekly for 12 weeks to
determine average tumor volume for each treatment group weekly. B. Final tumor
sizes at week 12 for each treatment group. Asterisk (*) denotes statistical
significance compared to SCBi mean tumor volume as calculated using a one-way
ANOVA with an overall statistical significance of p < 0.06.
Taken together, these results demonstrate that Notch-1 is required for
trastuzumab resistant tumor initiation and BCSC self-renewal in vivo. Furthermore,
Notch-1-mediated repression of PTEN is necessary for self-renewal of
trastuzumab resistant BCSCs.
Aim 3B: Discern the Co-Expression Profile of Notch-1 and PTEN and if this
Co-Expression Predicts Outcome in Women With Breast Cancer.
The data thus far suggest that an inverse relationship between Notch-1 and
PTEN expression may increase trastuzumab resistance as well as promote a
worse outcome for women with HER2+ breast cancer. We used the Oncomine
database (oncomine.org) to find three cohorts of microarray data sets that
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assessed Notch-1 and PTEN RNA transcript expression in human breast tumor
samples (Curtis et al., 2012; Bonnefoi et al., 2007; Hatzis et al., 2011). Analysis of
Notch-1 and PTEN co-expression as well as their effect on patient survival time
was performed by Dr. Jun Li from the University of Notre Dame. The goal of aim
3B is to determine if an inverse relationship between Notch-1 and PTEN
expression exists in breast tumors and if this relationship has an effect on overall
survival outcome in patients with breast cancer.
There is a potential inverse relationship between Notch-1 and PTEN coexpression in breast cancer patient tumors. RNA can be extracted from core
biopsies of breast cancer patient tumors and analyzed by microarray screening.
Analysis of microarray data can determine variations in gene expression between
patient samples. This high-throughput screening technology can determine
differences in gene expression between multiple patient samples. For instance,
gene expression profiling by microarray screening can determine gene alterations
in patients responding to a treatment compared to patients that aren’t responding
to a treatment. These data can determine if particular genes are up or
downregulated to induce resistance to a particular cancer treatment regimen.
Here, we identified three cohorts of microarray data sets (Curtis, Bonnefoi, and
Hatzis) that expressed Notch-1 and PTEN (Curtis et al., 2012; Bonnefoi et al.,
2007; Hatzis et al., 2011). First, Dr. Li used Spearman’s correlation coefficient to
assess if there is a relationship between Notch-1 and PTEN expression in each
cohort. Results of the analysis show that an inverse relationship between Notch-1
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and PTEN exists in the Bonnefoi cohort (Table 3, top). Conversely, there appears
to be no relationship between Notch-1 and PTEN in the Curtis or Hatzis cohorts as
this analysis did not reach statistical significance. It is important to note that these
cohorts contain both HER2-positive and HER2-negative patient samples. The
HER2+ patient samples were analyzed in the largest cohort (Curtis) but the
number of HER2+ tumors was very small and did not produce statistically
significant results.

Co-Expression Correlations of Notch-1 and PTEN
Rank Correlation
Curtis
0.0141
Bonnefoi
-0.1537
Hatzis
-0.03651
Cox Proportional Hazards Model
Hazard Function Estimate
Notch-1 Coeffecient
1.112
PTEN Coeffecient
-0.227

p-value
0.515
0.052
0.412
p-value
0.0636
0.0038

Table 3: Inverse expression of Notch-1 and PTEN in breast cancer patient
tumors is associated with poorer outcome.
Top, correlation of Notch-1 and PTEN co-expression in each of the three breast
microarray datasets as calculated by Spearman’s correlation coefficient. Bottom,
co-expression of high Notch-1 and low PTEN correlates with an overall increase
in patient survival time in the Curtis Breast dataset as determined by the Cox
proportional hazards model. The log-rank test p-value = 0.001262.
Co-expression of high Notch-1 and low PTEN predicts poorer breast
cancer patient survival outcome. If there is an inverse relationship between
Notch-1 and PTEN occurring one cohort of breast tumors, then this inverse
relationship may negatively affect patient survival time. To this end, the effect of
Notch-1 and PTEN expression on patient survival time was assessed using a Cox
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proportional hazards model in the largest cohort, the Curtis dataset. To this end,
we found that co-expression of high Notch-1 and low PTEN in patient tumors
significantly reduced survival time (p-value = 0.001262 by a log-rank test) (Table
3, bottom).
Overall, these data indicate that an inverse relationship between Notch-1
and PTEN occurs in 1 out of 3 microarray data cohorts. The inverse relationship
between Notch-1 and PTEN may be associated with decreased overall patient
survival time but we cannot say for sure as we would need further statistical
analysis of microarray cohorts. Further analysis may need to include another
variable such as P-ERK1/2, HER2+, or trastuzumab treatment.

CHAPTER 5
DISCUSSION

Trastuzumab has improved the treatment of HER2+ breast cancer by
specifically blocking HER2 receptor activity. Trastuzumab combined with
chemotherapy has been shown to reduce HER2-driven tumor growth.
Unfortunately, resistance to trastuzumab treatment remains a major clinical
problem. Determining the mechanism of trastuzumab resistance could improve
trastuzumab-based therapies, avoid development of resistance, and may shed
some light on mechanisms of resistance in other cancers. Here, we have shown a
novel mechanism for Notch-1 as it is directly recruited to the PTEN promoter which
correlates with reduced PTEN expression at the transcriptional level. Notch-1mediated inhibition of PTEN reduces dephosphorylation of ERK1/2 resulting in
increase MAPK pathway activity in resistant cells. The Notch-1-PTEN-ERK1/2
signaling axis promotes bulk cell proliferation as well as BCSC survival and selfrenewal. Notch-1-mediated inhibition of PTEN was shown to promote tumor
initiation of resistant BCSCs while inhibition of Notch-1 alone blocked tumor
formation in a mouse tumor xenograft model. Together these data present a new
role for Notch-1 in which Notch-1 directly binds to the PTEN promoter potentially
to inhibit PTEN transcript expression and promote trastuzumab resistant, HER2+
breast cancer stem cell survival and self-renewal through MEK1/2-ERK1/2
pathway activation.
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The transcription of Notch target genes is facilitated by the formation of a
Notch transcriptional complex (NTC). CBF-1 is a critical repressor of Notch target
genes when NICD is not present. CBF-1 binds to a number of CBF-1 binding sites
in the promoter of Notch target genes. Promoter bound CBF-1 recruits negative
co-regulators such as SHARP and CtBP to block gene transcription in the absence
of NICD (Oswald et al., 2005). Binding of NICD to CBF-1 allows the release of the
negative co-regulators and the recruitment of co-activators to form the NTC.
Proper NTC formation begins transcription of the Notch target gene. Our data
shows that Notch-1 is both necessary and sufficient to inhibit PTEN transcript RNA
levels possibly by directly binding to regions containing CBF-1 elements near the
PTEN promoter. Notch-1 enrichment on the PTEN promoter may inhibit
transcription in a number of ways. For instance, formation of the NTC may be
incomplete at the PTEN promoter. As such, the CBF-1:NICD1 complex may fail to
completely release all negative co-regulators or recruit all co-activators to initiate
transcription. NTC formation begins with MAML-1 which is the lynch pin to
formation of the NTC (Reviewed in Gordon et al., 2008). Previous work has shown
that recruitment of MAML-1 alone to the CBF-1:NICD1 complex is a potent inhibitor
of gene transcription in T-ALL (Weng et al., 2003). Additionally, failure to recruit
the histone acetyltransferase, p300, would result in nearby histones remaining in
a closed conformation with DNA, thereby blocking access of RNA polymerase II to
the initiation start site. Moreover, competition between transcription factors for coactivators has been shown to occur as some co-activators are in limited amounts
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in the nucleus. Previous work has shown that MAML-1 is necessary for the proper
formation of several transcription complexes such as p53 (Zhao et al., 2007) and
β-catenin (Alves-Guerra et al., 2007). These data allow us to form several
hypotheses as to how NICD1 could be involved in the inhibition of PTEN
transcription, all of which would require further investigation.
Notch-1-mediated inhibition of PTEN may be caused by interactions with
transcription factors that regulate transcription of PTEN. For instance, previous
work has shown that p53 can bind to MAML-1 in the NTC (Yun et al., 2015)
resulting in inhibition of Notch transcriptional activity in an in vitro breast cancer
model. By this rationale, an increase in p53 expression may increase recruitment
of p53 to the NTC thereby inhibiting NICD1 from activating transcription of PTEN.
In agreement with this scenario, it was shown that co-expression of HER2 and p53
correlated with higher rates of cancer recurrence and poorer overall survival
(Yamashita et al., 2003). Additionally, the cell models used here, BT474 and
HCC1954 have Y163C and E285K missense mutations, respectively, that have
been shown to increase the stability of p53 resulting in accumulation of a putative
active form of p53 in the nucleus (www.atcc.org).
Notch paralogues may compete to form NTCs and this competition could
regulate PTEN transcription. Our lab has observed that both Notch-3 and Notch-4
expression are increased in resistant cells upon HER2 blockade using
trastuzumab (Data generated by Dr. Kinnari Pandya). Presumably, the four Notch
paralogues form similar NTCs and may compete for CBF-1 binding as well as the
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recruitment of the co-activators needed for proper NTC formation. Competition for
p300 has been seen among different Notch paralogues and mutant forms of the
Notch receptor (Oswald et al., 2001) as well as between NFκB and estrogen
receptors in heart smooth muscle cells (Speir et al., 2000). Additionally, previous
research has demonstrated transcriptional inhibition among Notch paralogues
through cooperative binding between two CBF-1-NICD-MAML1 complexes. The
orientation of CBF-1-NICD-MAML complexes on the promoter determines their
ability to initiate transcription (Nam et al., 2007). But, inhibition of PTEN
transcription by Notch-1 has been previously described by Graziani et al. in which
NICD1 is directly recruited to the PTEN promoter to inhibit its transcription in a
NSCLC model (Graziani et al., 2008). Together these data indicate that NICD1
may inhibit transcription of PTEN through multiple possible mechanisms.
NICD1 overexpression in trastuzumab sensitive cells results in minimal
reduction of PTEN transcript expression indicating that the transcription of PTEN
in sensitive cells differs from transcription of PTEN in resistant cells. As the
sensitive cells are treated with trastuzumab over an extended period of time, we
presume they acquire changes in their genomic landscape that may alter how
PTEN transcription is activated or repressed. By this hypothesis, the promoter of
PTEN may be crowded with transcriptional activators that keep PTEN expression
high in sensitive cells. In sensitive cells, Tremendous over expression of Notch-1
may be able to interact with PTEN transcription factors on the PTEN promoter by
displacing or counter acting transcriptional activators of PTEN. The PTEN
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promoter in the resistant cell may lack some of the transcriptional activators at the
PTEN promoter compared to the sensitive cell or may have room for Notch-1 to
bind to and counteract these activators or actively repress PTEN transcript
expression in resistant cells. Regardless, thorough analysis or both sensitive and
resistant PTEN promoters and the effects of NICD1 on PTEN transcriptional
activity should be done to address these hypotheses.
Indirect inhibition of PTEN by Notch-1 has been shown to occur in several
types of cancer. PTEN inhibition by Notch-1 has been shown to occur through
Notch-1-mediated upregulation of the transcriptional repressor, HES-1 (Palomero
et al., 2007). Aberrant Notch-1 activity in T-ALL cells, due to mutations, results in
increased expression of HES-1, a direct Notch target gene. HES-1 is directly
recruited to the PTEN promoter to inhibit transcription of PTEN. Such is not the
case in trastuzumab resistant cells, as knockdown of HES-1 had no effect on
PTEN RNA transcript levels (Figure 33). Indirect inhibition of PTEN by Notch-1 has
been shown to occur through regulation of the NFκB pathway. Work by Du et al.
has shown that the p65 (RelA), a subunit of NFKB, increases PTEN transcription
in trastuzumab resistant cells (Du et al., 2014). In this work, Notch-1 was shown to
sequester p65 in the cytoplasm thereby inhibiting its ability to enter the nucleus
and initiate transcription of PTEN. Moreover, Notch-1 has been shown to
upregulate the NFkB pathway in TNBC (Li et al., 2016) and in HER2-negative
BCSCs (Mao et al., 2013) suggesting a possible feedback mechanism between
Notch-1 and NFκB in these breast cancer models. Although the conclusions of
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these data do not speak to direct inhibition of PTEN by Notch-1, indirect inhibition
of PTEN may also occur in our resistant cells to perpetuate PTEN downregulation.

Figure 33: HES-1 has no effect on PTEN RNA transcript expression.
BT474TR cells were transfected with SCBi or HES-1i for 48 hours. Post
transfection, relative expression of HES-1 (left) and PTEN (right) was measured
by RT-PCR.
Other than direct transcriptional repression of PTEN, inhibition of PTEN can
be facilitated by modification of the PTEN protein to block its phosphatase activity.
Post-translational modification of PTEN activity is exemplified by its acetylation.
Acetylation of PTEN promotes binding to PCAF which facilitates its entry into the
nucleus, loss of PI3K regulation, and an increase in cell cycling (Okumura et al.,
2006). Silent mating type information regulation 2 homolog 1 (SIRT1) has been
shown to facilitate inhibition of PTEN nuclear translocation by deacetylation of the
PTEN PDZ domain (Ikenoue et al., 2008) (Figure 9). Deacetylation of PTEN by
SIRT1 inhibits its nuclear activity such as dephosphorylation of MAPK effectors.
Co-expression of high Notch-1 and low SIRT1 correlates with shorter overall
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survival and DFS in breast cancer patients (Cao et al., 2014). These results
suggest that crosstalk between Notch-1 and SIRT1 may occur to regulate PTEN
protein activity as well in resistant cells.
The role of the Akt pathway in the trastuzumab resistant model presented
here remains controversial. Our results show that Notch-1-mediated inhibition of
PTEN has little to no effect on the phosphorylation status of Akt. This finding was
observed in two distinct models of trastuzumab resistant breast cancer cells,
BT474 and HCC1954. This finding is counterintuitive to the lipid phosphatase
activity of PTEN on PIP3. These results suggest that PTEN may have lost the ability
to dephosphorylate PIP3, PIP3 is not responsive to PTEN phosphatase activity, or
that Notch-1 may be regulating phosphorylation of Akt through other proteins
capable of changing the phosphorylation status of Akt. One other possible
explanation is that the resistant cells used in these experiments have a H1047R or
K111N PIK3CA missense mutation (www.atcc.org) resulting in increased catalytic
activity of the p110 subunit of PI3K that can counter act PTEN-mediated inhibition
of PI3K activity.
Characterization of our acquired resistant cells shows that these cells
express markers of trastuzumab resistance: increased IGF-1R and decreased
p27Kip1 compared to sensitive cells (Personal Communication with Dr. Pandya).
Additionally, the resistant cells express more Hrg-2 and less HER4 protein
compared to sensitive cells. Hrg-2 and HER4 are two novel markers of
trastuzumab resistance found by our laboratory (Reviewed in Figure 34). Previous
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work has shown that the expression of Hrg-1 is upregulated by an increase in
ectodomain shedding of nascent Hrg-1 by ADAM10 (Ebbing et al., 2016).
Upregulation of Hrg-1 results in increased activation of HER3 in acquired
trastuzumab resistant esophageal cancer. Analysis of our acquired trastuzumab
resistant HER2+ breast cancer cells showed an increase in Hrg-2 over Hrg-1
compared to sensitive cells hence Hrg-2 may be contributing to trastuzumab
resistance in our cell model (Data generated by Dr. Kinnari Pandya).
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Figure 34: Notch-1 is a master regulator of IGF-1R, p27Kip1, HER4, PTEN,
and Hrg-2 in trastuzumab resistant cells.
Notch-1 knockdown reverses the expression of proteins and RNA
transcripts associated with trastuzumab resistance (Personal Communication with
Dr. Pandya). This suggests that Notch-1 is potentially regulating many of the
markers of trastuzumab resistance. Furthermore, preliminary ChIP assays of
NICD1 enrichment at CBF-1 sites on the HER4, IGF-1R, and Hrg-2 promoters
show an increase in endogenous NICD1 enrichment in resistant compared to
sensitive cells as well as in sensitive cells overexpressing NICD1 compared to the
pcDNA3 vector control (Figure 36A-F). Regulation of trastuzumab resistant
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markers by Notch-1 may affect downstream phosphorylation of Akt. One such
Notch-1 target, HER4, is downregulated in resistant cells. Much like PTEN,
knockdown of Notch-1 increased HER4 protein and RNA expression (Personal
Communication with Dr. Pandya). Similarly, overexpression of NICD1 reduced
expression of HER4 RNA transcripts (Figure 35). HER4, like HER2, can increase
downstream phosphorylation of Akt. Notch-1-mediated inhibition of HER4 and
PTEN could potentially have compensatory effects on the phosphorylation status
of Akt. For example, Notch-1 knockdown would increase HER4 expression to
sustain PI3K activation and thus maintain Akt activity regardless of upregulation of
PTEN. As such, PTEN attenuates PI3K-mediated phosphorylation of Akt which
can be negated by HER4-mediated PI3K activation thereby limiting the overall
effect of Notch-1 on the phosphorylation of Akt and Akt activity. Taken together,
these data indicate that Notch-1 may act as a master regulator of several markers
of trastuzumab resistance. As such, Notch-1 may have little to no overall effect on
the phosphorylation of Akt and Akt pathway activity in HER2+, trastuzumab
resistant breast cancer.
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Figure 35: Notch-1 overexpression reduces HER4 transcript expression.
BT474TS cells were transfected with NICD1 or pcDNA3 expression vectors for 48
hours. Post transfection, relative expression of HER4 was measured by RT-PCR.
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Figure 36: Notch-1 is directly recruited to the HER4, IGF-1R, and Hrg-2
promoter.
A-C. BT474TR and BT474TS cells were fixed, fragmented, and chromatin was
immunoprecipitated by a C-terminal Notch-1 (Santa Cruz Notch-1 Ab) or control
IgG antibody. Purified DNA from Notch-1 or IgG immunoprecipitated chromatin
was used to quantify NICD1 enrichment of HER4 (A), IGF-1R (B), or Hrg-2 (C)
promoters by qPCR using primers specific to a CBF-1 binding site in the HER-4,
IGF-1R, or Hrg-2 promoter (maps above bar graphs). D-F. BT474TS cells were
transfected with NICD1 or pcDNA3 expression vectors for 48 hours. Post
transfection, cells were harvested, fixed, fragmented, immunoprecipitated by
Notch-1 or IgG antibodies, and NICD1 enrichment of HER4 (D), IGF-1R (E), or
Hrg-2 (F) promoters was quantified by qPCR using the same HER-4, IGF-1R, or
Hrg-2 primers as in A-C.
Notch-1 has been shown to regulate downstream effectors of the Akt
pathway. Previous work has shown that Notch-1 can upregulate cyclin D1 which
results in activation of CDK 4/6 to increase proliferation of T-ALL cells (Choi et al.,
2012). A similar increase of cyclin D1 has been observed in resistant breast
cancer, yet the role of Notch-1-mediated upregulation of cyclin D1 has yet to be
elucidated (Witkiewicz et al., 2014). Previous characterization of acquired resistant
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cells showed that expression of p27Kip1 is decreased (Nahta et al., 2004). Our
resistant cells display a decrease in p27Kip1 protein expression compared to
sensitive cells (Personal Communication with Dr. Pandya). More importantly,
Notch-1 knockdown caused an increase in p27Kip1 expression in resistant cells
suggesting that Notch-1 may regulate downstream p27Kip1 expression (Personal
Communication with Dr. Pandya). p27Kip1 downregulation may occur through
Notch-1-mediated upregulation of IGF-1R which has been shown to decrease
downstream p27Kip1 expression in trastuzumab resistant, SkBr3 cells (Lu et al.,
2004). These data suggest that Notch-1 may regulate proteins downstream of the
Akt pathway to contribute to resistant cell growth.
Specifically targeting Notch-1 in the resistant cell model may affect the
expression of other proteins in an effort to adapt to the loss of Notch-1 expression.
As seen in the development of trastuzumab resistance, HER2+ cancer cells can
adapt to specifically targeting the HER2 receptor through upregulation of Notch-1.
Similarly, T-ALL cells can adapt to GSI treatment by upregulating downstream Akt
pathway activity through inhibition of PTEN. Cancer cells take advantage of the
number of redundancies that control cell proliferation and survival in order to
continue to survive under a multitude of treatment conditions. By this hypothesis,
cancer cells can continue to grow and adapt to changing environmental conditions.
As such, specifically targeting Notch-1 may alter the expression of other proteins
in an effort to maintain the tumorigenicity of the trastuzumab resistant cell.
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The role of the MAPK-ERK1/2 pathway in trastuzumab resistant bulk breast
cancer cells may differ from its role in the resistant BCSCs. Our data show that
inhibition of ERK1/2 phosphorylation by treatment with the MEK1/2 inhibitor,
U0126 reduces both bulk (Figure 23A) and BCSC (Figure 28A and B) proliferation
and survival, respectively. Constitutive expression of an active MEK1 (MEK1DD)
rescues bulk resistant cell proliferation from Notch-1 inhibition (Figure 24A and B)
but does not have the same effect on BCSC survival (Figure 29A and B). These
data present a disconnect between MAPK activity in resistant bulk and BCSCs in
which MAPK activity is required to promote bulk cell proliferation but not BCSC
survival. It is important to note that the experiments using the MEK1DD expression
vector were done in triplicate. Also, the Notch-1i/MEK1DD transfected cells used
in the bulk cell proliferation assay were the same cells used in the mammosphere
assay thereby reducing technical mistakes between the two experiments. None
the less, expression of the MEK1DD plasmid may not have been able to maintain
phosphorylation of ERK1/2 in the mammosphere culture for 10 days. Alternatively,
hyper-activation of ERK1/2 could potentially be detrimental to the survival of
BCSCs. These studies need to be repeated using constitutively active MEK1DD
stable cell lines to confirm these results.
Differences in the effect of constitutive MEK1 activity in resistant bulk and
BCSCs may occur for several different reasons. One reason may be that the
mammosphere assay is unable to assess changes in the mesenchymal stem cell
population. The mammosphere assay is the standard experiment for determining

179
changes in the epithelial stem cell population through the formation of
mammospheres. FACS analysis can allow us to sort and analyze specific cell
populations such as the epithelial and mesenchymal BCSC subpopulations or the
bulk and BCSC subpopulations. Further assessment of the resistant BCSC
population may reveal Notch-1-mediating downstream pathways to promote
enrichment of the BCSC population, proliferation of stem cell-like populations, or
potentially dedifferentiating or transdifferentiating subpopulation of cells that are in
between stem and differentiated states. Additionally, we can determine the effect
of Notch-1 and/or PTEN knockdown on the different subpopulations within our
resistant cell models. Assessment of the role Notch-1 plays in augmenting the
stem-like state of resistant cells can be addressed in future studies.
The results presented here focus on downstream activity of the PI3K/Akt
pathway in bulk cells but not in the BCSC population. Preliminary data
demonstrated the ability of constitutively activated Akt (Myr-Akt) to partially rescue
trastuzumab resistant bulk cell proliferation from Notch-1 inhibition (Figure 37A-C).
One explanation for this effect is that any stimulation of a downstream pathway
that promotes cell survival will be taken advantage of by the cancer cell. Another
possible explanation is that the Akt pathway is used by the BCSCs to promote
differentiation and bulk cell proliferation. The Akt pathway has been implicated in
promoting enrichment of the BCSC population and drug resistance (Berns et al.,
2007). Here, resistant cells may be dependent on Akt activity in some capacity.
The development of trastuzumab resistance and the increase in the resistant
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BCSC population may have initially been mediated through the Akt pathway. Initial
Akt pathway activation could be mediated through repression of PTEN, or one of
the many other proteins regulated by Notch-1, enabling the cell to evade and
survive under constant trastuzumab treatment.

Figure 37: Constitutive activation of Akt promotes trastuzumab resistant
cell proliferation.
A-B. BT474TR cells were transfected with SCBi or Notch-1i and Myr-Akt1 or pUSE
expression vectors for 48 hours. Post transfection, cells were harvested and
seeded at 100,000 cells / well of a six well plate and treated daily with 20 μg/mL of
PBS (A) or trastuzumab (B) for 10 days. After treatment, the cells were harvested
and counted. Mean proliferation was calculated as the number of live cells
harvested / number of live cells seeded. Asterisk (*) denotes statistical significance
compared to SCBi or (**) Notch-1i mean proliferation as calculated using a oneway ANOVA with an overall statistical significance of p < 0.0001 from three
independent experiments. C. Total cellular Notch-1, Akt, β-Actin, phosphorylation
of Akt-1 at threonine308 (PThr308-Akt1) and serine473 (PSer473-Akt1) protein
expression from the transfected cells post 48 hour PBS (left) or trastuzumab (right)
treatment was analyzed by Western blot.
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Recent research has shown that a loss of PTEN can promote dependency
on the MAPK pathway as inhibition of PTEN was found to be required for MEK1
signaling in a HER2+ breast cancer model (Ebbesen et al., 2016). Initial
dependence of the resistant cell on Notch-1 mediated activation of the Akt pathway
through inhibition of PTEN could have switched to activation of the MAPK pathway
to promote bulk cell proliferation but not BCSC survival. Downstream pathway
activation may be dependent on the receptors available to dimerize with HER2. It
has been shown that HER2 homodimers increase downstream MAPK signaling
while HER2 heterodimers increase downstream Akt signaling (Reviewed in
Yarden and Sliwkowski, 2001) (Chan et al., 2005). In contrast, the BCSC
population is dependent on Akt pathway activity while the bulk cells are dependent
on MAPK activity. Moreover, Notch-1 may increase ERK1/2 phosphorylation by
non-canonical means as previous students in our lab have shown that membrane
bound Notch-1 may be required for increased ERK1/2 phosphorylation and MAPK
activation in vitro. Further assessment of the Akt and MAPK pathways during the
development of trastuzumab resistance in vitro may shed some light onto the
pathway used by bulk or BCSCs as resistance to trastuzumab treatment occurs.
Conclusion.
The crux of the research presented here demonstrates that trastuzumab
resistant, HER2+ breast cancer cells have shifted their growth dependence from
HER2 to Notch-1. Specifically targeting Notch-1 in resistant cell models inhibits
their ability to proliferate and form tumors through upregulation of PTEN. In the
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work presented here we describe an important mechanism by which Notch-1
promotes trastuzumab resistant, HER2+ breast cancer bulk cell proliferation and
BCSC survival and self-renewal by repressing PTEN to maintain MAPK-ERK1/2
activity (Summarized in Figure 12). We have set forth data that show the adverse
effect of Notch-1 and PTEN co-expression on the survival time of breast cancer
patients. Together, these data make the case for an investigation to determine the
importance of Notch-1 and PTEN co-expression status as predictive markers for
trastuzumab sensitivity in women with HER2+ breast cancer. Currently, clinical
trials using the Notch-1 specific antibody [OMP-52M51 (Brontictuzumab)] are
underway and should yield results soon (ACC trial, 2015). Furthermore, PTEN and
Notch-1 expression status could deliver information for a clinical trial to validate a
combinatorial approach using a Notch-1 biologic with a MEK-ERK inhibitor to
prevent or treat trastuzumab resistance.

CHAPTER 6
FUTURE INVESTIGATION

Our research demonstrates that Notch-1 represses PTEN in HER2+ breast
cancer cells. Inhibition of PTEN results in an increase in phosphorylation of MEK1ERK1/2 to promote resistant cell proliferation, BCSC survival and self-renewal, as
well as contributing to tumor initiating potential in a mouse tumor xenograft model.
An area of controversy in these data is that constitutive activation of MEK1
in resistant BCSCs is not sufficient to rescue BCSC survival from inhibition of
Notch-1. We would like to affirm these results by repeating this experiment using
a resistant cell line with stable expression of constitutively active MEK1.
Constitutive MEK1 activity will increase ERK1/2 phosphorylation and maintain
MAPK pathway activity in the cell. We propose to use the MEK1 stable cell line
with or without Notch-1 knockdown in primary, and possibly secondary,
mammosphere assays. These assays would determine if constitutive activation of
MEK1-ERK1/2 is sufficient to promote BCSC survival and self-renewal compared
to Notch-1 knockdown. These mammosphere experiments could provide some
insight into the dependency of the resistant BCSCs on Notch-1-mediated activation
of the MAPK pathway.
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These data presented here show that overexpression of NICD1 in sensitive
cells was not able to induce trastuzumab resistance. These studies could be
complimented with the creation of a stable sensitive cell line constitutively
expressing activated MEK1. Previous work has shown that an increase in Notch1 and Ras-MAPK pathway activity is necessary for TNBC BCSC survival and
possibly drug resistance. By this hypothesis, our sensitive cells may require an
increase in both Notch-1 and MAPK pathway activity to become resistant to
trastuzumab treatment. Under this assumption, constitutively active MEK1expressing sensitive cells can be transfected with NICD1 and treated with
trastuzumab to determine if they lose sensitivity to trastuzumab treatment.
Additionally, sensitive cells can be simultaneously transfected with NICD1 and
PTEN siRNA in an attempt increase downstream MAPK activity and induce
trastuzumab resistance. These experiments may determine the pathways
necessary for sensitive cells to acquire resistance to trastuzumab treatment.
PTEN phosphatase activity is dependent on its location within the cell. As
previous work has shown, cytoplasmic PTEN reverses the effects of PI3K on Akt
activity and promotes cell death whereas nuclear PTEN attenuates ERK1/2-MAPK
activity and promotes cell quiescence. Here, Notch-1 is shown to inhibit PTEN
resulting in increased phosphorylation of ERK1/2 to promote resistant cell
proliferation and possibly tumor initiating potential. This hypothesis presumes that
PTEN is dephosphorylating ERK1/2 in the nucleus to induce resistant cell
quiescence. This hypothesis can be tested by determining the location of PTEN in
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the resistant cells and its phosphatase activity in the nucleus or cytoplasm. To this
end, we can determine if PTEN nuclear localization drives dephosphorylation of
ERK1/2 in resistant cells using resistant cells that stably express NLS mutant
PTEN constructs that inhibit PTEN nuclear localization. Similar to previous work
done by Chung et al., resistant cells stably expressing the NLS mutant PTEN
construct will have PTEN localized to the cytoplasm while wild-type PTEN is able
to enter the nucleus. Additionally, the PTEN mutants are tetracycline inducible
meaning that we can control PTEN nuclear entry with tetracycline treatment. We
can assess the effects of cytoplasmic or nuclear PTEN by cell fractionation and
Western blot analysis of nuclear and cytoplasmic cell fractions to determine the
effect of PTEN on downstream Akt and ERK1/2 phosphorylation. Additionally, we
can fluorescently label PTEN, Notch-1, Akt, and ERK1/2 to visualize where PTEN
is localized in the cell in relation to Notch-1 and effectors of the Akt and MAPK
pathways by fluorescent microscopy. Furthermore, we can assess the apoptotic or
quiescent state of the resistant cells under Notch-1 and/or PTEN knockdown as
well as cells expressing NLS mutant PTEN by propidium iodide staining for FACS
analysis or terminal deoxynucelotide transferase dUTP nick end labeling (TUNEL)
for fluorescent microscopy. Together, these data will determine if the location of
PTEN effects its phosphatase activity as well as the state of resistant cells after
Notch-1 and/or PTEN inhibition.
Further assessment of NICD1 enrichment at gene promoters would be
necessary to better understand the role of Notch-1 in promoting resistant cell
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proliferation, BCSC survival, self-renewal, and tumor initiating potential. To further
assess the role of Notch-1 in trastuzumab resistance, we would do an unbiased
ChIP-on-ChIP microarray, and/or ChIP sequencing, to determine where on the
human genome, NICD1 is binding to in our resistant cells compared to our
sensitive cells. Additionally, we can use resistant cells with Notch-1 knockdown
and sensitive cells with NICD1 overexpression as controls in the ChIP microarrays
for comparison purposes. We have performed extensive ChIP studies that
demonstrate that increased Notch-1 recruitment to several different gene
promoters correlates with inhibiton of transcript expression of these genes in our
resistant cells. We can perform the Notch-1 ChIP-ChIP microarray with other
members of the NTC such as CBF-1, MAML-1, p300, or RNA polymerase II to
determine if the DNA enriched by NICD1 pull-down also contain members of the
NTC complex. In addition, we can perform luciferase assays to determine the
effect of Notch-1 on transcription of PTEN as well as use the Crisper-cas system
to mutate endogenous CBF-1 binding sites to confirm the role of Notch-1 in PTEN
transcription.
Additional in vivo studies would allow us to determine the effects Notch-1
and/or ERK1/2 inhibitors on growth of resistant tumor xenografts. Using the Notch1 antibody, Brontictuzumab, as well as an ERK1/2 inhibitor (PD 098059 or U0126)
in vivo could give us clinical insight into the effects of these drugs on resistant
tumor growth and recurrence. We would use a resistant tumor xenograft model
similar to the resistant BCSC tumor xenograft model used to generate data
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presented here. We would treat the mice with a Notch-1 antibody with or without a
MEK1/2 inhibitor to determine their effects on tumor growth. Additionally, we can
remove the treatments if complete regression is observed, to see if the tumors
recur. If the tumors recur upon treatment removal, we can resume the treatments
to assess their effect on reducing recurring tumors. Moreover, we can grow
sensitive and resistant patient derived tumor xenografts (PDX) to evaluate the
effects of Notch-1 and/or MEK-1 inhibition on patient tumors. These in vivo
experiments will give us an idea of the efficacy of these inhibitors on reducing
resistant tumor growth and recurrence as well as their potential for success in a
clinical setting.
An interesting result in the data presented here is that resistant cells depend
on activation of the MAPK pathway through inhibition of PTEN to promote bulk cell
proliferation and BCSC survival. This is in contrast to a number of publications that
show that an increase in Akt pathway activity, through the loss of PTEN, can drive
trastuzumab resistance as well as enrichment of the BCSC population. Our results
are more in line with current publications which state that the loss of PTEN is
necessary for MEK1-mediated activation of the MAPK pathway in HER2+ breast
cancer cells. The ability of PTEN to attenuate both Akt and MAPK pathways can
have many effects on cancer development and resistance. One possibility is that
inhibition of PTEN facilitates a shift from the Akt to the MAPK pathway as the cells
become resistant to trastuzumab treatment. Another possibility is that different
resistant cell subpopulations, such as bulk and BCSC populations, are dependent
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on either the Akt or the MAPK pathway. Further assessment of differences
between bulk and BCSC subpopulations could determine if Notch-1-mediated
inhibition of PTEN is driving dedifferentiation of bulk cells into BCSCs or keeping
cells in a stem-like state to increase the BCSC population (Figure 38A).

Figure 38: Sorting of BT474TR cells.
Resistant BT474 cells can be sorted into bulk and BCSC (A) or epithelial and
mesenchymal (B) BCSC subpopulations to discern differences in Akt and/or MAPK
pathway activity. Inhibition of Notch-1 will allow us to determine if Notch-1 can
regulate the number cells in each subpopulation.
We can further assess resistant cell subpopulations to determine if the
BCSCs are in more epithelial or mesenchymal cell states and how this effects
resistance and tumor growth. Previous work by Sun et al. demonstrated that
BT474TS and BT474TR PTEN deficient cells display epithelial (ALDH+) and
mesenchymal

(CD44+/CD24-)

morphology,

respectively.

They

generated

trastuzumab resistant cells by knockdown of PTEN combined with long term
trastuzumab treatment (BT474-PTEN-LTT). Trastuzumab treatment combined
with PTEN deficiency is proposed to transition epithelial stem cells into
mesenchymal stem cells ultimately transforming the phenotype of trastuzumab
resistant HER2+ cells to resemble that of TNBCs. We may be able to build from
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this work by proposing that Notch-1-mediated regulation of PTEN and downstream
activation of ERK1/2-MAPK may regulate EMT/MET in the resistant BCSC
population and how this effects BCSC survival, self-renewal, and potentially
tumorigenesis (Figure 38B). Sorting of resistant cells into subpopulations to
determine how the Notch-1-PTEN-ERK1/2 signaling pathway effects their survival
and/or proliferation would be important for future studies.
Development of the trastuzumab resistant model has been a source of
intrigue as it would be interesting to see how the cells adapt to anti-HER2 treatment
over time. Using the trastuzumab resistant cell model as an example, we would
develop two acquired resistant cell models from BT474 and SkBr3 cell lines. In
addition to these cell lines, we can acquire trastuzumab sensitive patient samples
to assess changes in these cells as they are consistently exposed to anti-HER2
treatment. We can use intrinsically resistant cell lines, such as the HCC1954 cells
and resistant patient samples, as positive controls for resistance. The use of
patient derived cells may give us a translational view of how cells from a patient
can develop resistance to anti-HER2 treatments. Mimicking the development of
the trastuzumab resistant cells, we will treat the sensitive cells with incrementally
increasing doses of trastuzumab, pertuzumab, lapatinib, or TDM-1 over a 6-month
period until they are resistant to high doses of the anti-HER2 treatment (Figure 39
top). Over the course of the treatment, we will take samples from the cells on a
monthly basis. These cells will be lysed and reverse transcribed into cDNA for
assessment of protein and RNA expression as the cells become resistant to their
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prescribed treatment. Additionally, we will freeze down a number of cells for future
assessment if need be. We can determine changes in Notch-1, PTEN, P-Akt, and
P-ERK expression in the cells as they become resistant to the anti-HER2
treatment. Moreover, we can sort the BCSC population from the bulk cell
population to determine changes in these subpopulations over prolonged
exposure to treatment. Together these data will determine if Notch-1 upregulation
is the preferred compensatory pathway in cells that acquire resistance to antiHER2 therapies.
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Figure 39: Experiment flow chart to determine efficacy of Anti-HER2 and
Anti-Notch-1 targeted treatments
Flow chart for the development of acquired resistant cells to anti-HER2 and antiNotch-1 (Brontictuzumab) targeted treatments in vitro (top). Sensitive and resistant
cells will be injected into mice (bottom) to form tumor xenografts that are sensitive
or resistant to their respective treatment. The tumors will be treated with the drugs
they showed sensitivity/resistance to in vitro thereby demonstrating tumor
sensitivity/resistance to the targeted treatment. Treatments can be stopped to
assess recurrence and altered to determine efficacy of changing treatments to
ablate tumor growth and/or formation.
Assessment of the cells as they become resistant may be better facilitated
by microarrays to analyze changes in the whole genome, transcriptome, and
proteome to give us an overall view of what is happening in the cell. Moreover, we
can sort cells by high Notch-1 and low PTEN to determine when these changes
start to occur as well as the effect of PTEN loss on the Akt or MAPK pathway.
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Sequentially sampling cells as they become resistant to targeted treatment over
time may allow us to pinpoint the time when cells acquire resistance.
If HER2+ cells can become resistant to targeted treatment of the HER2
receptor, then they can also acquire resistance to targeted treatment of the Notch1 receptor. In accordance with this hypothesis, we would also like to look at the
effect of persistent anti-Notch-1 (Brontictuzumab) treatment on trastuzumab
resistant cells. If resistant cells become dependent on Notch-1 then resistant cells
must become dependent on another receptor(s) or protein(s) when consistently
treated with Brontictuzumab over time. Similar to the development of GSI
resistance in T-ALL cells, we can assess our trastuzumab resistant cells for
resistance to Brontictuzumab therapy in vitro. Additionally, the Brontictuzumab
resistant cells may upregulate downstream Akt pathway activity to compensate for
the loss of Notch-1 as previously seen in GSI resistant T-ALL cells. Comparable
to the development and testing of trastuzumab resistant cell lines, we can also
develop Brontictuzumab resistant cell lines from our trastuzumab resistant cells in
an effort to predict how trastuzumab resistant HER2+ cancer may react to antiNotch-1 therapy (Figure 39 top).
Once we complete evaluation of acquired drug resistance to targeted
treatments in a cell model, we can attempt to recreate resistant tumors in an in
vivo mouse model. We will implant sensitive and resistant cells into mice to form
tumor xenografts. The sensitive and resistant tumor xenografts can be treated to
stop or not stop tumor growth thereby showing sensitivity and resistance to the
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prescribed treatment. The treatment of resistant tumors can be stopped and
started again to see if the treatment effects tumor recurrence. This method of
treating resistant tumors can be done for several different treatments in an effort
to mimic the in vitro course of acquiring resistance to targeted treatments. For
example, we could implant several different sensitive and resistant cells into mice
that resemble how the cells become resistant in vitro such as trastuzumab
sensitive and resistant cells as well as Brontictuzumab sensitive and resistant cells
(Figure 39). We would begin by treating the tumors with their respective drugs to
show sensitivity and resistance to the initial treatments. As such, we can treat the
trastuzumab resistant tumors with Brontictuzumab and the Brontictuzumab
resistant tumors with the treatment found to stop their proliferation in vitro.
Together, these data will give us insight into how resistance is developed in vitro
in an in vivo model that we hope will translate into patients.
Recreating acquired resistant cells will allow us to track the changes that
occur in cells as they become resistant to targeted treatments. Changes in protein
and gene expression can be used to create a panel of genes that are altered to
predict the acquisition of resistance in a patient. This panel could begin with
changes in protein expression commonly observed at the first treatment and end
with protein expression at the last treatment when the cells have acquired
resistance. It can present the changes in proteins/genes over time to indicate if
resistance is, or is not, occurring. Tendencies towards resistance or treatment
ineffectiveness can have alternative treatment options and similar panels can be
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produced to help the clinician determine if an alternative treatment is having an
effect or not. Creating a flow chart for how to tell if a treatment is working or if
resistance is occurring may help both the patient and the doctor react to developing
refractory disease.
Development of the trastuzumab resistant model has been a source of
intrigue as it would be interesting to see how the cells adapt to trastuzumab
treatment over time. The continued development of treatments that specifically
target one receptor or one protein may be promoting resistance in cancer. Cancer
cells seem to take advantage of redundancies in the signal transduction pathways
enabling them to grow and survive in a multitude of different treatments. By
targeting certain proteins in cancer cells we may be motivating the cells to become
more adaptive to targeted treatments. Like insects that are exposed to a number
of different pesticides, or bacteria that are exposed to a number of different
antibiotics, we may be creating cancer cells that are resistant to a number of
different therapies. By this hypothesis, we could attempt to track the changes in
the sensitive cell as they acquire resistance to trastuzumab, lapatinib, pertuzumab,
TDM-1, chemotherapy, or any other therapies used to treat HER2+ breast cancer
in the clinic today.
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